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Abstract 
Leishmaniasis is a neglected tropical parasitic disease that causes several 
debilitating manifestations. No commercially available vaccine exists against this 
disease, and treatment strategies are far from ideal with the emergence of 
resistance, coupled with toxic side effects of many of the drugs available. Rational 
drug design relies on knowledge of the cell biology of the parasite and the interplay 
between the parasite and its hosts. Production of secreted proteins, the secretome, 
has become a known strategy for parasite invasion and persistence in host cells, 
however, host-parasite interaction is still not well defined. Virulence factors 
secreted by the parasite mediate the host-parasite interaction and create a niche 
permissive for parasite proliferation. They therefore represent potential 
therapeutic targets and vaccine candidates. 
Here, the use of secretomics was implemented to investigate these virulence 
factors. Parasite conditioned culture supernatant, containing the secretome, was 
characterised by morphological, immunochemical and proteomic analyses. Here, 
we optimised and extended current methods and applied them to the medically 
relevant amastigote stage. Method development and validation was implemented 
to extract a reproducible secretome in vitro. Induction of cell stress was managed 
and cell viability maintained to minimise interference of intracellular proteins. 
A total of 256 proteins were reproducibly identified in the secretome of 
promastigotes and 36 proteins were reproducibly identified in the secretome of 
amastigotes. Analysis of their protein abundance index (emPAI) allowed comparison 
of the relative abundance of proteins and functions of the secretome throughout 
the parasite life cycle. Differences in the putative functions of nutrient salvage, 
protease production and antioxidant activity were observed. Analyses reveal that 
many proteins lack a signal peptide and as such are thought to be released by 
nonclassical secretion mechanisms. Several exosome-associated proteins and 
membrane proteins were also detected in the secretome, suggesting the 
occurrence of secretion by exosomes or microvesicles. 
Extended comparative analyses between the secretome of parasites with differing 
phenotypes allowed us to infer functionality of the secretome in the parasite’s 
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survival but also variations within the same species which result in differing disease 
outcomes. Dysregulation in the secretion of various proteins in attenuated parasites 
implicates these proteins in the virulence of the parasite. An increase in the 
secretion of pro-inflammatory mediators and destructive proteases by parasites 
isolated from patients with chronic cutaneous leishmaniasis compared to those 
from patients with self-healing lesions, indicates the role of the parasite in the 
chronicity of cutaneous leishmaniasis. 
Here, we demonstrate an applicable method for the study of the Leishmania 
mexicana promastigote and amastigote secretome. Results suggest that the 
secretome plays a role in disease progression and virulence. Proteomic analyses of 
the secretome, like this study presented here, provide crucial information on the 
host:parasite interaction for the identification of therapeutic targets and potential 
vaccine candidates for the provision of safer treatments and new vaccines for 
eradication of this disease.  
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1.1 Leishmaniasis 
The leishmaniases are a group of debilitating and often disfiguring diseases that 
are classed as ‘Neglected Tropical Diseases’, a term encompassing a group of 
infectious diseases affecting some of the world’s poorest tropical and subtropical 
areas (Utzinger et al. 2012). Leishmaniasis is caused by protozoan parasites of the 
genus Leishmania, of which over 20 species are known to infect and cause disease 
in humans (W.H.O. 2010). The differing species of Leishmania dictate the nature 
and severity of the disease, causing three main manifestations of the disease: 
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous 
leishmaniasis (MCL). The manifestations are not exclusive to, but most commonly 
caused by the species listed in Table 1-1 (W.H.O. 2010). CL affects the highest 
numbers of people and is characterised by localised open or closed skin lesions that 
can sometimes spread over the entire body and cause diffuse/disseminated CL. 
MCL leads to disfiguring destruction of the mucous membranes of the nose, mouth, 
and throat cavities. VL results in anaemia, weight loss, swelling of the spleen and 
liver, and is almost always fatal if left untreated (Utzinger et al. 2012). 
Table 1-1 Species of Leishmania affecting humans and their principal disease manifestation. 
List compiled in WHO Expert Committee report on Control of the Leishmaniases (2010) (W.H.O. 
2010). 
 
 
Figure has been removed due to Copyright restrictions. 
Chapter 1  18 
 
 
Figure 1-1 Geographical distribution of new cases of cutaneous and visceral leishmaniasis in 
2016. (a) Cases of cutaneous leishmaniasis, (b) Cases of visceral leishmaniasis. WHO Leishmaniasis 
update 2018 (W.H.O. 2018). 
The leishmaniases are widespread globally, with cutaneous leishmaniasis (CL) 
endemic in 87 countries (Figure 1-1a), and visceral leishmaniasis (VL) endemic in 
75 countries (Figure 1-1b) (W.H.O. 2018). In a recent comprehensive report on 
leishmaniasis from the World Health Organisation, over 200,000 new cases of CL 
were reported in 2016, and over 22,000 new cases of VL were reported in 2016 
(W.H.O. 2018). However, notification of incidence only occurred in 57 of the 87 CL-
affected countries in 2015 (W.H.O. 2017), increasing marginally to 62 out of 87 
a 
b 
Figure has been removed due to Copyright restrictions. 
Figure has been removed due to Copyright restrictions. 
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reporting in 2016 (W.H.O. 2018). And 54 of the 75 VL-endemic countries reported 
in 2015 (W.H.O. 2017) and 2016 (W.H.O. 2018). It is therefore highly likely that the 
number of cases of leishmaniasis is severely under-reported. In addition, many 
leishmaniasis cases are either asymptomatic or misdiagnosed, and outbreaks which 
occur in zones of extreme conflict or in remote rural areas seldom visited by 
healthcare officials are often unreported. It is therefore estimated that 0.7 to 1.2 
million cases of CL and 0.2 to 0.4 million cases of VL occur globally every year, 
resulting in an estimated 40,000 deaths per year world-wide (Alvar et al. 2012). 
1.1.1 Diagnosis, treatment and vaccination 
Early phase diagnosis of leishmaniasis has proved a challenge for diagnostic 
approaches as infection can be asymptomatic. This, coupled with geographical and 
logistical challenges of providing lab-based field diagnostics in remote and 
challenging environments where this disease is endemic, intensifies the complexity 
of providing a leishmaniasis diagnosis. Parasitological methods for the diagnosis of 
CL are highly specific and remain the gold standard over immunological diagnosis, 
which cannot distinguish between previous and current infections. In 
parasitological diagnosis, material from lesion biopsies or aspirates is examined by 
microscopy, by culturing from the sample, or by molecular PCR-based methods. 
Although the simplest and most applicable in the field, microscopy can be time-
consuming and error prone due to insensitivity and operator interpretation. This 
allows for the possibility of false negative diagnoses as parasites can be scarce at 
the lesion site. Culture of the parasite is definitive and allows species 
identification, but this method is limited by the need for significant expertise and 
laboratory facilities. This limitation also applies to molecular diagnostics. These 
techniques have the advantage of allowing rapid diagnosis and species 
identification, particularly where multiple species may be present, but requires 
access to laboratory infrastructure (W.H.O. 2010). 
Treatment of leishmaniasis also faces many problems and there is still no treatment 
strategy available that does not either incur damaging side effects, or substantial 
costs. Anti-leishmanial drugs currently available on the market have variable 
efficacy, are often administered over long treatment regimens, and often come 
with toxicity and adverse side-effects, summarised in Table 1-2 (de Menezes et al. 
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2015). Furthermore, many anti-leishmanial drugs are expensive, have shown to 
demonstrate resistance and cannot, with the exception of miltefosine, be 
administered orally, with the others requiring sterile equipment and trained 
personnel for safe administration over the course of the long treatment periods. 
Alternative treatment therapies include the use of controlled release systems, such 
as liposomes, including a liposomal formulation of amphotericin B (AmB), 
Ambisome (Davidson et al. 1994). However, there are high costs associated with 
these amendments and liposomal AmB is unstable at room temperature so requires 
a cold chain. Functionalised carbon nanotubes used as anti-leishmanial drug 
carriers show good efficacy and low toxicity in tests, but again are associated with 
high costs and are still under development (Prajapati et al. 2011). Thus, there 
remains the need to identify new targets and treatment therapies to overcome 
problems such as efficacy, toxicity and resistance. Several leishmaniasis vaccines 
have been developed and trialled in animal models (Kedzierski et al. 2006), of 
which a small number have begun phase I or II trials in human subjects, namely 
LEISH-F1 (Nascimento et al. 2010), LEISH-F3 (ClinicalTrials.gov 2012) and Leish-
111f, which has completed phase I and II trials in humans (Coler et al. 2007). 
However, as yet there are no commercially available vaccines for leishmaniasis in 
humans. 
Table 1-2 Anti-leishmanial drug therapies. Administration route abbreviations: intramuscular (IM), 
intravenous (IV), intralymphatic (IL). Adapted from de Menezes et al. 2015 (de Menezes et al. 2015). 
Drug Efficacy Treatment 
length 
Toxicity and Side effects Cost Resistance Administ. 
route 
Pentavalent 
antimonials 
35-95% 28-30 days Cardiotoxicity, pancreatitis, 
nephrotoxicity, 
hepatotoxicity 
High  Common  IM, IV, IL 
Amphotericin B >90% 15-20 days Nephrotoxicity, infusion 
complications, hypokalemia, 
fever 
High  Laboratory 
strains 
IV 
Liposomal 
amphotericin B 
>97% Single dose Infrequent and mild  
Rigors, chills, nephrotoxicity  
Very 
High 
None 
reported 
IV 
Miltefosine 60-94% 28 days Vomiting, diarrhoea, 
nephrotoxicity, 
hepatotoxicity, teratogenicity 
High India 2017 
(Khanra et 
al. 2017) 
Oral 
Paromomycin 46-84% 17 or 21 days 
dose dependent 
nephrotoxicity, ototoxicity, 
hepatotoxicity 
Low Laboratory 
strains 
IM, topical 
Pentamidine 35-96% Every other day, 
x4 injections 
Pancreatic damage leading to 
hyperglycemia, hypotension, 
tachycardia, 
electrocardiographic changes 
High None 
reported 
IM 
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1.2 The Leishmania parasite 
Leishmania have a digenetic life cycle and are spread to the human host by the 
bite of an insect vector. The vector for these protozoa are sand flies, of the genus 
Phlebotomus for Old World Leishmania species such as L. major and L. donovani, 
and Lutzomyia for New World species such as L. mexicana and L. braziliensis (Bates 
2007). The parasites maintain different morphologies corresponding to their 
survival in the vector or the host. Figure 1-2 depicts the life cycle of Leishmania. 
When sand flies take a blood meal from an infected host, they ingest amastigotes 
which differentiate in the midgut of the insect to procyclic promastigotes. Procyclic 
promastigotes divide in the midgut and migrate to the mouthparts, where 
differentiation into the infective metacyclic stage occurs. These metacyclic 
promastigotes are introduced to the human host by the bite of the sand fly and are 
phagocytosed by macrophages, where they differentiate into the amastigote form 
in order to survive and multiply by binary fission.  
The amastigotes are successful as intracellular parasites due to their ability to 
resist the host cell defence mechanisms and exploit host cell nutrients and 
proteins. However, it is unlikely that physical adaptation alone facilitates their 
survival. We hypothesise that they also secrete factors which manipulate the host 
cell environment. Other intracellular pathogens such as Mycobacterium (Wagner et 
al. 2005), Legionella (Manske & Hilbi 2014) and Coxiella (Larson et al. 2015), have 
been shown to create pathogen-induced microenvironments in the host cell for 
their survival. One of the primary mechanisms used by these pathogens is the 
secretion of proteins to modulate the surrounding environment or modulate host 
cell signalling. Mycobacterium spp. have been shown to induce iron-rich micro-
environments, Legionella employ a type IV secretion system and translocate 
hundreds of different effector proteins into host cells, and Coxiella secrete 
effector proteins which integrate into the parasitophorous vacuole (PV) membrane 
allowing for niche modification (Larson et al. 2015; Manske & Hilbi 2014; Wagner 
et al. 2005). The intracellular parasite Toxoplasma gondii actively secretes parasite 
proteins after invasion of the host cell, resulting in modification of the vacuole to 
render it permeable to small molecules and thus promoting nutrient acquisition 
(Sibley et al. 2013).  
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Studying the proteins secreted by the parasites at different stages in their life cycle 
could help to put together a picture of Leishmania survival mechanisms and most 
importantly how these might be targeted to aid parasite clearance and treat 
infection. 
 
Figure 1-2 The life cycle of Leishmania. Image adapted from Esch & Petersen, 2013 (Esch & 
Petersen 2013) 
 
1.3 Mechanisms of Leishmania parasite survival 
1.3.1 Promastigote survival in the sand fly vector 
Change of form 
Promastigotes change forms to adapt to the stresses of their environment in the 
vector as they migrate from the midgut to the anterior gut and finally to the 
mouthparts; nectomonad, leptomonad, and metacyclic, respectively (Figure 1-3). 
However, these parasites can also modulate their environment to facilitate their 
survival by secreting proteins and compounds which are thought to influence their 
niche and allow the establishment of infection and growth within the host 
(Lambertz et al. 2012; Silverman & Reiner 2012). 
Figure has been removed due to Copyright restrictions. 
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Figure 1-3 Life cycle of Leishmania in the sand fly vector. Ingestion of amastigotes during a blood 
meal from an infected mammalian host (1), followed by differentiation to procyclic promastigotes, then 
nectomonad-form promastigotes which can exit the peritrophic matrix (2, 3, 4). The promastigotes 
migrate to the thoracic midgut and stomodeal valve (5) where they differentiate into leptomonad forms 
that can subsequently differentiate to mammalian-infective metacyclics or haptomonad forms which 
attach to the stomodeal valve (6). Metacyclic promastigotes are transmitted to the mammalian host 
during a blood meal (7,8). From Sunter & Gull (2017) (Sunter & Gull 2017). 
Secretion of proteins for nutritional functions 
Promastigotes have been shown to secrete a number of enzymes which are thought 
to be released in the midgut of the vector to digest large sugars and other nutrients 
to smaller molecules for uptake. For example, glycosidases such as glucosidase and 
sucrase which hydrolyse maltose and sucrose into their individual subunits (BLUM 
& OPPERDOES 1994; Jacobson & Schlein 2001). Promastigotes also release a 
secreted acid phosphatase (SAP), an enzymatically active filamentous 
phosphoglycoprotein polymer (Ilg et al. 1991). The glycoprotein was found to be 
secreted via the flagellar pocket (Stierhof et al. 1994). The enzyme has broad 
substrate specificity, and as it is released into the insect midgut, is thought to have 
a nutritional function (Ilg 2000b). 
Secreted proteins with physical roles 
Promastigotes also secrete several unusual glycoproteins which have been found to 
play various roles in parasite pathogenesis. Filamentous proteophosphoglycan 
(fPPG) (Ilg 2000b; Ilg et al. 1996) is the main component of promastigote secretory 
Figure has been removed due to Copyright restrictions. 
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gel (PSG) (Rogers et al. 2002). PSG, released by the parasites into the sand fly 
midgut, causes a physical blockage and promotes regurgitation of the parasites into 
the bite site, and therefore transmission (Bates 2007). A secreted chitinase has also 
been identified (Joshi et al. 2005). Its putative substrate, chitin, is a structural 
polysaccharide found in arthropods and is one of the main structural components 
of the peritrophic matrix, a membrane surrounding the food in the insect’s midgut 
(Secundino et al. 2005). As such, the enzyme’s main roles are thought to be the 
breakdown of blocks and membranes inside the insect vector and physical egress 
from the peritrophic matrix (Joshi et al. 2005). This then allows migration to the 
thoracic midgut and further development from there. 
1.3.2 During transmission from vector to host 
Recruitment and alternative activation of host cells 
In addition to promoting regurgitation of parasites, secreted PSG also exacerbates 
cutaneous infection by other mechanisms. Firstly, PSG causes strong recruitment 
of macrophages to the site of infection and secondly, it has been shown to stimulate 
alternative activation of the macrophage (Rogers et al. 2009). Alternative 
activation of macrophages, directing a Th2 immune response, induces macrophage 
metabolism that is conducive to parasite growth and can also provide essential 
nutrients to the parasite. Classical activation upregulates production of inducible 
nitric oxide synthase (iNOS) which produces harmful NO during the conversion of L-
arginine to L-citrulline (Cecílio et al. 2014). During classical activation, directing a 
Th1 immune response, expression of arginase is downregulated and as such the 
metabolism of arginine is shifted towards this iNOS pathway. Conversely, during a 
Th2 response, the expression of arginase increases which shifts arginine metabolism 
away from the production of NO, promoting parasite survival and additionally 
increasing the availability of polyamines to the parasite (McConville & Naderer 
2011; Naderer & McConville 2008). Another way the parasite actively contributes 
to this alternative activation of the macrophage is by secretion of cysteine protease 
B (CPB) which has been correlated with IL-4 production and subsequent Th2 
response (Alexander et al. 1998; Denise et al. 2003). One of the actions of the CPB 
enzyme is to cleave CD23 and CD25, IgE and IL-2 receptors respectively, and thus 
promote a Th2 response (Pollock et al. 2003).  
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Promoting phagocytosis 
After injection into the host in the sand fly bite, promastigotes are then taken up 
by professional phagocytic cells. Phagocytosis is a receptor-mediated process by 
recognition and binding of pathogens to receptors on the macrophage surface 
(Flannagan et al. 2012). There are many different receptors that mediate the 
phagocytosis of foreign bodies. Pattern-recognition receptors detect pathogen 
molecules directly, and opsonic receptors bind foreign bodies via opsonins on the 
pathogen surface (Flannagan et al. 2012). At least three different receptors have 
been reported to be involved in the phagocytosis of infective promastigotes. These 
include the first complement receptor CR1, the third complement receptor CR3 
and fibronectin receptors (FnRs) (Ueno & Wilson 2012; Wenzel et al. 2012). L. 
major promastigotes have been found to be internalised by a CR1-mediated 
phagocytic process (Wenzel et al. 2012), and L. mexicana, L. amazonensis, L. 
donovani, L. infantum, and L. major promastigotes via CR3. Additionally, the 
parasites can be opsonised with fibronectin and the subsequent binding to 
fibronectin receptors can increase the attachment to the host cell for the 
engagement of other receptors (Ueno & Wilson 2012). This can be mediated by self-
produced factors, such as enolase and SMP-1 secretion, which bind plasminogen, a 
fibrinolytic protease precursor (Avilán et al. 2011; Figuera et al. 2013). 
Furthermore, parasite surface and secreted GP63 cleaves complement protein 3 
into C3b, which binds to CR1, and C3b into iC3b, which opsonises the parasite for 
CR3-mediated uptake (Brittingham et al. 1995; Ueno & Wilson 2012). 
1.3.3 Entry to the phagolysosome and differentiation 
Following internalisation, the newly formed phagosome is subjected to a rapid 
succession of biochemical changes; a process termed phagosome maturation. This 
involves a systematic chain of interactions with early endosomes, late endosomes 
and lysosomes, resulting in the production of an acidic, oxidative and hydrolytic 
microbicidal compartment (Flannagan et al. 2012). Following phagocytosis, 
Leishmania not only survives the microbicidal assault, but differentiates and thrives 
as its obligate intracellular form, the amastigote. A variety of promastigote 
extracellular and secreted effectors contribute to the maintenance of infection, 
allowing it to promote its own intracellular survival, differentiation and subsequent 
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division. The effectors impede the maturation of the phagosome and delay the 
formation of the acidic pH and other unfavourable conditions affording the parasite 
time to differentiate into its more adapted intracellular form, the amastigote. 
Delaying phagosome maturation 
The first mechanism the promastigote uses to prolong its survival in the phagosome 
is impairing phagosome fusion with the late endosomal system and lysosomes 
(Moradin & Descoteaux 2012; Scianimanico et al. 1999). L. donovani achieves this 
by f-actin accumulation around the phagosome which provides a physical barrier to 
vesicular trafficking to the phagosome. This has been shown to be induced by L. 
donovani LPG via retention of Cdc42, F-actin assembly proteins and Rac1 (Holm et 
al. 2001; Lerm et al. 2006; Lodge & Descoteaux 2005). Interestingly, f-actin 
accumulation has not been observed in all Leishmania species, like L. amazonensis 
(Courret et al. 2002), highlighting the species diversity in survival mechanisms. And 
while it has been shown that actively inhibiting phagosome-lysosome fusion in L. 
mexicana caused an increase in parasite multiplication, and promoting phagosome-
lysosome fusion inhibited parasite growth (Alexander 1981), the parasite driven 
mechanisms of this stage of promastigote survival have not been elucidated in L. 
mexicana. Additionally, LPG was found not to be essential for L. mexicana infection 
of macrophages suggesting an alternative mechanism for this species (Ilg 2000a). 
Phagosome maturation is also delayed by impaired regulation of interactions 
between the PV and late endosomes and lysosomes, due to poor recruitment of 
Rab7, a small GTPase associated with this regulation (Zhang et al. 2009). This could 
be a consequence of the F-actin barrier around the phagosome, but additionally, 
promastigote infection of host macrophage results in an up-regulation in host 
expression of Th2 cytokines, inhibiting a Th1 response, and down-regulation of 
Rab7 and Rab9 expression in the host cell (Ali et al. 2013). The promastigote slows 
the acidification of the phagolysosome by impairing the recruitment of the 
vesicular proton-ATPase (v-ATPase) to the phagosome (Moradin & Descoteaux 2012; 
Vinet et al. 2009). The presence of parasite LPG in the phagosome membrane has 
been shown to exclude Synaptotagmin V (SytV),a regulator of maturation, thereby 
interfering with the recruitment of v-ATPase to the phagosome (Vinet et al. 2009). 
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Evasion of ROS and NO 
Parasites also evade the mechanisms of reactive oxygen species (ROS) and nitric 
oxide (NO) killing by macrophages. As discussed previously, alternative activation 
of macrophages towards a Th2-type response downregulates production of iNOS 
and increases production of L-arginase. This shifts the metabolism of L-arginine 
away from NO production by iNOS (Rogers et al. 2009), a reduction of which 
encourages parasite survival (Green et al. 1990). A mechanism of ROS evasion is 
failure of NADPH oxidase complex formation in the PV membrane (Lodge et al. 
2006). In L. donovani, this is thought to be due to LPG disruption of PV membrane 
lipid microdomains by incorporation of LPG into macrophage membrane lipid rafts 
(Winberg et al. 2009). For other Leishmania species mechanisms of scavenging or 
neutralizing intracellular ROS have been described, for example L. major 
methionine sulfoxide reductase A plays an anti-oxidative role (Sansom et al. 2013). 
Parasite superoxide dismutase (SOD) also plays a role in ROS defence as parasites 
deficient in this enzyme are markedly more sensitive to ROS in vitro and display 
reduced survival in vivo (Ghosh et al. 2003). SOD also appears to initiate signalling 
for the differentiation of infective promastigotes to amastigotes, mediated by ROS 
(Mittra et al. 2017). Leishmania also express and secrete a number of intrinsic 
antioxidants including trypanothione reductase, tryparedoxin, peroxidoxin and 
thioredoxin-like protein (Castro et al. 2002, 2017). 
Inhibition of macrophage apoptosis 
Infection with Leishmania appears to actively increase the lifespan of macrophages 
during infection through release of proteins which influence and inhibit 
macrophage apoptosis (Moore & Matlashewski 1994). Various mechanisms have 
been described in different species to explain this effect, but what is clear is that 
despite the mechanism, this effect is occurring. Release of NdK in L. amazonensis 
prevents ATP-induced cytolysis of the macrophage (Kolli et al. 2008); L. major 
produces a human migration inhibitory factor (MIF)-like protein which was shown 
to inhibit macrophage apoptosis in vitro (Kamir et al. 2008); L. infantum 
promastigotes and soluble factors from spent media have been shown to inhibit 
actinomycin D-induced apoptosis in macrophages, but the effectors have not been 
identified (Lisi et al. 2005). In the following cases infection with Leishmania has 
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been demonstrated to inhibit apoptosis in macrophages induced with various 
compounds, including actinomycin D (Lisi et al. 2005; Ruhland et al. 2007), 
campothecin (Ruhland et al. 2007), staurosporine (Akarid et al. 2004), and 
cycloheximide (Donovan et al. 2009), but the mechanisms of inhibition are still 
unknown. 
1.3.4 Amastigote survival 
Leishmania survives within the microbicidal environment of the macrophage 
phagolysosome by differentiating into its highly adapted form, the amastigote. 
Amastigotes are the disease-causing mammalian stage of the parasite life cycle. 
The amastigote form is rounded with a non-emergent flagellum. In addition to 
resisting the microbicidal assault of the macrophage, it is evident that the 
amastigote adapts the niche itself in order to survive (Podinovskaia & Descoteaux 
2015). However, the mechanisms responsible for these adaptations to the niche are 
still poorly understood, but release of specific virulence factors has been 
elaborated in some studies and is a key area of investigation into the host-parasite 
interaction. 
The adaptations the parasite undergoes to enable its survival in the acidic 
phagolysosome environment have been investigated. The amastigote stage is 
optimised to the more acidic environment of the PV lumen, for example they 
express surface metalloproteinases which have an optimum pH of ~5.5-6.0 
(Zilberstein & Shapira 1994) and transport of glucose, and many other nutrients, 
are optimised to an acidic pH in amastigotes (Burchmore & Barrett 2001; Burchmore 
& Hart 1995). The parasite cytosol, however, is not acidic. The amastigote 
maintains a steep transmembrane pH gradient between its cytosol and the PV by 
expression of stage-specific proton pumps in the plasma membrane (Burchmore & 
Barrett 2001; Glaser et al. 1988; Zilberstein & Shapira 1994). 
Evasion of Host Proteases 
Serine peptidase inhibitors expressed by Leishmania act as virulence factors. 
Inhibitor of serine peptidase 2 (ISP2) is expressed in L. major metacyclics and 
amastigotes and inhibits a serine peptidase expressed by neutrophils, monocytes 
and macrophages (Goundry et al. 2018). The PV is also rich in hydrolytic enzymes 
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such as acid phosphatases, trimetaphosphatases A and B, β-glucuronidases, and 
cathepsins B, D, H and L (Antoine et al. 1998). Amastigotes are able to resist host 
proteases in the PV and have been found to contain high levels of host-derived 
glycosphingolipids in their plasma membrane, which could potentially act as a 
physical barrier to the host proteases (McConville & Blackwell 1991). Proteinase 
GP63 in the parasite membrane protects it from degradation in the phagolysosome, 
demonstrated by coating liposomes with gp63 resulting in their protection from 
phagolysosomal degradation (Chaudhuri et al. 1989). 
Evasion of Nutriprive and Active Nutrient Salvage 
In addition to the microbicidal mechanisms above, macrophages deprive the 
pathogens within the PV of nutrients; this is the nutriprive hypothesis (Appelberg 
2006). The parasites are competing with several nutrient transporters, lysosomal 
transporters which become associated with the PV during phagosome maturation. 
For example, host transporters gradually deplete iron from endosomes and 
lysosomes to avoid toxicity, but this too depletes iron availability for the parasite 
for essential cofactor functions (Huynh & Andrews 2008). The amastigote has many 
transporters of essential nutrients to overcome this, for example: 
nucleoside/nucleobase transporters (Dean et al. 2014); hexose transporters 
(Burchmore et al. 2003); iron transporters (Huynh & Andrews 2008); amino acid 
transporters (McConville et al. 2007); aquaporins for the transport of water, 
polyamines, biopterin, folate etc (Burchmore & Barrett 2001; McConville et al. 
2007). The parasite can also perform gluconeogenesis and de novo synthesis of 
inositol and mannose as the supply of hexoses in the PV is poor (Naderer & 
McConville 2008). L. amazonensis was also found to inhibit expression of the 
mammalian iron exporter ferroportin in macrophages to prevent iron export and 
promote its own intracellular growth (Ben-Othman et al. 2014). Although the 
mechanism behind this is still unknown, this is an example of an active modification 
to the phagolysosomal niche that enhances amastigote nutrient salvage. 
In addition to possessing a repertoire of nutrient transporters for nutrient salvage 
from the PV, Leishmania parasites have also been shown to secrete several enzymes 
which are thought to play a role in nutrient salvage. Leishmania are unable to 
synthesise purines de novo and as such produce and secrete a nuclease in L. 
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donovani promastigotes, and also express the nuclease in both axenic amastigotes 
and tissue-derived amastigotes (Joshi & Dwyer 2007). The hypothesis is that this 
secreted nuclease would hydrolyse nucleic acids from the host to facilitate purine 
uptake by the parasite by surface-membrane transporters (Joshi & Dwyer 2007). 
Amastigotes also express several plasma membrane nucleotidases which cleave 
phosphate from the nucleotides, and are thought to be involved in the salvage of 
nucleosides (Hassan & Coombs 1987). 
A similar mechanism has also been described for a Leishmania-secreted lipase. 
Leishmania are opportunistic facultative lipid scavengers, salvaging these 
macromolecules from their host. The secreted lipase would allow the parasite to 
break down lipids to salvage fatty acids from both the mammalian and insect host, 
for use in the synthesis of complex lipids or as substrates for beta oxidation and 
energy metabolism (Shakarian et al. 2010). Fatty acid oxidation can serve as a 
major source of energy in amastigotes as Leishmania can exploit glucose, amino 
acids or fatty acids as carbon sources (Hart & Coombs 1982). In macrophages, 
endocytosed lipoproteins are delivered to late endosomal compartments for 
degradation (Burchmore & Barrett 2001). Cholesterol esters from lipid droplets in 
the cytoplasm are also delivered to lysosomes by autophagy, so-called lipophagy, 
where they undergo lipolysis (Singh et al. 2009). Lipids are therefore available to 
amastigotes in the PV from the endocytosis and autophagic systems. 
Autophagosomes fuse with the endosomal system during autophagy in eukaryotes 
(Huang et al. 2015) and have been shown to fuse with the PV (Schaible et al. 1999) 
which resembles a late endosomal compartment (Russell et al. 1992). 
As demonstrated by the examples above, the autophagic system in macrophages 
appears to be a key process in the supply of cytoplasmic nutrients to the PV. 
Interestingly, autophagy is no longer considered to be a non-selective mechanism, 
for bulk degradation of the constituents of the cytoplasm. Preferential targeting of 
cargo for autophagic degradation has now been demonstrated (Weidberg et al. 
2011). It will be interesting to investigate if, in addition to their secretion of 
enzymes, amastigotes can enhance or alter this process as a mechanism of ‘hand-
delivering’ nutrients to the PV. 
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Evading Antigen Presentation  
The parasites can interrupt MHC class II antigen presentation by the host cell, by 
means of sequestering the complexes within the PV by blocking their egress or by 
internalisation and degradation of the MHC class II molecules (De Souza Leao et al. 
1995). In addition, other molecules in the antigen presentation pathway are also 
endocytosed by L. mexicana and L. amazonensis amastigotes (Antoine et al. 1999). 
In addition to sequestering MHC molecules to evade antigen presentation, 
Leishmania parasites can also actively degrade MHC by secretion of amastigote 
cysteine proteases. Cysteine protease B (CPB) is activated in the flagellar pocket 
and released into the PV where it has been shown to degrade MHC Class II molecules 
(De Souza Leao et al. 1995; Mottram et al. 2004). 
Expansion of the parasitophorous vacuole (PV) 
As discussed above, Leishmania promastigotes produce and secrete number of 
glycoconjugates. L. mexicana amastigotes also secrete an amastigote-specific 
proteophosphoglycan (aPPG) into the PV (Ilg et al. 1995). This was shown to induce 
vacuolisation in macrophages, and is therefore thought to be involved in the 
expansion of the large PVs of the L. mexicana complex (Peters et al. 1997b). The 
secreted aPPG has also been shown to activate and therefore locally deplete 
complement, and so an additional role of the aPPG may be in helping the parasites 
to avoid complement lysis when released from macrophages (Ilg 2000b; Peters et 
al. 1997b). 
Amastigote-mediated evasion of NO killing 
L. mexicana amastigotes may prevent increased NO synthesis, usually formed by 
the conversion of arginine to citrulline and NO, by rapidly depleting the substrate, 
the host arginine pool, via secretion of a parasite-derived arginase(Gaur et al. 
2007). Depletion of the substrate prevents the macrophage from synthesising the 
highly microbicidal molecule NO, thus increasing parasite survival in the PV. 
Interference with host signalling 
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Leishmania subverts the macrophage translation machinery using its cell-surface-
expressed and soluble secreted GP63 protease (Jaramillo et al. 2011). GP63 has 
been shown to cleave a serine/threonine kinase that is involved in regulation of a 
translational repressor molecule, resulting in activation of this translational 
repressor. This interaction promotes parasite survival and proliferation (Jaramillo 
et al. 2011). 
1.4 Protein secretion 
Eukaryotes have differing methods of secreting proteins to the cell membrane or 
extracellular space. The conventional or ‘classical’ secretory pathway, and other 
non-classical secretion mechanisms. The classical secretory pathway, summarised 
in Figure 1-4, is endoplasmic reticulum (ER) and Golgi-dependent. The proteins 
secreted by this pathway contain an N-terminal or internal secretion-signal peptide 
which directs them to the ER during the sorting process. Once in the ER, they are 
trafficked through the ER-Golgi secretory pathway to be released in specially 
coated vesicles (Nickel & Rabouille 2009). Non-classical protein secretion occurs 
independently of the Golgi and/or the ER, summarised in Figure 1-5. Four main 
mechanisms have been proposed for unconventional secretion of soluble 
cytoplasmic proteins: non-vesicular plasma membrane translocation (Zehe et al. 
2006), translocation into and release by secretory lysosomes (Andrei et al. 2004), 
microvesicle shedding (MacKenzie et al. 2001), and capture of the protein from the 
cytoplasm during formation of intracellular endosomes, and exosome release 
thereafter from multivesicular bodies (Nickel & Rabouille 2009). The ESCRT 
(endosomal sorting complex required for transport) pathway consists of three 
complexes (ESCRT‐I, ESCRT‐II, ESCRT‐III) and is a key mediator of MVB biogenesis, 
regulating membrane budding at cell surfaces and at the level of late endosomes 
(Raposo & Stoorvogel 2013). These evolutionarily conserved proteins assemble into 
four multiprotein complexes: ESCRT-0, -I, -II, and -III, which associate with 
accessory proteins (e.g., Alix and VPS4). The ESCRT-0, -I, and -II complexes 
recognize and sequester ubiquitinated membrane proteins at the endosomal 
delimiting membrane, whereas the ESCRT-III complex is responsible for membrane 
budding and actual scission of vesicles (Schmidt & Teis 2012). 
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Figure 1-4 Eukaryotic classical secretion pathway. Image adapted from Nickel & Rabouille 2009. 
 
Figure 1-5 Eukaryotic non-classical secretion pathways. 1. Non-vesicular plasma membrane 
translocation, 2. Translocation into and release by secretory lysosomes, 3. Microvesicle shedding, 4. 
Formation of internal vesicles in endosomes and exosome release from multivesicular bodies. 
Question marks indicate unknown transporter identities. Image adapted from Nickel & Rabouille 2009. 
1.4.1 Trypanosomatid secretion 
There is evidence for the presence of both classical and non-classical secretion 
pathways in Leishmania (Cuervo et al. 2009; Silverman et al. 2008; Stierhof et al. 
1994). The classical secretory pathway appears to be polarised and restricted to a 
small area of plasma membrane, the flagellar pocket (Figure 1-6), at the anterior 
Figure has been removed due to Copyright restrictions. 
Figure has been removed due to Copyright restrictions. 
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pole of the cell. The majority of uptake and secretion in Leishmania is thought to 
be confined to the flagellar pocket as there is a lack of microtubule attachment to 
the flagellar pocket membrane whereas the rest of the cell body is supported by 
closely spaced subpellicular microtubules which are believed to be prohibitive for 
membrane vesicle fusion or fission. This region is where the classical endocytic 
/exocytic machinery is found (McConville et al. 2002; Overath et al. 1997). 
Classical secretion is mediated via the endoplasmic reticulum and the Golgi 
apparatus. The Leishmania endoplasmic reticulum (ER) is made up of functionally 
distinct domains (Figure 1-6), the nuclear envelope (NE), cortical ER and an 
extension of the ER, the transitional ER (tER). The tER has a ribosome-free 
membrane facing the Golgi and is thought to be essential in sustaining high levels 
of lipid and protein transport to the cell surface in rapidly dividing cells (McConville 
et al. 2002). Little is known about the unusual organelle, the lysosome–
multivesicular tubule, thought to be a site where the endocytic and secretory 
pathways converge. The secretion of proteins such as secretory acid phosphatase 
and GP63 have been shown to be Rab1-mediated in L. donovani, a GTPase which 
localises to the Golgi and facilitates the conventional secretory pathway (Bahl et 
al. 2015). 
Non-classical secretion has been proposed for the targeting of hydrophilic acylated 
surface proteins (HASPs) in Leishmania. These proteins have been detected at the 
flagellar pocket and extracellular plasma membrane of the parasites but lack the 
classical N-terminal signal sequence for secretion. Although the exact translocation 
mechanism is unknown, adding the N-terminal region of HASPB to GFP was 
sufficient to target it to the exterior cell surface and as this domain was found to 
direct both N-myristoylation and palmitoylation, the protein export was 
determined to be acylation-dependent (Denny et al. 2000; Stegmayer et al. 2005). 
Furthermore, the acylation process, addition of fatty acid moieties such as 
myristate and palmitate to proteins, was found to be essential for the survival and 
infectivity of trypanosomatids as genetic knockout of N-myristoyltransferase 
compromised virulence (Goldston et al. 2014). 
An exosome-based secretion mechanism has also been suggested in Leishmania 
(Hassani et al. 2011; Silverman et al. 2008, 2010a). This was initially proposed after 
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the visualisation of membrane vesicles on the entire surface of the parasite by 
scanning electron microscopy (SEM), the collection and analysis of which showed 
that they contained proteins (Hassani et al. 2011; Silverman et al. 2008). The 
exocytosis of vesicles from the entire parasite surface, however, was considered 
unlikely due to the subpellicular corset as mentioned above, and the appearance 
of these vesicles in the SEM images may be artefactual as a result of sample 
preparation, or an example of apoptotic blebbing due to cell stress. Despite this, 
exosomal proteins and intact exosomes have been identified in the spent media of 
these parasites, indicating that this process is occurring whether from the flagellar 
pocket or from the entire surface of the parasite. There is additional evidence for 
the subpellicular microtubules not constituting a barrier to exocytosis. The ER has 
been shown to associate with the plasma membrane in Leishmania which 
demonstrates passage through the microtubule corset (Pimenta & de Souza 1985). 
Additionally, other pathogens, for example Toxoplasma gondii, have a stable 
cortical cytoskeleton which was thought to inhibit accessibility to the plasma 
membrane. However, dense granules have been found to penetrate the cortical 
skeletal complex to secrete their contents (McConville et al. 2002; Ngô et al. 2000). 
Therefore bulk secretion of exosomes may represent another method of Leishmania 
secretion, not previously described or thought to occur (Hassani et al. 2011; 
Silverman et al. 2008, 2010a; Silverman & Reiner 2012). 
 
Figure 1-6 Schematic of secretory and endocytic organelles in Leishmania mexicana 
promastigotes. The nuclear envelope (NE) and cortical endoplasmic reticulum (ER) are connected 
to the specialised transitional ER (tER). These are in close proximity to the Golgi apparatus (G) and 
flagellar pocket (fp). Early endosomes (EE) and multivesicular bodies (MVBs) are also pictured, 
anterior to the highly unusual lysosome-multivesicular tubule (L-MVT) which spans the length of the 
parasite. Adapted from McConville et al. (McConville et al. 2002). 
Figure has been removed due to Copyright restrictions. 
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1.5 Proteomics 
The proteome comprises all proteins encoded by a genome within a cell, tissue or 
organism. The proteome has additional complexity compared to the genome due 
to its dynamic nature, responding to change in genetic and environmental factors 
and cues, intensified by the occurrence of post translational modifications of the 
proteins themselves. The overarching goal of modern proteomics is to identify and 
quantify all, or as many as possible, of the proteins associated with a particular 
state, metabolic snap-shot or dynamic change of an organism or a cell type evoked 
by a specific environment, chemical treatment, or altered cell phenotype. 
Moreover, the dynamic range of protein abundance within many proteomes make 
protein studies even more challenging. 
1.5.1 Gel-based proteomics 
Traditional proteomic approaches utilise gel-based methods for protein separation 
and visualisation. Outlined by Laemmli (1970), sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) is a common method for separating 
proteins by electrophoresis using a discontinuous polyacrylamide gel as a support 
medium and sodium dodecyl sulphate (SDS) to denature the proteins. Proteins are 
separated according to size. Although SDS-PAGE is relatively easy to use and has 
low cost, it has low resolution, low accuracy and samples of high complexity are 
unable to be adequately separated. 
To overcome the constraints of SDS-PAGE, researchers moved to 2-dimensional gel 
electrophoresis (2-DE), pioneered by O’Farrell (1975). This technique separates 
proteins from complex samples based on both their isoelectric points and molecular 
weights. In the first dimension, proteins are separated by their isoelectric point 
(pI) by isoelectric focusing (IEF) and in the second dimension they are separated by 
their molecular weight by SDS-PAGE. After separation, proteins can be visualised, 
cut out of the gel, and identified by mass spectrometry (MS) following enzymatic 
processing and chromatography separation. Digestion with trypsin creates peptides 
that can be replicated in silico. For comparative purposes, samples are loaded on 
separate gels and protein spot patterns and spot intensities are compared visually 
using 2D gel analysis software. Despite its powerful resolving capabilities, the 2-DE 
technique lacks reproducibility and is laborious (Delahunty & Yates III 2005). 
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Additionally, there are several challenges for automatic software-based analysis 
such as incompletely separated (overlapping) spots, weak spots/noise, running 
differences between gels, as well as unmatched or undetected spots (Westermeier 
et al. 2008). Nevertheless, many researchers employ 2-DE coupled with MS as a 
standard protocol of proteomics, where automated in-gel digestion of protein spots 
is subjected to subsequent identification of the proteins by MS. 
To overcome issues with reproducibility and gel to gel variation, difference gel 
electrophoresis (DiGE) can be employed. Proteins from different samples can be 
labelled with different size-matched, charge-matched spectrally resolvable 
fluorescent dyes (e.g. Cy3, Cy5, Cy2) and then mixed, making it possible to directly 
compare different samples on a single gel. Interesting spots with differential 
fluorescent intensity between the dyes are cut from a preparative gel, run in 
parallel to the analytical gel, after staining with Coomassie Blue in order to allow 
protein identification by MS analysis (Westermeier et al. 2008). Limitations of this 
method include: it is a time-consuming technique, and limited sensitivity, which as 
a consequence, proteins with a low concentration may fail to be selected for 
further analysis and subsequently missed (Ünlü’ et al. 1997). It requires large 
amounts of protein sample for adequate identification by MS and for required 
replicates, along with multiple sample preparation steps which can result in loss of 
sample (Anand et al. 2017). 
1.5.2 Gel-free proteomics 
Gel-free proteomic methods and technologies are typically employed in studies 
dealing with complex protein samples, where gel approaches are unsuitable for the 
analysis of low concentrations of proteins within the sample to minimise protein 
loss. These methods typically employ direct proteolysis of the sample to produce 
peptides, followed by chromatographic separation coupled with MS analysis of the 
peptides, without prior in-gel separation. 
Shotgun Proteomics  
Shotgun proteomics is the untargeted analysis of a proteome, whereby in theory, 
the entire proteome is sampled and analysed. In shotgun proteomics, the aim is to 
provide an untargeted analysis of a proteome, following protein digestion into 
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peptides, which can then be separated using LC and analysed using MS (Matallana-
Surget et al. 2010). Peptide digestions use proteolytic enzymes, typically trypsin 
which has high cleavage specificity, cleaving exclusively at arginine and lysine 
residues, to digest proteins into peptides before MS analysis. This allows a database 
of protein sequences of the target organism to be experimentally cleaved in silico, 
allowing fragmentation spectra to be matched to expected values. In 
Multidimensional Protein Identification Technology (MudPIT), complex proteome 
samples are enzymatically digested with the creation of a large number of peptides 
which are then separated by 2-dimensional liquid chromatography (LC) before 
being analysed using MS/MS (Wolters et al. 2001). 
Liquid Chromatography (LC) 
LC is used for separation of peptides following proteolysis. It is employed to reduce 
complexity in samples as many discrete peptides can have similar molecular 
masses, producing a single peak of overlapping peptides in the MS spectrum 
(Karpievitch et al. 2010). It also increases the overall dynamic range of the peptides 
measured. Separation of peptides is typically carried out by reversed phase (RP) 
chromatography using C18 columns. However, strong cation exchange (SCX) 
chromatography can be utilised prior to RP to increase the separation of peptides 
in a 2-dimensional liquid chromatography analysis. 
Ionisation and mass spectrometry (MS) 
After peptide separation using LC, MS can be used in to determine the accurate 
mass of the peptides in the fractions, thus creating a peptide mass fingerprint. The 
initial stage of MS is ionisation. Different methods of ionisation exist with 
electrospray ionisation (ESI) commonly employed. ESI results in charged molecular 
ions of peptides in a gas-phase created from highly charged liquid solvent droplets 
and a high electric field. These ions then pass into the mass spectrometer. 
Following ionisation, a mass analyser coupled with a detection system, detects 
charged species and can resolve ions according to their mass to charge ratio. 
Furthermore, tandem mass spectrometry (MS/MS) can be utilised, whereby ions are 
formed and analysed in the first instant by mass to charge ratio, but the most 
abundant precursor ions are then selected and fragmented by collision induced 
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dissociation or other means and then detected. Peptide sequencing is then possible 
in comparison to a parent peptide library of known proteins via database searching 
1.5.3 Quantitative MS-based proteomics 
Quantitative proteomics aims to not only identify proteins in a given proteome but 
provide quantitative analysis between proteins present. This allows for changes in 
protein abundance to be studied, for example in response to environmental or 
genetic changes, such as drug treatment or between different cell phenotypes.  
Label-free quantitation is a relatively straightforward method for performing 
quantitative proteomics as it does not require any labelling of proteins. 
Consequently, it is more cost-effective and sample preparation is less time 
consuming than with label-based methods. The quantitation in label-free 
approaches comes from recording precursor signal intensity or spectral counting, 
whereby the signal intensity of a peptide precursor ion is measured or the number 
of fragmentation spectra are counted, respectively (Anand et al. 2017; Wong & 
Cagney 2010). The exponentially modified protein abundance index (emPAI) is a 
spectral counting quantification method, where, in simplified terms, the number 
of observed peptides is divided by the number of theoretically observable tryptic 
peptides for each protein (Ishihama et al. 2005). There are many other methods of 
label-free quantitation, and their strengths lie in their ability to be applied to any 
proteomics sample. A disadvantage of LFQ is run to run variation as samples are 
run separately, resulting in low replicate precision. Technical variation in the 
preparation of samples must be kept to an absolute minimum as there is no sample 
combination in this method. LFQ also requires more instrument time with the 
addition of more comparisons, unlike label-based methods which can be 
multiplexed. 
Label-based quantitation approaches involves the incorporation of stable-isotopes 
into one or more of the samples being investigated. Labels such as 3H, 13C, 15N and 
18O are chemically or metabolically incorporated into peptides or proteins. These 
isotope labels can then be detected and enable discrimination between labelled 
and unlabelled proteins. Through calculation of the label ratio, quantitation can 
be achieved and information regarding protein abundance can be generated.  
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One approach is Stable Isotope Labelling by Amino acids in Cell culture (SILAC). 
This approach incorporates stable-isotope-labelled amino acids into the cell culture 
medium to metabolically label the cells (Ong & Mann 2007). Dimethyl labelled, 
extracted proteins are digested with trypsin and differentially labelled with 
formaldehyde or deuterated formaldehyde. Chemical reductive amination of all 
primary amines, the N-terminus and ε-amino groups of L-lysine residues, is 
performed (Hsu et al. 2003). Differentially labelled peptide samples are 
subsequently combined and analysed by MS/MS. The labelling generates a mass 
increase of 28 Da and 36 Da in the light- and heavy-labelled peptides, respectively. 
Since stable isotope dimethyl labelling occurs at the peptide level, and not at the 
protein level as the SILAC labelling does, the sample preparation is prone to the 
introduction of more technical errors which could result in possible sample loss and 
variability. SILAC allows sample combination at the protein level which in theory 
should provide more precise and reproducible quantitative results. Other label 
approaches include Isotope-coded affinity tags (ICAT) (Gygi et al. 1999), and 
isobaric tags such as Isotope tags for relative and absolute quantification (iTRAQ) 
(Ross et al. 2004), or tandem mass tags (TMT™) (Thompson et al. 2003), whereby 
peptides are labelled with tags of the same nominal mass which cleave during 
fragmentation producing reporter ions with differing mass allowing quantitation in 
in MS/MS spectrum. This approach provides a more accurate quantitative 
comparison between replicates than other previously described approaches. 
1.5.4 Secretomics 
Secretomics is the study of all the proteins and small molecules secreted by a cell. 
The term secretome was first used in the literature in 2000, and was used to 
describe all the genes in the Bacillus subtillis genome which were identified as 
containing a secretory signal peptide sequence (Tjalsma et al. 2000). In the 
absence of established proteomic methods to study secretomes, they were 
originally identified by genome-wide searches for secretory-signal peptide 
sequences. However, this did not take into account those proteins which are 
secreted by non-classical mechanisms. Additionally, genome-based and mRNA 
based studies are not always reliable measures of protein expression as there are 
always discrepancies between the levels of mRNA expression and respective protein 
expression. This is particularly relevant for Leishmania as the regulation of gene 
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expression in these parasites is largely post-transcriptional (Clayton 2002). 
Proteomics is therefore considered to be a more representative method of 
investigating the Leishmania secretome. Metabolomics is a complementary 
technique that could be applied alongside proteomics, to look for different types 
of secreted molecules and additionally with the possibility of assessing secreted 
enzyme function. Secretomics is a powerful technique in cancer studies in the 
search for secreted biomarkers and for investigations of cell-to-cell signalling and 
the molecular mechanisms of carcinogenesis (Lin et al. 2013; Xue et al. 2008). 
Further to this, secretomics is also used to identify secreted virulence factors in 
the search for drug and vaccine targets for pathogens such as parasites and bacteria 
(Antelmann et al. 2001; Braga et al. 2014). 
1.5.4.1 Secretomic studies in Leishmania 
Several secretomic studies have been performed for global analysis of protein 
secretion in Leishmania. These analyses comprise promastigote exoproteomes of 
L. donovani (Silverman et al. 2008), L. braziliensis (Cuervo et al. 2009), L. 
mexicana (Hassani et al. 2011) and L. infantum (Braga et al. 2014; Santarém et al. 
2013b), performed using exponential phase (Braga et al. 2014; Cuervo et al. 2009), 
and stationary phase (Hassani et al. 2011; Silverman et al. 2008) promastigotes. 
Relatively few classically secreted proteins were detected in the exoproteome of 
Leishmania, with only ~5% containing a classical secretion signal in L. braziliensis 
(Cuervo et al. 2009), 9% in L. donovani (Silverman et al. 2008), and 6% in the L. 
infantum secretome (Braga et al. 2014), demonstrating that alternative secretion 
mechanisms must be used by the parasites. Known eukaryotic exosomal proteins 
were also detected from L. donovani, which suggests a method of vesicle-based 
secretion (Silverman et al. 2008). A comparative analysis of three of the secretome 
studies found that the average molecular weight per protein is lower than in the 
intracellular proteomes. The average isoelectric point of the exoproteomes is also 
lower than in the proteomes of the parasites (Peysselon et al. 2013). Bias towards 
a lower pI could indicate their increased stability in the acidic conditions of the PV, 
and their lower molecular weight would facilitate their secretion. 
The exoproteomes in all but one of these studies were obtained by a short 
incubation in serum-free growth media (Braga et al. 2014; Cuervo et al. 2009; 
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Hassani et al. 2011; Silverman et al. 2008). There are inherent problems associated 
with this method, however. These stressful conditions may modify the secretome 
and cause a different protein profile as would be seen in vivo and may additionally 
induce cell death and introduce intracellular protein contamination into the culture 
media. It is therefore essential to minimise these stresses as far as possible by 
assessing and reducing incubation times in the serum-free media and slowing 
centrifugation speeds to obtain the cell-free spent media. The studies all attempt 
to monitor and quantify the amount of cell death in the cultures to exclude any 
low levels of intracellular proteins contamination from the analysis. This was done 
by a combination of cell viability monitoring by cell counting or flow cytometry, 
intracellular marker enzymatic assays, for example using glucose-6-phosphate 
dehydrogenase (Silverman et al. 2008) and exclusion from the proteomic data 
proteins which fell below a threshold set by the abundant intracellular contaminant 
histone H2B (Silverman et al. 2008). 
Global functionality was also assessed in some of the studies, for example by 
exposing the L. mexicana temperature-induced exoproteome to macrophages. This 
induced cleavage and activation of some host proteins, and also inhibited nitric 
oxide production (Hassani et al. 2011). 
1.5.4.2 Secretion of exosomes 
As mentioned above, there is compelling evidence for the existence of bulk 
exosome secretion in Leishmania and Trypanosoma species (Atyame Nten et al. 
2010; Silverman et al. 2010a). Hassani et al. observed budding of surface 
exovesicles in response to an increase in temperature from L. mexicana 
promastigotes (Hassani et al. 2011). This observation gives rise to a potential 
function of promastigote exosomes for priming of macrophages after entry to the 
host in the sand fly bite and the subsequent change in environmental conditions. 
Secretion of exosomes containing GP63 and EF-1α by Leishmania were found to 
influence the macrophage response (Silverman & Reiner 2012). The exosomes were 
shown to directly interact with naïve host cells (Silverman et al. 2010a) and have 
immunomodulatory properties such as promoting enhanced IFN-γ induced IL-10 
production to direct macrophage activation towards an infection-promoting profile 
(Figure 1-7) (Silverman et al. 2010a; Silverman & Reiner 2012). 
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Figure 1-7 Schematic of proposed outcomes of Leishmania promastigote exosomal secretion. 
Promastigote exosomes containing GP63 and EF1α play an immunomodulatory role by directing 
macrophage activation towards an anti-inflammatory response. Image adapted from Silverman & 
Reiner, 2012(Silverman & Reiner 2012)  
Figure has been removed due to Copyright restrictions. 
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1.6 Summary and Aims 
To summarise, it is evident that both life cycles stages of Leishmania secrete 
effectors which play many different roles in parasite survival in the host, from 
immunomodulation, to nutrient salvage, to physical modification of the PV. In many 
cases, particularly with the amastigote stage, the modulatory effect the parasite 
has on the host cell has been deduced but the parasite-derived mechanism or 
effector has not yet been identified and our knowledge of these amastigote-host 
interactions is still very limited. 
In addition to furthering our knowledge on the cell biology of these parasites and 
their interactions with the mammalian host, particularly in the medically relevant 
disease-causing stage, studying factors secreted by the pathogen is highly 
significant, as exogenous factors represent a source of antigens for the 
development of vaccines, and essential and parasite-specific proteins and pathways 
are potential targets for drug development. 
The overall aim of this project is to identify mechanisms by which Leishmania 
promastigotes and amastigotes might enhance their nutritional environment, their 
surroundings for survival or augment macrophage signalling by examining the 
secretion of proteins. Following on from previous secretomics work on 
promastigotes of L. donovani, L. braziliensis, L. mexicana and L. infantum (Braga 
et al. 2014; Cuervo et al. 2009; Hassani et al. 2011; Santarém et al. 2013b; 
Silverman et al. 2008), these methods will be utilised and adapted to define the 
secretome of axenic amastigotes to begin to understand the mechanisms by which 
amastigotes may modify their niche within the macrophage by secretion of 
proteins. The secretome of promastigotes and amastigotes will be isolated to 
facilitate a comparative analysis which should illustrate the hypothesised 
differences between the two lifecycle stages due to their inherent differences in 
environment and target proteins. Furthermore, comparison of the secretome of 
parasites with differing phenotypes with respect to virulence and disease outcome 
will shed light on key secreted effectors in parasite pathogenicity. 
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 Materials & Methods 
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2.1 Materials 
All reagents and chemicals were purchased from Sigma-Aldrich, Dorset, UK, unless 
stated otherwise. 
2.2 Parasite culture 
The species and strain of Leishmania used in this study was L. mexicana M379. For 
storage, mid log phase promastigotes in culture were cryopreserved 1:1 in 70% 
heat-inactivated foetal bovine serum (HiFBS) (Life Technologies) / 30% glycerol. 
Promastigote parasites were recovered and cultures were expanded in 
haemoflagellate minimal essential medium (HOMEM) (GE Healthcare) 
supplemented with 10% FBS (cHOM) at 25°C, and maintained in logarithmic phase 
culture by routine passage every 2-3 days. Axenic amastigotes were cultured in 
Schneider’s Drosophila Medium (Gibco) adjusted to pH 5.5 supplemented with 20% 
FBS and 3ml of 2.5mg/ml haemin in 50mM NaOH (cSDM). Amastigotes are 
transformed from promastigotes by placing 1 x 106 cells/ml late log/stationary 
phase promastigotes in cSDM and incubating at 32°C with 5% CO2, and were 
maintained in culture by weekly passage. For experiments using defined growth 
media (NM, (Nayak et al. 2018)), the parasites were washed 3 times to remove 
residual serum and sub-cultured into the defined growth medium. Parasite growth 
was monitored by counting using a haemocytometer by diluting 1:1 in 2% 
formaldehyde, followed by placing 10 µl of the fixed cells on a Neubauer 
haemocytometer. Following cell counting, a parasite growth curve could be 
formulated by plotting cell number vs. culture time. 
Doubling time = 
𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛∗log⁡(2)
𝑙𝑜𝑔(𝐹𝑖𝑛𝑎𝑙𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)−𝑙𝑜𝑔(𝐼𝑛𝑖𝑡𝑎𝑙𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
 
Parasite viability was assessed by counting before and after 4 h serum-free 
incubation using the Trypan Blue dye exclusion method as previously described 
(Cuervo et al. 2009). The cells were counted using a haemocytometer, as described 
above. 
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2.3 Alamar blue assay 
An alamar blue metabolic assay was also employed to quantify the viability of the 
parasites after incubation in the medias, using a modified transformation assay 
(Jain et al. 2012). Briefly, viable axenic amastigotes were cultured in cSDM and 
prepared by washing in PBS and sfSDM. The parasites were then split to the same 
density across four medium types and incubated in a 96-well plate for 4 hours at 
32.5°C. After incubation, the amastigotes were recovered from the medias by 
centrifuging and the medium replaced with cHOM to transform any live amastigotes 
to promastigotes. The plate was then incubated at 25°C for 48 hours. Parasite 
viability was evaluated by the addition of 10 µl resazurin dye, followed by 
incubation for a further 24 hours. Plates were read for standard fluorescence using 
a PHERAstar FSX microplate reader (BMG Labtech) at 544 nm excitation, 590 nm 
emission. 
2.4 Secreted protein isolation 
For secretion assays, ~5-10 x 109 parasites were harvested from two 150 ml late log 
/ stationary phase cultures by centrifugation at 1000 ×g for 10 min in a bench top 
centrifuge. The parasite pellet was then washed three times to remove residual 
serum using pre-warmed PBS by centrifuging as above. The parasites were 
resuspended to a density of 1 x 108 cells/ml in pre-warmed serum-free media and 
incubated for 4 h at 25°C or 32°C with 5% CO2 for promastigote and amastigote 
cultures, respectively. Secreted parasite proteins in the spent culture supernatant 
were isolated by pelleting the parasites at 700 xg for 20 min at 4°C in a bench top 
centrifuge. The supernatant was collected, kept on ice and protease inhibitors 
were added (E64 10 µM E64, 5 µg/ml Pepstatin A, 2 mM 1,10-phenanthroline, 500 
µg/ml Pefabloc, 100 µg/ml leupeptin, 1 mM EDTA). The supernatant was then 
further clarified by centrifugation at 3200 xg for 30 min at 4°C in a bench top 
centrifuge. 
The proteins in the supernatant fraction were then concentrated down to 10 ml 
using Vivaspin® 20 10 kDa MWCO centrifugal filters (Vivaproducts, Littleton, MA, 
USA), by loading 14 ml at a time and centrifuging at 8000 xg, 4 °C, in a HeraeusTM 
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MegafugeTM bench top centrifuge with fixed rotor (Thermo Scientific, Waltham, MA, 
USA) for 45 min and then reloaded. 
As an alternative protein concentrating method, a carrier assisted TCA method was 
utilised. The clarified supernatant was kept on ice and then 10% (w/v) sodium 
lauroylsarcosinate solution (sarkosyl and dH2O) was added to a final concentration 
of 0.1% and mixed by vortexing briefly. Ice cold 100% (w/v) TCA solution (TCA and 
dH2O) was then added to a final concentration of 7.5% and incubated on ice for 2 
h. Following incubation, the mixed protein-detergent precipitate was centrifuged 
at 10 000 xg for 10 min, 4 °C using a bench top centrifuge. The supernatant was 
then removed and the protein pellet washed with tetrahydrofuran by resuspending 
in 10 ml of ice-cold tetrahydrofuran by vortexing. This wash was then repeated 
leaving a protein pellet. Finally, the pellet was dissolved in 100 µl 1x  laemmli 
buffer (2% SDS, 10% Glycerol, 62.5 mM Tris-Cl pH 6.8), using bath sonication for 30 
min.  
Acetone precipitation was performed by addition of four times sample volume of -
20°C acetone and incubation at -20°C for >1hr to overnight. The resulting 
precipitate was pelleted by centrifugation at 10,000 xg for 10 min at 4 °C. The 
pellet was washed in 80% acetone in dH2O at -20 °C and pelleted again as above. 
2.5 Whole cell protein lysate collection 
The cell pellets from the spent media collection are also retained and used to 
produce whole cell lysate samples. After pelleting and supernatant removal, the 
cells were washed twice in 1x PBS and collected by centrifugation at 1000 xg for 
10 min at 4°C in a bench top centrifuge. The cells were then lysed by resuspension 
in 1x laemmli buffer with protease inhibitors (2% SDS, 10% Glycerol, 62.5 mM Tris-
Cl pH 6.8, 200 mM DTT, 2 mM 1,10-Phenanthroline, 1 mM EDTA, 10 µM E-64, 500 
µg/ml Pefabloc, 100 µg/ml leupeptin, 5 µg/ml Pepstatin A) and probe-sonicated on 
ice for 1 sec, 3 times. The protein extracts were then clarified by centrifugation at 
14,000 xg for 10min at 4°C using the HeraeusTM centrifuge described above and 
precipitated in 100% acetone as described above, followed by two washes in 80% 
acetone and stored at -20°C . 
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2.6 Protein assay 
For measurement of the secretome protein concentration, the Biorad DC Protein 
Assay was used in conjunction with the low-concentration assay (Table 2-1), 
adapted for use with the Nanodrop spectrophotometer. 
Protein assay standards ranging from 5–250 µg/ml protein were made using BSA in 
1x RIPA buffer. Only 4 µl of sample or standard are required per assay, which is 
mixed with a reagent mix and then absorbance measured at 750 nm, from triplicate 
samples. 
Table 2-1 Detergent compatible (DC) Protein Assay (BioRad) recommended concentrations 
and reagent volumes. 
Protein 
Concentration 
Test Tube Microplate Nanodrop 
High-concentration 
assay 
0.2–1.5 mg/ml protein 0.2–1.5 mg/ml protein - 
 
100 µl sample 5 µl sample - 
 
500 µl reagent A 25 µl reagent A - 
 
4.0 ml reagent B 200 µl reagent B - 
Low-concentration 
assay 
5–250 µg/ml protein 5–250 µg/ml protein 5–250 µg/ml protein 
 
200 µl sample 20 µl sample 4 µl sample 
 
100 µl reagent A 10 µl reagent A 2 µl reagent A 
 
800 µl reagent B 80 µl reagent B 16 µl reagent B 
 
2.7 1D SDS-PAGE  
For 1-dimensional gel electrophoresis, protein samples were mixed 1:4 with 4x 
laemmli sample buffer with protease inhibitors (2% SDS, 10% Glycerol, 62.5 mM 
Tris-Cl pH 6.8, 200 mM DTT, 2 mM 1,10-Phenanthroline, 1 mM EDTA, 10 µM E-64, 
500 µg/ml Pefabloc, 100 µg/ml leupeptin, 5 µg/ml Pepstatin A). Following this, 
0.002% bromophenol blue was then added to each sample and the protein samples 
and molecular weight (MW) marker (New England Biolabs, Ipswich, MA, USA) were 
then heated to 60°C for 5 min to denature. ~10 µg of protein was then separated 
by SDS-PAGE using 4-20% gradient polyacrylamide gels (BioRad) run at 40 mA per 
gel using the Mini-PROTEAN TetraCell system (BioRad). After running, the gels were 
washed in Milli-Q® deionised water (ddH2O) to remove residual SDS, and stained 
with colloidal Coomassie G-250 according to Kang’s method for increased 
sensitivity(Dyballa & Metzger 2009). Coomassie stained gels were imaged using a 
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G:Box (SynGene, Cambridge, UK) with combined transilluminator and upper white 
light, and GeneSnap software (SynGene). Or gels were stained using the Pierce™ 
Silver Stain Kit (Thermo Fisher) according to the manufacturers instructions. 
2.8 Western blotting 
Antibodies to Leishmania HASPB, EF1a and OPB were kindly gifted by Prof. Jeremy 
Mottram, U of York. Antibodies to Leishmania GP63 monoclonal and polyclonal 
antisera, secretory acid phosphatase and cysteine protease were kindly gifted by 
Dr Martin Wiese, U of Strathclyde. Antibodies to ENO, GDH and B-Tub KMX were 
kindly gifted by Prof Michael Barrett and Dr Tansy Hammarton, U of Glasgow. 
For Western blot analysis of secreted material, 0.3 µg of secretome in LDS sample 
buffer (Expedeon) was resolved on 4-20% RunBlue SDS protein gels using a TEO-
tricine-based buffer system (RunBlue™, Expedeon). Samples were then transferred 
to a PVDF membrane and membranes blocked with 5% skimmed milk powder in PBS-
T (0.05% Tween 20) prior to probing with primary antibodies. Bound antibody was 
detected using anti-mouse, anti-sheep or anti-rabbit secondary antibodies 
conjugated to horseradish peroxidase (Invitrogen). Membranes were imaged using 
the Pierce™ ECL Plus Substrate (Thermo Fisher) and chemiluminescence imager. 
2.9 2D electrophoresis 
Here, 2 types of 2D electrophoresis were performed, namely: difference gel 
electrophoresis (DiGE), for the comparison of two proteomes; and preparative gels. 
2.9.1 Gel casting using the Ettan DALT system 
To cast the 24 cm acrylamide gel, first the bottom gel plate was treated with a 
1:1000 dilution of bind-silane solution (bind-silane in ethanol/acetic acid/dH2O). 
The solution is rubbed on the surface of the plate until dry after which the plate is 
left to further air dry for 1 h. Following drying the plates were polished with 70% 
ethanol and then left to air dry for 30 mins. Once the plates were dry the plates 
were placed and aligned together. White guide spots were placed over the spot 
markers on the inside of the plate. 
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The acrylamide was prepared in dH2O and stored at 4°C. All reagents were then 
mixed and filter sterilised prior to use. To cast the gels, an Ettan DALT gel casting 
tank was used to cast up to 6 gels at once.  Immediately prior to casting, the temed 
was added to the acrylamide mixture and mixed by inversion. Following this the 
acrylamide mixture was poured into the casting tank. After pouring the acrylamide, 
1ml of water saturated butanol was pipetted in between the plates of all six gels 
on top of the acrylamide, providing a thin protective layer on top of the gel to level 
the acrylamide. The gels were then left to polymerise for 2 h after which the tank 
was dismantled and excess gel was removed from the outside of the plates. Plates 
containing the gels were kept wet and stored at 4°C prior to using.  
2.9.2 Difference gel electrophoresis (DiGE) sample preparation 
Samples were initially thawed on ice. To check the pH of the samples was within 
the alkaline range, required for DiGE to be successful, the Litmus test was 
performed by placing a small aliquot of sample onto a piece of Litmus paper. For 
DiGE, 10µl of each sample to 1 µl CyDyes was used to allow for the correct ratio of 
protein to dye. If the samples were too concentrated they were diluted before use 
to ~5 µg/µl in rehydration buffer. 50 µg of each sample was therefore added into 
the appropriate CyDye. Following incubation with the CyDyes, 1 µl of lysine was 
then added to each tube and incubated for 10 minutes to quench the reaction. 
Samples were then ready for IPG strip rehydration. 
For isoelectric focussing, samples were prepared by placing the sample into a fresh 
Eppendorf and making up to a total volume of 460 µl with rehydration buffer. 
Preparative gels were run simultaneously by adding 250 µg of each protein sample 
to be separated and compared on one gel, into a fresh Eppendorf and mixed by 
vortexing (250 µg of protein sample 1 + 250 µg of protein sample 2 = 500 µg of total 
protein). The total volume was made up to 460 µl with rehydration buffer. 
2.9.3 Isoelectric focussing (1st dimension) 
IPG strips were stored at -20°C. When required for use the strips were placed in 
strip coffins where protein samples with rehydration buffer were distributed evenly 
along the length of the strip. A coffin lid was then placed on top and the coffin was 
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incubated at room temperature for 30 mins to allow rehydration. After incubation 
the strips were overlaid with 1 ml of mineral oil (dry strip cover fluid). The coffins 
containing the strips were then placed in the IPGphor isoelectric focusing unit set 
to reach a maximum of 80,000 volt/hours. Isoelectric focusing was performed in 
the dark due to the light sensitivity of some samples. Following isoelectric focussing 
the strip was removed from the coffin using forceps and blotted to remove excess 
mineral oil. The strip was washed by dunking in 1x running buffer twice. 
To equilibrate the strips following isoelectric focusing, the strips were placed into 
a strip tube and 10 ml of SEB with DTT (10 mg/ml) was added. The tube was then 
shaken on its side ensuring complete coverage of the strip at 75 RPM for 15 mins.  
After equilibration the SEB+DTT was poured off and replaced with 10 ml SEB with 
IAA (25 mg/ml), and shaken again for 15 mins. 
2.9.4 Molecular weight separation, SDS-PAGE (2nd dimension) 
For the second dimension, molecular weight separation the IPG strip is placed along 
the runway of a gel plate containing a cast gel. The strip was then pushed down to 
make contact with the DALT gel edge. 1 ml of agarose was then used to seal the 
strip onto the top edge of the gel. Following strip attachment to the gels the gels 
were placed in the running tank containing 1x running buffer. The gels were run in 
darkness if samples were light sensitive, as in the case of DiGE samples. The gels 
were run over night until the dye front reached the bottom of the gel. Following 
separation, gels were stored moist at 4°C until analysis. If gels were required to be 
stained and imaged, for example preparative gels, the plates were separated and 
the gel bound to the bottom plate was placed in fixing solution. Once fixed the gel 
was stained with either Coomassie or Sypro orange. 
2.9.5 Gel imaging 
Images of the gels were taken with the Typhoon 9400 Series Variable Mode Imager 
using the following settings: for Cy3, 532 nm excitation laser and 580 BP 30 emission 
filter; for Cy5, 633 nm excitation laser and 670 BP 30 emission filter. The resulting 
images were processed using DeCyder Differential Analysis software v5.0. The 
experimental design and relationship between samples was assigned in DeCyder. 
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The protein spots were filtered to include only proteins that demonstrated a 
significant change in abundance (p < 0.005). 
2.10 Spot Picking and Processing 
Protein spots were selected and automatically picked from the preparative and 
DiGE gels using the Ettan spot picker (GE Healthcare). Spots were stored in ddH2O 
until processing. Following protein spot picking, the dH2O was removed and the gel 
pieces were washed in 50 µl of 100 mM ammonium bicarbonate and then 150 µl of 
50% acetonitrile/100 mM ammonium bicarbonate, each for 1 h, at room 
temperature, shaking at 120 RPM, on a bench top shaker. After discarding the final 
wash, the gel pieces were then shrunk by adding 50 µl of acetonitrile for 10 mins. 
The solvent was then removed and the gel piece was dried in a vacuum centrifuge 
(SPD1010 SpeedVac, Thermo Scientific). A vial of trypsin was resuspended in 1 ml 
of 2 mM ammonium bicarbonate. Sufficient trypsin, 10 µl at a time, was added to 
the dried gel pieces in order to rehydrate the gel. Once the gel piece had appeared 
fully hydrated and swollen to its previous size the digest sample was incubated for 
12 h at 37 °C. Following incubation, all liquid from the protein digestion was 
transferred to a fresh V-bottom 96 well sample plate. To this 20 µl of 5% formic 
acid was added to the gel pieces and incubated for 20 mins on a bench top shaker 
set at 75 RPM. After incubation 40 µl of acetonitrile was added to the formic acid 
and incubated once again on the shaker for a further 20 min. after 20 mins all liquid 
was transferred to a fresh plate. Samples were pooled if previously separated. 
Samples were the dried down in a vacuum centrifuge as above and stored at -20°C 
until analysis. 
2.11 Trypsin digestion 
The gel-free protein samples were processed for LC-MS/MS analysis using the filter-
aided sample preparation (FASP) method (Expedeon). The protein samples 
solubilised in 1x laemmli buffer with DTT, were heated at 60°C for 5min to 
denature and reduce the proteins. ~100µg of protein was then loaded into a 30 kDa 
MWCO filter (Microcon YM-30) and centrifuged at 14,000xg for 15min. The proteins 
are washed and buffer exchanged on the membrane with 200µl 8 M urea in 0.1 M 
Tris–HCl pH 8.5 followed by centrifugation as above. The proteins are then alkyated 
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by adding 0.05 M iodoacetamide prepared in urea buffer and incubated for 20 min, 
in the dark. The iodoacetamide is then removed by further centrifugation and 
washing twice with fresh urea buffer. The proteins are then washed three times in 
100µL of 50mM ammonium bicarbonate (ABC) and centrifuged at 14,000 × g for 10 
min. Trypsin is then added to the samples at an enzyme-to-protein ratio of 1:100 
and digested for 24 h at 37°C. After digestion, the filter units were transferred to 
new collection tubes and the tryptic peptides recovered by adding 40µl of 50mM 
ABC followed by centrifugation at 14,000 × g for 10 min. Any filter-bound peptides 
were washed out by adding 50µl of 10% acetonitrile (CAN) to the unit followed by 
centrifugation at 14,000 × g for 10 min. This step eliminates the need for desalting 
of the peptides and the samples can be immediately dried down in the wells of a 
96-well plate ready for LC-MS/MS analysis. 
2.12 TMT™ Labelling 
For multiplex relative quantitation by mass spectrometry, samples were 
differentially labelled using the TMT Mass Tagging kit from Thermo Scientific, as 
per the manufacturer’s instructions with some modifications. Reagents were 
prepared by equilibrating to room temperature. 41 µL of anhydrous acetonitrile 
was added per 0.8 mg of TMT tag reagent and allowed to dissolve for 5 minutes 
with occasional vortexing. 5% Hydroxylamine HCl was prepared by dissolving 50 mg 
of hxdroxylamine HCl in 1 mL of 100 mM TEAB.  
Briefly, equal concentrations of each protein sample were first buffer-exchanged 
and trypsin digested using the FASP kit from Expedeon as described in section 2.11. 
The resulting tryptic peptides for each sample were then resuspended in 100 µl 100 
mM TEAB and 41 µL of the TMT Label Reagent was added to 25-100 µg of digested 
sample. The reaction was incubated for 1 hour at room temperature. The reaction 
was quenched by the addition of 8 µl of 5% hydroxylamine HCl per sample and 
incubated for a further 15 min. The differentially labelled samples could then be 
combined and 6 µg of sample mixture dried down using a SpeedVac (Thermo 
Scientific) for LC-MS/MS analysis. For peptide samples of 25 µg or less, the method 
was adjusted to resuspend the tryptic peptides in 50 µl of 100 µM TEAB, and 18 µl 
of TMT Label Reagent was added to the samples. 
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2.13 Peptide/protein identification by nLC-ESI-MS/MS 
Following FASP to create tryptic peptides, samples were analysed using nanoflow 
HPLC coupled to electrospray tandem mass spectrometry (nLC-ESI-MS/MS). 
Peptides were solubilized in 0.05 % formic acid and fractionated on a nanoflow 
uHPLC system (Thermo RSLCnano) before online analysis by electrospray ionisation 
(ESI) mass spectrometry on an AmaZon ion trap MS/MS (Bruker Daltonics), or the 
Orbitrap Elite (Thermo Scientific) where specified.  
Prior to analysis on the AmaZon Ion Trap, peptide separation was performed on a 
Pepmap C18 reversed phase column (LC Packings), using a 5 - 85% v/v acetonitrile 
gradient (in 0.1% v/v formic acid) run over 45 min at a flow rate of 300nl/min. Mass 
spectrometric (MS) analysis was then performed on the AmaZon Ion Trap using a 
continuous duty cycle of survey MS scan followed by ten MS/MS analyses of the most 
abundant peptides, choosing the most intense multiply charged ions with dynamic 
exclusion for 120s.  
Prior to analysis on the Orbitrap Elite, peptides were desalted and concentrated 
for 4 min on trap column  before being transferred to the analytical column using 
starting solvent conditions (4% solvent B). A water- acetonitrile gradient was used;  
4 - 40% v/v solvent B from 12 - 102 min, 40 % to 100% v/v solvent B from 102.1 - 
116 min, held at 100 % v/v solvent B 116 - 121 min and re-equilibrated at starting 
conditions (4 % solvent B) for a total time of 125 min. Solvent A – Water + 0.1% 
formic acid. Solvent B – 80% acetonitrile + 0.08 % formic acid. A fixed solvent flow 
rate of 0.3 µL / min was used for the analytical column. The Orbitrap Elite acquires 
a high resolution precursor scan at 60,000 RP (over a mass range of m/z 400 - 2000), 
followed by CID fragmentation and detection of the top 20 precursors in the linear 
ion trap. Singly charged ions are excluded from selection, while selected precursors 
are added to a dynamic exclusion list for 180s. 
For TMT-labelled samples, peptides were analysed by LC-MS/MS using the Orbitrap 
Elite. Peptides were desalted and concentrated for 4 mins on the trap column 
before being transferred to the analytical column using starting solvent conditions 
(5% solvent B). A water- acetonitrile gradient was used; 5 - 45% v/v solvent B from 
4 - 154 min, 45 - 100% v/v solvent B 154 - 154.1 min, held at 100% v/v solvent B 
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154.1 - 160 min and then re-equilibrated at starting conditions (5% solvent B) for a 
total time of 165 mins. A fixed solvent flow rate of 0.3 µL/min was used for the 
analytical column as before. The Orbitrap Elite acquired a high-resolution precursor 
scan at 60 000 RP (over a mass range of m/z 380 – 1800) followed by CID 
fragmentation and detection of the top 3 precursor ions from the MS scan in the 
linear ion trap. The 3 precursor ions were also subjected to HCD in the HCD collision 
cell followed by detection in the orbitrap. Singly charged ions are excluded from 
selection, while selected precursors are added to a dynamic exclusion list for 180s. 
2.14 Mascot 
The Mascot search engine was then used to search the resulting mass spectra 
against an in-house Leishmania protein database obtained from GeneDB to 
generate protein identities. Tandem mass spectra were submitted to database 
searching using the Mascot program (Matrix Science) (Cottrell 2011). Spectra were 
searched against the Leishmania mexicana database LmexicanaMHOMGT2001U1103 
from TriTrypDB.org. Search criteria specified for AmaZon Ion Trap: Enzyme, 
Trypsin; Maximum missed cleavages, 1; Fixed modifications, Carbamidomethyl (C); 
Variable modifications, Oxidation (M); Peptide mass tolerance, 0.4Da; Fragment 
mass tolerance, 0.4 Da. Significance threshold set to 0.05. Search criteria specified 
for Elite Orbitrap: Enzyme, Trypsin; Maximum missed cleavages, 1; Fixed 
modifications, Carbamidomethyl (C); Variable modifications, Oxidation (M); 
Peptide mass tolerance, 0.4Da; Fragment mass tolerance, 0.4 Da. Significance 
threshold set to 0.05. 
Only those identifications over the significance threshold of 0.05 and with a protein 
score of ≥30 were included in the protein list and analysis. The protein score is a 
number calculated by Mascot for every protein match and indicates the confidence 
of the match. Higher scores therefore indicate a more confident match. The score 
is formulated from the combined ion scores of each of the mass spectra matched 
to an amino acid sequence within the protein. These individual ion scores are based 
on the calculated probability, P, that the observed match between the 
experimental data and the database sequence is a random event, with a 95% 
confidence threshold. Peptide matches were excluded from the protein 
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identification when their p-value exceeded the significance threshold indicated for 
an FDR of 1%, or 2% where specified. 
−10 ∗ 𝑙𝑜𝑔10(𝑃) Where P is absolute probability. 
2.15 Following TMT labelling  
Proteome Discoverer™ (Thermo Fisher Scientific) was utilised for processing of the 
raw MS data to annotate and quantitate the peptides and the reporter tags. A strict 
FDR of 0.01 was set in the analysis of identified peptides. 
2.16 Analyses of the L. mexicana secretome 
Proteins were categorised by gene ontology (GO) using the annotations found in 
TriTrypDB (Aslett et al. 2010) (http://tritrypdb.org/tritrypdb/), and distributed 
into categories according to their assigned biological function. Proteins for which 
no annotation was assigned were placed in the unknown category or assigned based 
on sequence homology to annotated proteins in other Leishmania species or based 
on published data if known. Other predicted features of Leishmania proteins such 
as isoelectric point, molecular weight and transmembrane domains were also 
exported from the TriTryp Database. The SignalP 4.1 Server found at 
(http://www.cbs.dtu.dk/services/SignalP/) was used to predict the presence of 
signal peptides. SignalP predicts the presence and location of signal peptide 
cleavage sites in amino acid sequences from different organisms: Gram-positive 
prokaryotes, Gram-negative prokaryotes, and eukaryotes. The method incorporates 
a prediction of cleavage sites and a signal peptide/non-signal peptide prediction 
based on a combination of several artificial neural networks. Proteins with signal 
peptides are targeted to the secretory pathway, but are not necessarily secreted 
(Nielsen 2017). The SecretomeP 2.0 Server found at 
(http://www.cbs.dtu.dk/services/SecretomeP/) was used to predict non-classical 
secretion, with the scoring cut-off set to mammalian. Non-classically secreted 
proteins should obtain an NN-score / SecP score exceeding the threshold, but not 
at the same time be predicted to contain a signal peptide. The recommended 
thresholds are 0.5 for bacterial sequences and 0.6 for mammalian sequences.
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3.1 Introduction 
Secretomics, as defined in Section 1.5.4 of this thesis, is an expanding area of 
research which has been applied to many different single and multicellular 
organisms, and cell types. Secretome studies have been applied to human cells in 
the study of various cancers with the subsequently derived secretome implicated 
in various disease pathologies (Lin et al. 2013; Makridakis & Vlahou 2010; Xue et 
al. 2008). Furthermore, in studies of pathogenic bacteria and parasites, the 
secretome has been shown to be involved in pathogenesis and is therefore a 
promising source of new therapeutic targets (Dwivedi et al. 2016; Hakimi & 
Bougdour 2015; Soni et al. 2016; Szempruch et al. 2016a). In Leishmania, 
secretome studies have been applied to investigate the host-parasite interaction in 
the insect vector, and upon parasite entry to the mammalian host, focusing on 
procyclic (Atayde et al. 2015; Braga et al. 2014; Cuervo et al. 2009; Santarém et 
al. 2013b) and metacyclic (Chenik et al. 2006; Hassani et al. 2011; Silverman et al. 
2008) promastigote populations, respectively. There have been no studies to date 
on the secretome of amastigotes, the intracellular stage that resides in 
macrophages of the mammalian host. 
3.1.1 Axenic cell culture in secretomic studies 
Axenic cell culture systems are methods whereby only a single species or strain of 
cell or organism is present, and mimic as far as possible the in vivo environment of 
the organism (Hine & Martin 2015). These culture systems are particularly useful 
for creating a controlled environment in which to study intracellular pathogens, 
such as Leishmania amastigotes (Bates et al. 1992), free from the host cell. Axenic 
cell culture is highly amenable to secretome studies as it ensures there is no 
interference or interaction from different cell types, and allows ease of separating 
cells from the secretome using separation methods such as centrifugation. The 
methods used for secretome collection vary greatly between different secretome 
studies, dependent on the organism or cell type being investigated, discussed 
below. The methods vary in their starting concentration and number of cells, 
depending on the secretion yield of the cell type, collection method, concentration 
method and further processing. There are, however, problems that must be 
overcome for successful secretome isolation and characterisation. 
Chapter 3  60 
3.1.1.1 Addition of an undefined supplement in cell culture 
Previous secretome studies have highlighted issues with regard to studying the 
secretome (Chevallet et al. 2007). One of the main confounding factors is the 
addition of serum or other animal products, such as brain: heart infusion, to most 
culture media. These supplements introduce heterologous and undefined molecules 
to the extracellular environment such as proteins, electrolytes, lipids and 
hormones (Stein 2007). While the proteins in the supplements could theoretically 
be determined before addition to the media and excluded from secretome results 
during data analysis, they exhibit high batch to batch variation (Stein 2007), thus 
requiring analysis of every batch which is not feasible for routine secretome 
analyses. Another dominant issue is the fact that the abundance of specific proteins 
in these supplements is very high. As much as 6–10 mg/ml total protein has been 
reported in media supplemented with 10% serum (Broedel Jr. & Papciak 2003). The 
abundance of these serum proteins may be high enough to mask proteins of interest 
that are secreted, at a much lower concentration, from the cells under 
investigation. This is a problem particularly when using techniques such as Data-
Dependent Acquisition (DDA) MS analysis to identify the secreted proteins, as this 
technique is confounded by dynamic range because only the most abundant 
peptides in each scan are selected for fragmentation and therefore identification 
(Doerr 2015). 
3.1.1.2 Culturing without serum affects cell viability 
One solution to these issues would be to remove undefined, protein-rich 
supplements from the media. However, many cell types cannot be maintained for 
any significant period of time in a serum-free medium. Suboptimal culture 
conditions may lead to cell stress, decreased proliferation and cell lysis, in turn 
altering the secretome and contaminating it with intracellular proteins (Alcolea et 
al. 2016). As such, previous secretome studies have used methodologies where cells 
are removed from their serum-containing medium, washed and placed into a 
serum-free medium for a short amount of time. The incubation time varies based 
on cell type, from 24-96 hours for many mammalian cell lines (Chevallet et al. 
2007; Makridakis & Vlahou 2010) down to 2-8 hours for Trypanosoma and 
Leishmania species (Atyame Nten et al. 2010; Braga et al. 2014; Cuervo et al. 2009; 
Hassani et al. 2011; Silverman et al. 2008). For cells or parasites such as nematodes 
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which can be maintained in a serum-free medium as part of their general culture, 
samples can be taken at any time point during their culture, with less concern 
about stress or parasite death which may result in the release of molecules that 
would not normally be secreted (Hewitson et al. 2013; Sotillo et al. 2014). For 
those that can only be incubated for a short time their viability in these suboptimal 
conditions must be monitored to ensure excessive cell lysis does not contaminate 
the secretome, and the incubation times adjusted accordingly. However, reducing 
the time in culture reduces the yield of secreted proteins therefore culture volumes 
tend to be increased to compensate for this. 
Beyond studies like these looking specifically at molecules within the culture 
supernatant, concerns with the addition of undefined supplements to culture media 
are far reaching, raising ethical issues and difficulties with reproducibility and 
standardisation across laboratories. Consequently, there is a great deal of research 
into the development of defined media (DM) for cell culture (Broedel Jr. & Papciak 
2003; Nayak et al. 2018; Santarém et al. 2013a; van der Valk et al. 2010). Many DM 
are now in use and can be purchased commercially for a variety of cell types, with 
online databases dedicated to the curation of serum-free alternatives (van der Valk 
et al. 2010, 2018). However, for Leishmania and other parasites, developments in 
DM are very much in their infancy (De Paula Lima et al. 2014; Nayak et al. 2018; 
Santarém et al. 2013a). For this reason, DM are still not commonly employed in 
secretome studies.  
There are methods designed to retain the use of supplemented culture media whilst 
avoiding the problem of abundant and undefined serum proteins. Methods 
employing click chemistry can be used to pull out specifically modified proteins, 
for example click chemistry of glycoproteins (Kuhn et al. 2012), and are used when 
a known class of secreted proteins are to be investigated. However, these types of 
methods are not useful for studies aiming to obtain a global coverage of the whole 
secretome. Other methods of click chemistry using cells labelled with a labelled 
analogue of a certain metabolite, such as a methionine analogue, are effective at 
isolating secreted proteins in the presence of serum. However this method relies 
on the cells being auxotrophic for certain metabolites, and adapting to culture 
where they must utilise the analogue metabolically and in the case of this particular 
method, also take up heavy lysine and arginine to allow SILAC labelling (Eichelbaum 
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& Krijgsveld 2014). And so due to the aim of analysing the full life cycle of 
Leishmania and the potential use of non-culture adapted field strains in this 
project, labelling with metabolic analogues and isotopes was not used. 
3.1.2 Isolating the secretome of Leishmania 
L. mexicana is suited to secretome analysis due to the ability to cultivate the 
complete life cycle of this species in vitro, culturing the distinct cell morphologies 
from both the vector and host stages, the promastigote and amastigote, 
respectively (Bates 1994). Metacyclogenesis in Leishmania is induced in vitro by 
low pH and nutrient exhaustion (Bates 2007). Both the metacyclic and procyclic 
forms generated in vitro are morphologically similar to their insect counterparts 
(Sacks 1989; Debrabant et al. 2004). Axenic amastigotes of L. mexicana have been 
extensively characterised and found to be very similar to lesion-derived 
amastigotes (Bates 1994; Bates et al. 1992; Gupta et al. 2001). They are 
characterised by a combination of morphology, for example the presence of 
amastigote-specific megasomes and non-emergent flagellum; biochemical 
analyses, to detect increased protease and nuclease activity and decreased protein 
content and secretory acid phosphatase; and immunochemistry and molecular 
characterisation, using amastigote-specific antibodies and detection of amastigote-
specific gene expression (Gupta et al. 2001). Axenic culture also provides the cell 
numbers required for studies such as these where large quantities of cells are 
required to generate enough secreted protein for analysis. It also eliminates the 
need for host cells, consequently avoiding the complexity of differentiating 
between host and parasite proteins. 
Proposed global secretome collection methods from Leishmania spp. are listed in 
Table 3-1. An important consideration when extracting the Leishmania secretome 
is the growth-phase at which samples are collected. The studies described in Table 
3-1 have only sampled promastigotes, at both logarithmic or stationary phases in 
axenic culture, corresponding to procyclic- or metacyclic-enriched populations, 
respectively (Burchmore & Hart 1995; Mallinson & Coombs 1989). We aim to extend 
these analyses to the amastigote stage of the parasite life cycle.
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Table 3-1 Methods employed for collection of the secretome from Leishmania spp. Abbreviations not included in common abbreviations table: NR – not reported, 
Ppn – precipitation, dm – defined media, sf – serum free, Leu – leupeptin, AN – antipain, PS – pepstatin, CS – chymostatin, AP – aprotinin, STBI – soya bean trypsin 
inhibitor, PMSF -phenylmethylsulfonyl fluoride. 
Leishmania 
Species 
Wash Collection 
medium 
Protease 
inhibitors 
Cell density Incubation 
time 
Centrifugation 
speeds 
Concentration 
method 
Viabilty 
monitoring 
Identification 
method 
Reference 
L. major 
stationary 
promastigotes 
PBS sf RPMI Leu, AN, PS, CS 
at 2 µg/ml, AP 
at 16 µg/ml 
2 x 107 cells/ml 
Total NR 
6 h 4000 x g Centricon YM-
10 filter 
Trypan blue 
/counting 
anti-secretome sera + 
immuno-screening 
cDNA expression library 
(Chenik et 
al. 2006) 
L. donovani 
stationary 
promastigotes 
HBSS sf M199 + 
HEPES  
+ L-glut 
SBTI during 
collection 
108 cells/ml 
Total >2x109 cells 
4-6 h 300 x g 10% TCA OR 
pyrogallol red 
Ppn 
G6PD assay SILAC, + LC-MS/MS / IEF 
+ LC-MS/MS 
(Silverman 
et al. 2008) 
L. braziliensis 
log-phase 
promastigotes 
PBS sf RPMI + 
HEPES  
+ L-glut 
NR 5x108 cells/ml 
Total 2.5x109 cells 
3 h 2000 x g, 100,000 x g 10% TCA Ppn Trypan blue 
/counting 
2DE + MALDI-TOF/TOF (Cuervo et 
al. 2009) 
L. mexicana 
stationary 
promastigotes 
PBS sf DMEM or 
RPMI 
NR 108 cells/ml 
Total NR 
2-4 h 4000 rpm 15% TCA Ppn 
OR 10KD filter 
PI staining 
/FACS 
LC-MS/MS (Hassani et 
al. 2011) 
L. infantum 
log-phase 
promastigotes 
N/A dm cRPMI 
(Santarém et 
al. 2013a) 
1mM PMSF 106 cells/ml 
starting inoculum 
Total NR 
24-96 h Parasite removal 
speed NR, 0.2 µm 
filter, 10,000 x g, 
100,000 x g 
3 KD Ultracel 
filter + dialysis 
against PBS 
AnnexinV-Cy5 
 + 7-AAD 
staining / FACS 
1DE + LC-MS/MS (Santarém et 
al. 2013b) 
L. infantum 
log-phase 
promastigotes 
sf RPMI sf RPMI NR 107 cells/ml 
Total 2.4x109 cells 
2-8 h 1276 x g NR PI staining 
/FACS 
LC-MS/MS (Braga et al. 
2014) 
L. major 
stationary 
promastigotes 
PBS sf RPMI NR 108 cells/ml 
Total NR 
4 h 3000 rpm, 10,000 rpm, 
0.45 µm + 0.20 µm 
filters 
N/A exosome 
collection only 
PI staining 
/FACS 
LC-MS/MS (Atayde et 
al. 2015) 
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A commonly overlooked difficulty with secretome analysis, is that the resulting 
‘conditioned’ culture media will contain a very dilute concentration of secreted 
proteins. For this reason, many previous studies increased the cell numbers in the 
secretion medium to increase the yield of secreted material. However, 
concentration methods must still be employed post-collection of the secretome, 
such as protein precipitation or molecular weight cut-off (MWCO) filter 
centrifugation, in order to gain high enough concentrations of protein to be 
analysed by methods such as gel separation or mass spectrometry. Other factors to 
be considered include the length of incubation time, methods to monitor cell 
viability, and the inclusion of protease inhibitors during the collection process. 
Having successfully collected the secreted proteins, most studies have then utilised 
mass spectrometry for protein identification (Atayde et al. 2015; Braga et al. 2014; 
Cuervo et al. 2009; Hassani et al. 2011; Santarém et al. 2013b; Silverman et al. 
2008). There has also been a non-MS-based method for detecting 
excreted/secreted proteins of Leishmania, through the generation of antibodies to 
stationary culture supernatant, followed by immunoscreening of a cDNA expression 
library and sequencing of the positive hits to identify the candidate proteins 
(Chenik et al. 2006).  
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3.2 Aims and hypotheses 
As evidenced above, many different methods for secretome collection and 
variations thereof have been used, and every method has advantages and 
disadvantages. Here, we aimed to implement and optimise a method for secretome 
extraction and analysis from L. mexicana. We evaluated and adapted current 
methods for secretome extraction from Leishmania promastigotes and applied 
them to both L. mexicana promastigote and amastigote cultures, with the aim that 
application of these methods would allow us to obtain and characterise the global 
secretome from both life cycle stages. These analyses could then be used to 
evaluate and further understand the differences between the promastigote and 
amastigote life cycle stages and their interactions with the vector and the host. 
• We hypothesised that the extracellular proteome of Leishmania parasites in 
axenic culture would differ from the intracellular proteome, and that this 
could therefore be categorised as the secretome fraction. 
• We hypothesised that, like promastigotes, amastigotes would secrete 
proteins in axenic culture, and that previous promastigote secretome 
collection and analysis methods could be adopted and further optimised for 
the study of the amastigote secretome. 
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3.3 Results 
3.3.1 Evaluation of media for secretome collection 
To establish a viable cell culture of Leishmania mexicana M379, in vitro methods 
were employed to culture the cells axenically. Figure 3-1a shows a growth curve 
for L. mexicana WT promastigotes in axenic culture in HOMEM medium with added 
serum (cHOM), displaying clear logarithmic and stationary growth phases between 
0-50 hours and 100-150 hours, respectively. In the logarithmic growth phase the 
doubling time of the promastigotes was approximately 7.2 hours. Figure 3-1b shows 
a growth curve for L. mexicana axenic amastigotes, cultured in SDM medium with 
added serum (cSDM), displaying logarithmic growth over the course of 7 days with 
an average doubling time of 36 hours, a slower growth rate than the promastigote 
stage. 
 
Figure 3-1 Growth of Leishmania mexicana in vitro. (a) Growth of axenic promastigotes in cHOM 
(circles), serum-free HOM (filled triangles) or Nayak medium (open triangles), (b) growth of axenic 
amastigotes in cSDM pH 5.5 (circles), serum-free SDM pH 5.5 (filled triangles) or Nayak medium pH 
5.5 (open triangles). Error bars ±SD, n=3. 
Due to the undefined nature of the serum added to the culture media and the highly 
abundant proteins found in it such as albumin, it is necessary to collect the 
secretome of these cells in a serum free environment. We tested the applicability 
of two methods to achieve this. 
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3.3.1.1 Defined media for L. mexicana 
Similar to the method of Santarém et al. (Santarém et al. 2013b), we tested the 
applicability of using a complete defined medium for the culture of L. mexicana, 
which contains all the nutrients required for in vitro growth of the parasites without 
adding serum or any other undefined cell culture products (Nayak et al. 2018). 
Promastigotes grown in cHOM were washed in PBS and transferred to Nayak medium 
(NM). The promastigotes grew slightly slower in NM than in cHOM (Figure 3-1a), but 
continued to grow logarithmically with a doubling time of 10.4 hours, reaching a 
maximum density of 7.5 x 106 cells/ml after 96 hours. Amastigotes did not respond 
as well to NM, only reaching a maximum density of 4.5 x 106 cells/ml after 144 
hours and exhibiting an apparent doubling time of 66.4 hours (Figure 3-1b). 
3.3.1.2 Serum-free incubation 
In parallel, we also evaluated the frequently used method of using a serum-free 
media and short incubation to collect the secretome. Parasites were cultured in 
complete medium (cHOM, cSDM), then washed and transferred to serum-free 
medium (sfHOM, sfSDM pH 5.5) to investigate their growth and viability prior to 
secretome collection. No overall growth was observed when promastigotes were 
cultured in sfHOM, with the small increase in cell number at 24 hours likely to be 
an artefact of previously dividing cells at the time of transfer (Figure 3-1a). 
Amastigotes appeared to continue dividing in sfSDM, reaching a maximum density 
of 4 x 106 cells/ml at 120 hours before dropping (Figure 3-1b). The growth rate 
during this period was slower than in the cSDM culture with a doubling time of 53.2 
hours. Although it appears that the amastigotes were growing in the serum free 
medium, they only reach a density equivalent to ‘two doublings’, which is similar 
to the promastigotes which increased from 1 x 105 to 3.5 x 105. Therefore again, 
this may be an artefact of previously dividing cells at the time of transfer, coupled 
with the amastigotes’ slower growth rate and therefore slower response rate. 
To allow for a comparison of the protein profiles of the promastigote and 
amastigote secretome, both samples were obtained by incubation in serum-free 
base media, Homem or Schneider’s Drosophila Medium pH 5.5 for promastigotes or 
amastigotes, respectively. As with previous studies (Braga et al. 2014; Cuervo et 
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al. 2009; Hassani et al. 2011; Silverman et al. 2008), the incubation time in serum-
free media was limited, in this case to 4 hours, to minimise the stress to cells. 
3.3.2 Cell viability is monitored during secretome isolation 
In order to demonstrate that we have minimised the release of intracellular 
proteins through cell lysis, any cell death during the 4 hour incubations was 
monitored and quantified by counting using a cell viability stain, Trypan blue. 
Figure 3-2a shows that the cell viability of stationary promastigote culture and of 
amastigote culture is maintained to the same level before and after incubation in 
serum-free media.  
An alamar blue metabolic assay was also employed to quantify the viability of the 
parasites after incubation in the medias, using a modified transformation assay 
(Jain et al. 2012). Viable axenic amastigotes were cultured in cSDM and prepared 
by washing off the complete medium and incubating in PBS, cSDM or sfSDM for 4 
hours. After incubation, the medium was replaced with cHOM to transform any live 
amastigotes to promastigotes. Parasite viability was evaluated by the addition of 
resazurin dye which is metabolised by live parasites to a fluorescent product. Figure 
3-2b shows the comparison of the metabolism of viable promastigotes after being 
incubated in the stated media for 4 hours as amastigotes. The parasites incubated 
in water showed no fluorescence as there were no viable parasites remaining to 
metabolise the reagent after the 4 hour incubation. This observation was 
significantly different from the incubations in PBS, cSDM or sfSDM, and the results 
in these media showed no statistical difference between them. 
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Figure 3-2 Viability of L. mexicana during secretome collection. (a) Viability of axenic stationary 
phase promastigotes and amastigotes before and after 4 h incubation in sfHOM or sfSDM, 
respectively, measured by counting on a haemocytometer with trypan blue dye exclusion. (b) Viability 
of amastigotes incubated in various named media and measured using the alamar blue metabolic 
assay. Error bars +SD (n=6). *** p=<0.0001, comparison to cMedia, PBS and sfMedia. 
3.3.3 Supernatant recovery and concentration 
After incubation of the parasites in the secretion media, the parasites were 
separated from the supernatant using centrifugation, beginning at relatively slow 
speeds of 700 x g followed by 1000 x g, to separate the intact parasite cells from 
the supernatant without imposing undue mechanical stress that might result in cell 
crushing and lysis. Once the cell-free supernatant containing the secretome was 
isolated, this was subjected to further centrifugation at a higher speed of 3270 x g 
to remove any cell debris that may be present. 
We then sought to optimise the recovery of the proteins from the large volumes of 
media. Figure 3-3 shows promastigote supernatant samples concentrated using two 
different precipitation methods, acetone precipitation and a carrier-assisted TCA 
precipitation using sodium lauryl sarcosinate (TCA-NLS) (Chevallet et al. 2007), 
compared to applying no protein concentration method. Comparing the methods 
visually by SDS-PAGE and Coomassie staining, greater concentration and recovery 
of proteins was achieved using acetone precipitation compared to no precipitation, 
but TCA-NLS provided the greatest concentration and recovery compared to the 
other approaches. These samples were also compared to a known amount of cell 
lysate protein (10 µg) to help estimate the amount of protein in the secretome 
samples. Although incremental improvements were observed, it is clear the 
secretome recovery is still very low. TCA-NLS precipitation was also applied to the 
Viability 
(%) SD 
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After incubation 94.8 ± 4.97
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amastigote secretome (Figure 3-4). Filter concentration with 10 kDa MWCO 
centrifugal filters was also investigated to provide an alternative method of sample 
concentration. This method resulted in the greatest recovery of protein (Figure 
3-5).  
An additional step of including a detergent-based buffer (RIPA buffer) with the 
filter concentration method was included to lyse any exosomes on the filter, and 
to promote recovery of any proteins which had stuck to the membrane during 
concentration (Figure 3-5). This step also functioned to denature the secreted 
proteins to retain more low MW proteins on the membrane. 
 
Figure 3-3 Comparison of protein concentration methods for L. mexicana promastigote 
secretome by SDS-PAGE. Three different methods were compared, no concentration (P2) where a 
sample of the supernatant was applied to the gel, acetone precipitation (P2Ace) and a carrier-assisted 
TCA precipitation using NLS (P2Tca). These were compared to each other and to 10µg of 
promastigote cell lysate protein (CL). Samples run on 4-20% poly-acrylamide gel with molecular 
weight marker (MW) P7702 broad range NEB. Stained with colloidal Coomassie G-250 (Dyballa & 
Metzger 2009). 
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Figure 3-4 Secretome collection from L. mexicana axenic amastigotes and promastigotes. 
Protein extracts from the lysed cells (lys) of both life cycle stages and from the secretome run by 4-
20% SDS-PAGE and stained with colloidal Coomassie G-250, samples 1 or 2 indicate two repeats. 
A2-13 indicate amastigote secretome sample ID’s for MS analysis. P8-12 promastigote secretome 
sample ID’s. 
 
Figure 3-5 SDS-PAGE of L.mexicana secretome and lysate. Secretome (A, P) and whole cell 
extract (Lys) from amastigotes and promastigotes were stained with colloidal Coomassie G-250 (a) 
and Sypro Orange (b). Secretome samples 16 and 22 were extracted with the addition of a cocktail of 
protease inhibitors (1 µM PepstatinA, 0.1 mM Pefabloc, 10 µM leupeptin, 1 mM 1,10-phenanthroline) 
and concentrated using 10 kDa MWCO filters. 
3.3.4 Amastigote secreted proteins are degraded by proteolysis 
After secretome collection from promastigotes and amastigotes, aliquots of both 
the lysed cell pellets and the secreted protein samples were run side by side to 
evaluate the profiles of the two fractions. Due to the absence of high molecular 
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weight proteins in the amastigote secretome samples and an abundance of diffuse 
low molecular weight material, proteolytic degradation was suspected. To address 
this, the method was modified to add a cocktail of protease inhibitors to the 
secretome after parasite removal from the spent media  
A cocktail of protease inhibitors (Table 3-2, initial concentration) was added to 
both the promastigote and amastigote collections (Figure 3-5) (Ambit et al. 2011). 
As a result, there were more higher molecular weight proteins visible in Figure 3-5, 
and a reduced area of diffuse staining. This was further optimised by adding 
specific metalloprotease inhibitor EDTA (Woessner 1999) and irreversible cysteine 
protease inhibitor E64 (Barrett et al. 1982) to the cocktail, and increasing the 
concentrations of the other inhibitors in the amastigote mix. Addition of these 
protease inhibitors (Table 3-2) after the collection of the secretome improved the 
detection of high molecular weight bands in amastigote secreted material (Figure 
3-6a), and improved the resolution of the promastigote secretome (Figure 3-6b). 
Table 3-2 Protease inhibitors added to the L. mexicana secretome. The following concentrations 
of protease inhibitors were added to the secretome after removing the parasites by centrifugation. Pro 
– promastigotes, Ama – amastigotes. 
Inhibitor Supplier Initial Conc. Final Conc. (Pro) Final Conc. (Ama) 
E64 Sigma/E3132 / 10 µM 50 µM 
Pepstatin A Sigma/P5318 1 µM 1 µM 5 µM 
Pefabloc Sigma/76307 0.1 mM 0.1 mM 0.5 mM 
Leupeptin Sigma/L2884 10 µM 10 µM 50 µM 
1,10-Phenanthroline Sigma/P9375 1 mM 1 mM 2 mM 
EDTA Sigma/E6758 / 1 mM 2 mM 
 
Improvements in protein visualisation were also observed with the application of 
SyproOrange staining to the samples (Figure 3-5). The improvements in the 
collection of both secretomes and from the use of staining using silver stain is 
evident in Figure 3-6. There is clear defined banding in both secretome samples 
with distinct banding patterns between the secretome and the lysates, and 
between promastigote and amastigote samples. There are fewer bands in the 
amastigote secretome compared to the promastigote secretome. 
0.22 µm filters have previously been used to ensure complete removal of cells from 
the secretome sample (Atayde et al. 2015; Atyame Nten et al. 2010; Santarém et 
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al. 2013b). This method was tested to investigate if this would adversely affect the 
secretome, as future experiments may involve application of the secretome to host 
cells. However, addition of this step showed some protein loss and therefore was 
not used in the final method for characterisation of the secretome (Figure 3-6a). 
 
Figure 3-6 L. mexicana promastigote and amastigote secretome compared to cell lysate. (a) 
Amastigote secretome, NF – non-filtered, F – filtered through 0.22 µM membrane after removal of 
parasites by centrifugation. (AW1) indicates sample name for MS analysis. (b) Amastigote proteome 
(Lys) and secretome samples (W1-3). (c) Promastigote proteome (Lys) and secretome (W1-2) 
samples. Secreted proteins from conditioned axenic culture supernatant separated on 4-20% SDS-
PAGE and silver stained. MW marker used was NEB broad range (2-212 kDa). Secretome samples 
were treated with a cocktail of protease inhibitors specific for promastigotes or amastigotes (Table 
3-2) and with RIPA buffer, and concentrated using 10 kDa MWCO centrifugal filters. 
The profiles of the secretome and cell lysate were also compared by a 2D-GE 
analysis. This was performed for both promastigote and amastigote cell lysate and 
secretome (presented in Chapter 4, Figure 4-2). Visualisation of the differing 
fractions in higher resolution clearly displays the fundamental differences between 
the lysate and secretome samples. 
3.3.5 Protein quantitation 
The low concentration of secreted proteins and their collection in salt- and 
metabolite-rich culture media presented an additional problem with quantitation 
of the samples prior to analysis. Two commonly used commercial protein assays, 
the Bradford assay (BioRad) and the BCA assay (Thermo), were unsuitable for 
quantitation of the secretome samples. This was due to the addition of detergents 
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during sample concentration in the case of the Bradford assay, and the presence of 
free cysteine and other small molecules which interfere with the BCA assay. To 
combat this, the detergent-compatible (DC) Protein Assay (BioRad) was used which 
was compatible with all components of the sample. In addition, to avoid using up 
10 µl of the secretome sample per assay replicate in the standard microplate 
format, which would consume up to 40% of the total sample amount if three 
replicates were assessed as per the manufacturers’ instructions, we implemented 
the colorimetric nanodrop spectrophotometer method. This was used in 
combination with the ‘low-concentration’ protocol of the DC protein assay using 
standards ranging from 5–250 µg/ml protein. Only 4 µl of sample or standard are 
required per assay, which is mixed with a reagent mix and then absorbance 
measured at 750 nm, from triplicate samples (Methods 2.6). Unknown protein 
concentrations in the sample are ascertained by comparison to a standard curve 
using known protein concentrations. Post extraction of the secretome, we were 
able to calculate and quantify the protein yield obtained (Table 3-3). Promastigotes 
were found to secrete approximately five-fold more protein than amastigotes per 
cell. 
Table 3-3 Estimated secreted protein yield from L. mexicana. Pro WT – wild type axenic 
promastigotes, biological replicates 1-3, Ama WT – wild type axenic amastigotes, biological replicates 
1-3. 
Cell type Total number  
of cells 
Total yield of  
secreted protein(µg) 
Yield per 108  
cells (µg) 
Pro WT 1 3.5 E8 19.5 5.6 
Pro WT 2 3.5 E8 22 6.3 
Pro WT 3 3.4 E8 12.6 3.7 
Ama WT 1 9.92 E8 15.1 1.5 
Ama WT 2 7.04 E8 9 1.3 
Ama WT 3 9.6 E8 10.2 1.06 
 
3.3.6 Identification of secretome proteins by mass spectrometry 
Alongside the development and visual assessment of the method by gel 
electrophoresis, aliquots of secreted material were also digested with trypsin and 
the resulting peptides analysed by mass spectrometry to identify the secreted 
protein components. In early analyses (Figure 3-3; sample P2), secreted material 
was not sufficiently concentrated and the small aliquot used for mass spectrometry 
generated very few peptides. These initial analyses resulted in poor protein yields 
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and identifications. The first MS runs of both the promastigote and amastigote 
secretome samples yielded significant matches to trypsin only (Table 3-6, Table 
3-7). The introduction of the steps described above led to significant improvements 
in the number of proteins identified with confidence. 
After protein concentration with TCA-NLS and increasing the volume of starting 
culture, the next promastigote secretome analyses P8 and P10 yielded 24 and 23 
protein identifications but with high false discovery rates indicating peptide 
matches with poor confidence. These investigations were improved upon using 
10kDa filter concentration and a protease inhibitor cocktail as discussed above, 
resulting in 32, 15 and 38 confident protein identifications with false discovery 
rates of <1% and applying a threshold of 30 to the internal Mascot scoring system. 
The results of these early promastigote analyses are summarised in Table 3-4. After 
further method development using a combination of filter concentration, improved 
protease inhibitor cocktail and solubilisation of exosomal proteins and any protein 
stuck to the filter membrane using detergent, the secretome samples depicted in 
Figure 3-6 were analysed by mass-spectrometry. From the analysis of the 
promastigote secretome, 256 proteins were identified over the significance 
threshold (P=<0.05), with a Mascot score exceeding 30 and in at least three 
replicates, as shown in Chapter 4, Table 4-2. 
In parallel, the amastigote collection method was tested and samples of the 
amastigote secretome were digested with trypsin for mass spectrometry analysis. 
The total number of protein identifications generated from each amastigote 
secretome sample are summarised in Table 3-5. Samples A2 – A13, which produced 
very diffuse LMW stained regions on polyacrylamide gels (Figure 3-4), only 
generated up to four significant protein identifications. The majority of these were 
low-scoring hypothetical proteins (Table 3-7). Samples A16 and A22 were generated 
using filter concentration coupled with the addition of a limited cocktail of 
protease inhibitors (Figure 3-5), and this resulted in 11 and 19 protein 
identifications (Table 3-7). Finally, using a combination of filter concentration, a 
specific cocktail of protease inhibitors and addition of lysis buffer during processing 
to recover stuck proteins and exosomes, samples AW1 and W1-3 were generated 
(Figure 3-6) which resulted in the identification of 33 – 39 proteins in the amastigote 
secretome. Proteins which exceeded significance and scoring thresholds of P=<0.05 
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and 30, respectively, and were present in a minimum of three replicates were 
included in the final list of amastigote secreted proteins, which totalled 36 proteins 
(Chapter 4, Table 4-3). Blank serum-free media, HOM and SDM pH 5.5, were also 
submitted for MS analysis to control for any media additives or contaminants which 
may influence the results. These analyses resulted in the identification of two 
peptides matching to porcine trypsin and one peptide matching to a hypothetical 
Leishmania protein, the same protein in both blank samples (Table 3-8), later found 
to be a spurious match. 
 
Table 3-4 Summary of L. mexicana promastigote secretome identifications by LC-MS/MS 
Sample 
ID 
Number of 
significant hits 
FDR applied (if 
known) 
Mascot score 
cut-off 
Mass Spec 
P2_24 0 / / AmaZon Speed 
P2_4 0 / / AmaZon Speed 
p8 24 4.81% ≥30 AmaZon Speed 
p10 23 4.73% ≥30 AmaZon Speed 
p12 54 4.94% ≥30 AmaZon Speed 
p12 32 <1% ≥30 AmaZon Speed 
p16 20 4.8% ≥30 AmaZon Speed 
p16 15 <1% ≥30 AmaZon Speed 
p22 46 5% ≥30 AmaZon Speed 
p22 38 <1% ≥30 AmaZon Speed 
W1 296 <1% ≥30 Orbitrap Elite 
W2 296 <1% ≥30 Orbitrap Elite 
W3 247 <1% ≥30 Orbitrap Elite 
 
Table 3-5 Summary of L. mexicana amastigote secretome identifications by LC-MS/MS 
Sample 
ID 
Number of 
significant hits 
FDR applied (if 
known) 
Mascot score 
cut-off 
Mass Spec 
A2 0 / / AmaZon Speed 
A8 1 / / AmaZon Speed 
A12 2 / ≥30 AmaZon Speed 
A13 4 / ≥30 AmaZon Speed 
A16 11 / ≥30 AmaZon Speed 
A22 19 / ≥30 AmaZon Speed 
AW1 39 <2% ≥30 Orbitrap Elite 
W1 33 <1% ≥30 Orbitrap Elite 
W2 33 <1% ≥30 Orbitrap Elite 
W3 33 <1% ≥30 Orbitrap Elite 
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Table 3-6 L. mexicana promastigote secretome identifications from method development. Secreted proteins identified by LC-MS/MS of tryptic peptides. 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P2
 2
4
h
 0
 sig 
h
its 1 LmxM.29.0050 hypothetical protein, conserved  14 87528 0 0   
2 LmxM.36.3260 hypothetical protein, conserved  14 22438 0 0   
1 SWISS-PROT:P00761 Trypsin - Sus scrofa (Pig) 91 25078 5 1  0.13 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P2
 4
h
 0
 sig 
h
its 1 LmxM.17.1290 eukaryotic translation initiation factor 3 subunit b  22 81180 0 0 3.1  
2 LmxM.16.0050 hypothetical protein, conserved  14 74109 0 0 1.2  
3 LmxM.07.0240 hypothetical protein, conserved  13 68066 0 0 1.2  
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P8
 FD
R
 4
.8
1
 
2
4
 sig h
its 
1 LmxM.36.6480 histidine secretory acid phosphatase, putative  1270 128157 45 11 10.6 0.37 
2 LmxM.08.1171 hypothetical protein  354 50319 16 6 16.5 0.6 
3 LmxM.13.0280 alpha tubulin  232 61058 10 6 14.4 0.39 
4 LmxM.14.1160 enolase  117 46743 2 2 7 0.16 
5 LmxM.24.0850 triosephosphate isomerase  89 27265 2 1 4.8 0.13 
6 LmxM.09.0910 calmodulin, putative  87 16814 2 1 7.4 0.48 
7 LmxM.09.0891 polyubiquitin, putative  74 14962 1 1 12.5 0.24 
8 LmxM.31.2950 nucleoside diphosphate kinase b  72 16891 3 2 11.9 0.48 
9 LmxM.36.1940 inosine-guanosine transporter  63 54565 2 2 5.2 0.13 
10 LmxM.34.0500 proteophosphoglycan ppg3, putative  56 121456 2 2 1.6 0.06 
11 LmxM.29.2980 glyceraldehyde 3-phosphate dehydrogenase, glycosomal  55 39326 2 1 3.9 0.09 
12 LmxM.23.0200 endoribonuclease L-PSP (pb5), putative  51 17122 2 1 9.8 0.47 
13 LmxM.17.0080 elongation factor 1-alpha  51 49575 1 1 2.4 0.07 
14 LmxM.14.0850 small myristoylated protein-3, putative  50 13055 3 1 8.7 0.28 
15 LmxM.34.2210 kinetoplastid membrane protein-11  49 11271 1 1 9.8 0.33 
16 LmxM.22.1110 dynein heavy chain, cytosolic, putative  46 627131 1 1 0.3 0.01 
17 LmxM.15.1010 glutamate dehydrogenase  44 115208 1 1 1.2 0.03 
18 LmxM.28.2770 heat-shock protein hsp70, putative  41 71482 2 1 1.8 0.05 
19 LmxM.23.0840 hypothetical protein, unknown function  40 57431 1 1 1.5 0.06 
20 LmxM.28.2910 glutamate dehydrogenase, putative  40 49561 1 1 2.4 0.07 
21 LmxM.34.3230 cystathione gamma lyase, putative  39 45102 1 1 2.2 0.08 
22 LmxM.24.0960 hypothetical protein, conserved  38 108178 2 1 0.8 0.03 
23 LmxM.32.0312 heat shock protein 83-1  38 81035 1 1 1.7 0.04 
24 LmxM.32.2540 metallo-peptidase, Clan MA(E) Family M32  38 57378 1 1 2 0.06 
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Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P1
0
 FD
R
 4
.7
3
 
2
3
 sig h
its 
1 LmxM.36.6480 histidine secretory acid phosphatase, putative  2097 128157 97 10 8.7 0.3 
2 LmxM.08.1171 hypothetical protein  303 50319 13 5 14.4 0.52 
3 LmxM.09.0910 calmodulin, putative  238 16814 6 1 7.4 0.42 
4 LmxM.13.0280 alpha tubulin  157 61058 6 3 5.7 0.16 
5 LmxM.14.1160 enolase  80 46743 1 1 3.5 0.07 
6 LmxM.14.0850 small myristoylated protein-3, putative  66 13055 3 1 8.7 0.25 
7 LmxM.31.2950 nucleoside diphosphate kinase b  62 16891 2 1 6 0.19 
8 LmxM.31.1820 iron superoxide dismutase, putative  58 21994 1 1 7.2 0.14 
9 LmxM.24.0850 triosephosphate isomerase  56 27265 1 1 4.8 0.12 
10 LmxM.23.0840 hypothetical protein, unknown function  56 57431 3 1 1.5 0.05 
11 LmxM.36.1960 phosphomannomutase, putative  53 28231 1 1 4.5 0.11 
12 LmxM.17.0080 elongation factor 1-alpha  53 49575 1 1 2.4 0.06 
13 LmxM.09.1340 histone H2B  49 11957 1 1 9.3 0.27 
14 LmxM.36.1940 inosine-guanosine transporter  49 54565 2 2 3.8 0.12 
15 LmxM.34.3230 cystathione gamma lyase, putative  48 45102 2 1 2.9 0.07 
16 LmxM.09.0891 polyubiquitin, putative  45 14962 1 1 12.5 0.22 
17 LmxM.15.1040 tryparedoxin peroxidase  41 22557 1 1 5.5 0.14 
18 LmxM.29.2980 glyceraldehyde 3-phosphate dehydrogenase, glycosomal  38 39326 1 1 3.9 0.08 
19 LmxM.34.2210 kinetoplastid membrane protein-11  35 11271 1 1 9.8 0.29 
20 LmxM.31.3310 dihydrolipoamide dehydrogenase, putative  35 51083 1 1 2.5 0.06 
21 LmxM.30.0010 5-methyl4hydropteroyl3glutamatehomocysteinemethyltransferase  putative  34 86681 1 1 1.3 0.04 
22 LmxM.26.1420 hypothetical protein, conserved  33 258393 1 1 0.4 0.01 
23 LmxM.16.0760 transaldolase, putative  33 37238 1 1 3.6 0.08 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P1
2 FD
R
 <1
%
 
3
2
 sig h
its >3
0
 sco
re
 
1 LmxM.36.6480 histidine secretory acid phosphatase, putative  3510 128157 102 10 10 0.3 
2 LmxM.13.0280 alpha tubulin  461 61058 20 6 13.3 0.35 
3 LmxM.08.1171 hypothetical protein  317 50319 17 8 22.6 0.62 
4 LmxM.09.0910 calmodulin, putative  245 16814 6 2 18.8 0.69 
5 LmxM.14.1160 enolase  143 46743 5 3 9.1 0.21 
6 LmxM.36.1940 inosine-guanosine transporter  139 54565 7 3 8 0.18 
7 LmxM.28.2910 glutamate dehydrogenase, putative  125 49561 6 5 15.7 0.36 
8 LmxM.23.0840 hypothetical protein, unknown function  116 57431 3 3 6.8 0.17 
9 LmxM.32.0312 heat shock protein 83-1  110 81035 4 3 5.6 0.12 
10 LmxM.31.1820 iron superoxide dismutase, putative  98 21994 2 1 7.2 0.14 
11 LmxM.23.0200 endoribonuclease L-PSP (pb5), putative  96 17122 2 1 9.8 0.19 
12 LmxM.28.2770 heat-shock protein hsp70, putative  90 71482 4 3 6.3 0.14 
13 LmxM.31.2950 nucleoside diphosphate kinase b  88 16891 2 1 6 0.19 
14 LmxM.17.0085 elongation factor 1-alpha  81 45620 4 3 8 0.22 
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15 LmxM.09.1340 histone H2B  78 11957 3 1 9.3 0.27 
16 LmxM.36.2020 chaperonin HSP60, mitochondrial precursor  75 60610 3 2 4.2 0.11 
17 LmxM.30.2310 3~-nucleotidase/nuclease  73 41697 1 1 2.9 0.07 
18 LmxM.14.0850 small myristoylated protein-3, putative  70 13055 2 2 18.3 0.56 
19 LmxM.09.0891 polyubiquitin, putative  70 14962 2 1 12.5 0.21 
20 LmxM.29.2980 glyceraldehyde 3-phosphate dehydrogenase, glycosomal  70 39326 2 1 3.9 0.08 
21 LmxM.34.3230 cystathione gamma lyase, putative  70 45102 4 2 5.1 0.14 
22 LmxM.15.1230 nucleoside transporter 1, putative  68 54462 2 1 2.9 0.06 
23 LmxM.16.0760 transaldolase, putative  66 37238 1 1 2.7 0.08 
24 LmxM.15.1040 tryparedoxin peroxidase  66 22557 2 2 10.1 0.3 
25 LmxM.34.0500 proteophosphoglycan ppg3, putative  62 121456 2 1 0.7 0.03 
26 LmxM.25.2010 hypothetical protein, conserved  60 30664 2 1 3.9 0.1 
27 LmxM.32.2540 metallo-peptidase, Clan MA(E) Family M32  59 57378 1 1 2.2 0.05 
28 LmxM.24.0850 triosephosphate isomerase  59 27265 2 2 10 0.24 
29 LmxM.23.1020 hypothetical protein, unknown function  56 12671 2 2 22.2 0.58 
30 LmxM.30.1440 hypothetical protein, unknown function  54 49700 1 1 4.2 0.06 
31 LmxM.05.0350 trypanothione reductase  54 53710 1 1 2.6 0.06 
32 LmxM.11.0630 metallo-peptidase, Clan MF, Family M17  46 57922 1 1 3 0.05 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P1
6 FD
R
 <2
%
 
1
5
 sig h
its >3
0
 sco
re
 
1 LmxM.36.6480 histidine secretory acid phosphatase, putative  893 128157 32 6 7 0.15 
2 LmxM.09.0910 calmodulin, putative  276 16814 9 3 26.8 1.02 
3 LmxM.13.0280 alpha tubulin  182 61058 8 4 8.6 0.22 
4 LmxM.14.1160 enolase  76 46743 3 3 11.2 0.21 
5 LmxM.34.3230 cystathione gamma lyase, putative  71 45102 2 2 6.1 0.14 
6 LmxM.08.1171 hypothetical protein  69 50319 1 1 2.7 0.06 
7 LmxM.23.1020 hypothetical protein, unknown function  64 12671 2 1 8.5 0.26 
8 LmxM.05.0380 microtubule-associated protein, putative  62 89588 1 1 1.7 0.03 
9 LmxM.31.2950 nucleoside diphosphate kinase b  59 16891 1 1 6 0.19 
10 LmxM.14.0850 small myristoylated protein-3, putative  59 13055 2 1 9.6 0.56 
11 LmxM.15.1160 tryparedoxin peroxidase  57 22538 1 1 7 0.14 
12 LmxM.25.2010 hypothetical protein, conserved  56 30664 1 1 3.9 0.1 
13 LmxM.16.0760 transaldolase, putative  55 37238 1 1 4.2 0.08 
14 LmxM.36.1940 inosine-guanosine transporter  54 54565 1 1 2.6 0.06 
15 LmxM.28.2770 heat-shock protein hsp70, putative  
 
 
 
 
52 71482 1 1 2.4 0.04 
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Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI P2
2
 FD
R
 <1
%
 
3
8
 sig h
its >3
0
 sco
re
 
1 LmxM.36.6480 histidine secretory acid phosphatase, putative  1898 128157 68 9 9.4 0.27 
2 LmxM.13.0280 alpha tubulin  252 61058 10 5 11.1 0.28 
3 LmxM.14.1160 enolase  239 46743 8 5 16.6 0.38 
4 LmxM.16.0760 transaldolase, putative  174 37238 8 5 18.5 0.5 
5 LmxM.09.0910 calmodulin, putative  171 16814 4 2 18.8 0.42 
6 LmxM.23.1020 hypothetical protein, unknown function  151 12671 7 3 30.8 0.98 
7 LmxM.34.0500 proteophosphoglycan ppg3, putative  145 121456 8 4 3.5 0.11 
8 LmxM.08.1171 hypothetical protein  126 50319 7 5 14.9 0.35 
9 LmxM.28.2770 heat-shock protein hsp70, putative  107 71482 3 3 5.8 0.14 
10 LmxM.34.3230 cystathione gamma lyase, putative  97 45102 3 2 6.8 0.14 
11 LmxM.31.2950 nucleoside diphosphate kinase b  90 16891 4 2 13.9 0.42 
12 LmxM.23.0840 hypothetical protein, unknown function  86 57431 2 1 3.4 0.05 
13 LmxM.17.0080 elongation factor 1-alpha  85 49575 4 4 10.2 0.28 
14 LmxM.31.1820 iron superoxide dismutase, putative  83 21994 1 1 7.2 0.14 
15 LmxM.34.0520b hypothetical protein (pseudogene) (fragment)  78 549866 3 3 0.8 0.02 
16 LmxM.23.0200 endoribonuclease L-PSP (pb5), putative  70 17122 1 1 9.8 0.19 
17 LmxM.25.2010 hypothetical protein, conserved  69 30664 2 1 3.9 0.1 
18 LmxM.29.2980 glyceraldehyde 3-phosphate dehydrogenase, glycosomal  67 39326 1 1 3.9 0.08 
19 LmxM.11.0630 metallo-peptidase, Clan MF, Family M17  67 57922 1 1 3 0.05 
20 LmxM.24.2060 transketolase, putative  65 72496 1 1 1.6 0.04 
21 LmxM.28.2910 glutamate dehydrogenase, putative  64 49561 2 2 6.4 0.13 
22 LmxM.23.0110 mannose-1-phosphate guanyltransferase  63 41849 2 1 2.9 0.07 
23 LmxM.30.1440 hypothetical protein, unknown function  63 49700 1 1 4.2 0.06 
24 LmxM.30.0010 5-methyl4hydropteroyltriglutamate homocysteinemethyltransferase, putative  61 86681 1 1 1.8 0.04 
25 LmxM.09.0891 polyubiquitin, putative  58 14962 1 1 12.5 0.21 
26 LmxM.30.2020 succinyl-diaminopimelate desuccinylase-like protein  58 51477 1 1 3.2 0.06 
27 LmxM.36.6650 2,3-bisphosphoglycerate-independentphosphoglyceratemutase  55 61118 1 1 2.5 0.05 
28 LmxM.14.0850 small myristoylated protein-3, putative  54 13055 2 1 8.7 0.25 
29 LmxM.26.1570 thimet oligopeptidase, putative  53 77680 1 1 1.6 0.04 
30 LmxM.20.1310 small myristoylated protein 1  52 15167 1 1 8.4 0.21 
31 LmxM.15.1230 nucleoside transporter 1, putative  51 54462 1 1 2.9 0.06 
32 LmxM.32.0312 heat shock protein 83-1  51 81035 1 1 1.7 0.04 
33 LmxM.15.1040 tryparedoxin peroxidase  51 22557 2 1 5 0.14 
34 LmxM.01.0770 Eukaryotic initiation factor 4A-1  51 51225 1 1 2.2 0.06 
35 LmxM.33.0140 malate dehydrogenase  49 33945 1 1 7 0.09 
36 LmxM.05.0960 metallo-peptidase, Clan M-, Family M49  47 76027 1 1 1.6 0.04 
37 LmxM.36.0180 elongation factor 2  46 94852 1 1 1.8 0.03 
38 LmxM.21.1700 proteasome alpha 2 subunit, putative  46 25301 1 1 5.6 0.12 
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Table 3-7 Secreted proteins from L. mexicana amastigotes. Secretome representative of three independent repeats. Where >1 accessions are listed, all peptides 
matched to these sequences. aAccession number from TriTrypDB.org. bMascot protein score, derived from the sum of individual probability-based ions scores 
[10*LOG10(P)] + corrections, Matrix Science. cPredicted protein mass from genome sequence. dNumber of spectra matched to peptide sequences in the protein. 
eNumber of different peptide sequences matched. f% coverage of the protein sequence. gemPAI. P<0.05 significance threshold at level of identity. 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI A2
  
0
 sig h
its 
1 LmxM.05.1020 hypothetical protein, conserved 21 104936 1 1 1 0.03 
1 P00761 Trypsin - Sus scrofa (Pig). 18 25078 1 1 3.5 0.13 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI A8
  
1
 sig h
it 
1 P00761 Trypsin - Sus scrofa (Pig). 130 25078 9 3 16.5 0.43 
1 LmxM.24.0960 hypothetical protein, conserved  30 108178 1 1 0.8 0.03 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI A1
2
  
2
 sig h
its 
1 P00761 Trypsin - Sus scrofa (Pig). 44 25078 2 2 7.8 0.27 
1 LmxM.24.0960 hypothetical protein, conserved  39 108178 1 1 0.8 0.03 
2 LmxM.36.5800 hypothetical protein, conserved  31 206526 1 1 0.3 0.01 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI A1
3 
4
 sig h
its 
1 P00761 Trypsin - Sus scrofa (Pig). 68 25078 5 1 3.5 0.13 
2 P00924 Enolase 1 48 46830 4 1 1.4 0.07 
1 LmxM.17.0080 elongation factor 1-alpha  61 49575 2 1 1.8 0.06 
2 LmxM.24.0960 hypothetical protein, conserved  36 108178 2 1 0.8 0.03 
3 LmxM.26.1320 hypothetical protein, conserved  36 30638 2 1 2.9 0.1 
4 LmxM.28.2230 cyclin dependent kinase-binding protein, putative  31 99259 1 1 0.7 0.03 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI A1
6 
1
1
 sig h
its 
1 LmxM.09.0891 polyubiquitin, putative  254 14962 8 3 24.2 0.8 
2 LmxM.08.1080 cathepsin L-like protease, putative  200 39285 8 4 15.3 0.36 
3 LmxM.14.0850 small myristoylated protein-3, putative  115 13055 6 2 18.3 0.56 
4 LmxM.23.0200 endoribonuclease L-PSP (pb5), putative  114 17122 4 2 16 0.41 
5 LmxM.09.0910 calmodulin, putative  106 16814 8 3 20.8 0.7 
6 LmxM.24.0850 triosephosphate isomerase  86 27265 3 3 14.7 0.39 
7 LmxM.09.0770 oligopeptidase b  79 84275 2 1 2.3 0.04 
8 LmxM.08_29.1160 tryparedoxin 1, putative  45 16739 2 1 8.3 0.19 
9 LmxM.13.1360 hypothetical protein, conserved  40 91686 1 1 1.6 0.03 
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10 LmxM.36.2840 Flagellar Member 2  34 126576 1 1 0.6 0.02 
11 LmxM.34.5320 hypothetical protein, conserved  30 67351 1 1 1.2 0.05 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI A2
2
 
1
9
 sig h
its 
1 LmxM.09.0891 polyubiquitin, putative  104 14962 3 2 19.5 0.55 
2 LmxM.26.0750 hypothetical protein, conserved  94 185432 3 1 0.8 0.02 
3 LmxM.09.0910 calmodulin, putative  92 16814 4 3 27.5 0.8 
4 LmxM.08_29.0290 hypothetical protein  43 41544 1 1 2.4 0.08 
5 LmxM.34.3240 hypothetical protein, conserved  43 91111 2 1 1 0.04 
6 LmxM.21.0825 plectin, putative  41 360915 2 1 0.3 0.01 
7 LmxM.20.0160 wd40 repeat domain-containing protein  40 88864 1 1 1 0.04 
8 LmxM.08_29.2590 hypothetical protein, conserved  38 73482 1 1 2.5 0.05 
9 LmxM.33.2030 hypothetical protein, conserved  38 131098 2 1 0.6 0.03 
10 LmxM.08_29.1410 hypothetical protein, unknown function  38 128642 3 2 1 0.05 
11 LmxM.09.0770 oligopeptidase b  37 84275 1 1 2.3 0.04 
12 LmxM.12.1210 hypothetical protein, conserved  36 103312 2 1 1.1 0.03 
13 LmxM.04.1180 hypothetical protein, conserved  36 254100 1 1 0.3 0.01 
14 LmxM.07.0960 hypothetical protein, conserved  34 128579 1 1 0.7 0.03 
15 LmxM.23.1020 hypothetical protein, unknown function  34 12671 1 1 7.7 0.29 
16 LmxM.15.0710 hypothetical protein, conserved  33 364956 2 1 0.3 0.01 
17 LmxM.32.0370 hypothetical protein, conserved  32 78370 1 1 0.8 0.04 
18 LmxM.36.5200 hypothetical protein, conserved  30 108104 1 1 0.9 0.03 
19 LmxM.19.1130 hypothetical protein, conserved  30 620168 1 1 0.2 0.01 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI AW
1
 FD
R
<2
%
 
3
9
 sig h
its 
1 LmxM.29.2490 heat shock 70-related protein 1, mitochondrial precursor, putative  463 72990 11 6 11 0.47 
2 LmxM.08.1030a hypothetical protein  452 58965 12 6 14.6 0.75 
3 LmxM.24.0850 triosephosphate isomerase  372 27265 9 5 25.1 1.36 
4 LmxM.09.0891 polyubiquitin, putative  279 14962 9 4 36.7 2.46 
5 LmxM.10.0460 GP63, leishmanolysin  203 70995 5 4 7.6 0.3 
6 LmxM.28.2770 heat-shock protein hsp70, putative  197 71482 6 4 6.1 0.39 
7 LmxM.14.0850 small myristoylated protein-3, putative  161 13055 4 3 19.1 1.89 
8 LmxM.06.0030 hypothetical protein, conserved  151 75520 4 2 3.6 0.13 
9 LmxM.36.1960 phosphomannomutase, putative  148 28231 3 2 10.5 0.4 
10 LmxM.26.0620 10 kDa heat shock protein, putative  136 10695 3 2 26 1.38 
11 LmxM.23.0200 endoribonuclease L-PSP (pb5), putative  134 17122 3 2 16 0.73 
12 LmxM.36.3210 14-3-3 protein 1, putative  104 29782 3 2 8.5 0.37 
13 LmxM.17.0620 hypothetical protein, conserved  99 11466 1 1 19.4 0.5 
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14 LmxM.36.0970 hypothetical protein, conserved  94 22506 1 1 7.6 0.23 
15 LmxM.24.2210 60S ribosomal protein L12, putative  93 17698 2 1 9.1 0.3 
16 LmxM.31.1820 iron superoxide dismutase, putative  89 21994 2 1 7.2 0.24 
17 LmxM.13.0450 ALBA-domain protein 1  86 13372 2 1 10.7 0.42 
18 LmxM.08_29.0820 CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like  86 38009 2 1 5.6 0.13 
19 LmxM.21.1780 40S ribosomal protein S6, putative  85 28302 2 1 6.4 0.18 
20 LmxM.36.2020 chaperonin HSP60, mitochondrial precursor  74 60610 2 1 2.1 0.08 
21 LmxM.26.2700 6-phosphogluconolactonase  71 28690 1 1 6 0.18 
22 LmxM.31.2260 hypothetical protein, conserved  67 20318 2 1 5.9 0.26 
23 LmxM.07.1000 RNA binding protein-like protein  65 38691 1 1 3.6 0.13 
24 LmxM.28.1200 luminal binding protein 1 (BiP), putative  60 71919 2 1 1.7 0.07 
25 LmxM.08_29.1160 tryparedoxin 1, putative  60 16739 6 1 9 1.3 
26 LmxM.07.0990 nucleolar RNA-binding protein, putative  53 36307 2 1 2.3 0.14 
27 LmxM.15.1040 tryparedoxin peroxidase  52 22557 2 1 5.5 0.23 
28 LmxM.32.1750 macrophage migration inhibitory factor-like protein  51 12846 1 1 7.1 0.43 
29 LmxM.08.0470 small ubiquitin protein, putative  48 12738 2 1 12.8 0.44 
30 LmxM.06.0010 histone H4  48 11436 2 1 10 0.5 
31 LmxM.28.0960 40S ribosomal protein S14  48 15667 2 1 9 0.35 
32 LmxM.31.2950 nucleoside diphosphate kinase b  47 16891 1 1 6 0.32 
33 LmxM.36.0540 ubiquitin-like protein, putative  47 33141 1 1 4.4 0.15 
34 LmxM.19.1420 cysteine peptidase A (CPA)  46 39177 1 1 2.5 0.13 
35 LmxM.19.1160 hypothetical protein, conserved  43 41571 1 1 2.7 0.12 
36 LmxM.14.1100 kinesin K39, putative  43 536483 1 1 0.2 0.01 
37 LmxM.34.1300 ubiquitin-conjugating enzyme E2, putative  42 16783 1 1 4.7 0.32 
38 LmxM.09.0910 calmodulin, putative  40 16814 1 1 7.4 0.32 
39 LmxM.04.1230 actin  40 42350 1 1 2.7 0.12 
 
Table 3-8 Identifications from MS analysis of serum-free base medium. sfHOM – serum-free HOMEM before use for the culture of promastigotes, sfSDM – serum-
free Schneider’s drosophila medium before use for the culture of amastigotes. 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI sfH
O
M
 
o
n
ly 1 LmxM.31.1700 hypothetical protein, conserved 32 90069 1 1 1 0.03 
1 P00761 Trypsin - Sus scrofa (Pig). 82 25078 4 2 7.8 0.27 
Hit # Accession Description Score Mass Matches Sequences Coverage (%) emPAI sfSD
M
 
o
n
ly 1 LmxM.31.1700 hypothetical protein, conserved 29 90069 1 1 1 0.03 
1 P00761 Trypsin - Sus scrofa (Pig). 194 25078 7 2 7.8 0.27 
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3.3.7 Validation of the secretome by comparison to lysate 
The proteome of the cells was also analysed by LC-MS/MS to experimentally 
compare the intracellular proteome of the parasites with the secreted proteome. 
Comparison of the cellular proteome to the secretome shows enrichment of certain 
proteins in the spent media samples. These distinct protein profiles indicate that 
the proteins detected in the spent media are unlikely to be artefacts present due 
to cell lysis during serum-free incubation or processing. There are 67 proteins 
unique to the promastigote secretome, and 189 proteins in common between the 
cellular proteome and the secretome of promastigotes (Figure 3-7a). 8 proteins are 
unique to the amastigote secretome, with 28 proteins in common between the 
proteome and secretome from amastigotes (Figure 3-7b). However, in order to 
understand these observations further, the relative abundance of each protein 
detected in cellular and secreted proteomic analyses were compared. A 
quantitative measure of protein abundance is the exponentially modified protein 
abundance index (emPAI) (Ishihama et al. 2005). Figure 3-8 and Figure 3-9 correlate 
the relative abundance of each protein in the proteome and secretome, from 
promastigote and amastigote respectively, by comparing lists of proteins ranked 
according to their emPAI. This reveals that the proteins that are in common 
between the lysate and secretome are not simply those that are most abundant in 
the lysate, as would be expected if their presence in the secreted sample was due 
to a degree of cell lysis during sample generation. Additionally, there are many 
abundant lysate proteins that do not appear in the secretome.  
 
Figure 3-7 Venn diagrams illustrating the proteins in common between lysate and secretome 
protein samples of L. mexicana. (a) promastigote proteome Vs secretome, (b) amastigote 
proteome Vs secretome (protein descriptions, some redundancies). 
http://bioinformatics.psb.ugent.be/webtools/Venn/  
a b 
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Figure 3-8 L. mexicana promastigote whole cell proteins versus secretome proteins arranged 
in order of decreasing abundance. Tick marks and values from 1 to 548 on the left hand axis denote 
each protein in the promastigote cell lysate ranked from 1 to 548 in order of decreasing emPAI. Where 
a line is present, this represents a protein also present in the promastigote secretome. Where there is 
no line, no corresponding protein was present in the secretome. Proteins identified by LC-MS/MS. 
Proteins marked by a yellow line are in the top 50 most abundant in the cell lysate, those in blue are 
enriched in the secretome and less abundant in the lysate. Proteins in red were enriched in the 
secretome but below the detection limit in the lysate.  
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Figure 3-9 L. mexicana amastigote whole cell proteins versus secretome proteins arranged in 
order of decreasing abundance. Tick marks and values from 1 to 497 on the left hand axis denote 
each protein in the amastigote cell lysate ranked from 1 to 497 in order of decreasing emPAI. Where 
a line is present, this represents a protein also present in the amastigote secretome. Where there is 
no line, no corresponding protein was present in the secretome. Proteins identified by LC-MS/MS. 
Proteins marked by a yellow line are in the top 50 most abundant in the cell lysate, those in blue are 
enriched in the secretome and less abundant in the lysate. Proteins in red were enriched in the 
secretome but below the detection limit in the lysate.  
20
10
1
30
0
50
100
150
200
250
300
350
400
450
500
Lysate Proteins Secretome Proteins
P
ro
te
in
s 
R
an
ke
d
 B
y 
A
b
u
n
d
an
ce
←
Le
as
t 
A
b
u
n
d
an
t 
 /
  M
o
st
 A
b
u
n
d
an
t→
Chapter 3  87 
3.4 Discussion 
3.4.1 Axenic culture systems are advantageous for secretome 
studies 
The complete developmental cycle, including the promastigote and amastigote 
stages of Leishmania mexicana M379 can be cultured axenically (Bates 1994), and 
for multiple passages. Axenic culture of promastigotes and amastigotes allows 
confidence in extractions being free from contamination by host or other exogenous 
proteins. However, these in vitro cultures do not fully represent the in vivo 
situation, where promastigotes develop in the sand fly vector and amastigotes 
within the macrophage host cell, encountering a much more complex and 
potentially hostile environment than that presented by culture media. The relative 
contributions of host and parasite activities to the outcome of the interaction are 
challenging to disentangle and there is obvious potential in the study of axenic 
parasite systems to reveal the input from the parasite. Model systems for axenic 
culture in vitro are regularly used for many different cell types and are very 
amenable to secretome studies. Subsequent analyses and conclusions from in vitro 
studies employing these methods generate greater insight into mechanisms 
employed by the parasite and can highlight leads that can be followed up at the 
individual protein level using in vivo methods. 
As outlined previously, serum and other undefined supplements added to axenic 
culture systems can present problems with batch variability, reproducibility and 
highly abundant serum proteins which mask the proteins of interest. To combat 
this, we have chosen a method of secretome collection in serum-free medium. We 
assessed the use of serum-free base media for short incubations, and defined NM 
(Nayak et al. 2018) to allow longer serum-free incubations. NM was found to be 
good for increasing the protein yield for the promastigote secretome (Appendix 1), 
however this media is not yet applicable to amastigote culture. Therefore, for 
comparison and conclusions to be drawn between both lifecycle stages both 
methods were kept similar using a 4 hour incubation in serum-free base media. The 
number of parasites per secretion assay was increased to approximately 109 
parasites to increase the protein yield due to the short incubation times. 
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3.4.2 Secretion and isolation processes 
During the secretion process, viability monitoring is important to show that cell 
viability is maintained during transfer to and incubation in different media. 
Experiments described here show cell viability to be maintained in vitro in the 
employed culture medium. Amastigote viability was also demonstrated in various 
media, complete growth medium (cSDM), serum-free medium (sfSDM), water or 
PBS, using the alamar blue viability reagent. The alamar blue assay is routinely 
used for evaluation of growth and viability of kinetoplastids in response to drug 
treatment (Räz et al. 1997). Blue resazurin dye is reduced by mitochondrial NADH 
into resorufin, a pink coloured product which fluoresces with an excitation 
wavelength of 530 nm and with an emission wavelength of 590 nm. The assay can 
also be measured colorimetrically at 570 nm. However, even with the presence of 
individual controls for each of the medium types, the differing compositions of the 
media caused too much variability in the fluorescence readings to quantify the 
viability of the amastigotes directly after the incubations. Serum in the medium 
has been reported to cause some quenching of the fluorescence and therefore it is 
best to have the same medium composition for all samples and controls (Page et 
al. 1993). An incubation and transformation assay (Jain et al. 2012) was therefore 
employed to quantify the viability of the parasites after incubation in the various 
media. The methods were adapted from Jain et al. (2012) by starting with the 
incubation of axenic amastigotes in the various media, then live amastigotes were 
differentiated back to promastigotes by temperature and pH change using cHOM. 
The addition of alamar blue reagent thereafter displayed the presence of 
metabolically active cells by production of a coloured and fluorescent product. 
Cells incubated in a non-isotonic control for four hours showed no metabolism of 
the substrate, whereas those in control media (cSDM), experimental media (sfSDM) 
and isotonic nutrient-deprived control (PBS) displayed significantly increased 
metabolism. No significant difference in cell viability was observed between sfSDM 
and cSDM after four hours of incubation. Results also showed no significant 
difference in cell viability between cSDM and PBS. However, this assay only takes 
cell death into account and does not account for cell stress or any other factors. 
We sought to maintain the cell culture environment as closely as possible and 
minimise stress as far as possible, so for this reason we chose to continue using the 
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same media for secretome collection with the only difference being the removal of 
serum.  
There is little benefit to monitoring cell viability during the secretion process if 
incidental lysis is to occur during the isolation process. Therefore, to maintain cell 
integrity while separating the parasites from the spent medium, the parasites were 
separated from the supernatant using progressive centrifugation, starting relatively 
slowly and increasing in speed at each stage with the supernatant from the previous 
stage. This approach ensured the parasites were pelleted in a manner that would 
avoid crushing and mechanical lysis, followed thereafter by pelleting any remaining 
cell debris. The supernatant was removed carefully at each stage. At this point 
other studies (Hassani et al. 2011, 2014) have used 0.22 or 0.45 μm filters to ensure 
complete sterility, however we have opted not to use this method in the standard 
process to minimise loss of protein, as demonstrated in Figure 3-6a. 
3.4.3 Overcoming challenges of secretome extraction 
An overlooked problem with secretome studies is in the concentration of the dilute 
protein solutions. Protein recovery from culture media can present various 
challenges such as co-precipitation of culture media salts or poor yields at low 
protein concentrations (Chevallet et al. 2007). Various protocols were therefore 
compared to extract the secreted proteins from the media: acetone precipitation, 
carrier-assisted TCA precipitation and molecular weight cut-off (MWCO) filters. 
Methods such as dye-binding precipitation with pyrogallol red, used in previous 
Leishmania secretome analyses (Silverman et al. 2008), were not evaluated due to 
previous evidence of poor recovery of acidic proteins and glycoproteins (Marshall 
& Williams 1996). The first method investigated was acetone precipitation. 
Addition of acetone and other organic solvents to aqueous protein solutions 
precipitates the protein by reducing the polarity of the solution and decreasing the 
solubility of the proteins (Goldring 2015). We tested the efficacy of the acetone 
precipitation protocol against a carrier-assisted TCA precipitation method and 
found acetone precipitation to be the least effective for this type of sample (Figure 
3-3). Additionally, this method requires the addition of four times the sample 
volume of acetone in order to create the conditions. As large culture volumes are 
required to isolate adequate concentrations of secreted protein, acetone 
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precipitation, alongside other organic solvents such as methanol precipitation 
where nine volumes of methanol are required, were deemed to be unsuitable from 
a practical perspective. Carrier-assisted precipitation is specifically designed to 
improve the precipitation and recovery of proteins from dilute solutions (Chevallet 
et al. 2007). It functions to bind to the protein in solution and precipitate the 
carrier along with the protein. The carrier is then washed off during subsequent 
steps. In our hands, this method did improve the recovery of the secreted proteins, 
but only incrementally (Figure 3-3). Finally, centrifugal filters with a 10 kDa 
molecular weight cut-off (MWCO) were tested. This method proved the most 
effective at concentrating and recovering the secreted proteins from the culture 
media. An additional benefit of a 10kDa filter concentration step is the removal of 
any contaminating salts, nutrients and peptides from the spent media. The 
amastigote culture media SDM contains a yeastolate extract which may contain 
peptides (Thermo Fisher Scientific n.d.). However, as part of the yeastolate 
production process it is sterilised by passing through a 10kDa filter before its 
addition to the medium, therefore the yeastolate only contains supplements 
smaller than 10kDa (SAFC Biosciences 2006). We are retaining anything larger than 
10kDa on the filter as our sample. 
Improvement of the amastigote secretome was achieved with higher 
concentrations of protease inhibitors, crucially E64 and EDTA, for the inhibition of 
cysteine proteases (Barrett et al. 1982) and metalloproteases (Woessner 1999). 
There are known to be abundant cysteine proteases (Mottram et al. 1998) and 
metalloproteases (Cuervo et al. 2006) in Leishmania. In addition, proteases in 
general are more abundant in amastigotes (Pupkis & Coombs 1984). Moving from a 
standard working concentration of all protease inhibitors to using a fivefold 
increased concentration for the amastigote samples, generated greater secretome 
coverage. Addition of RIPA buffer would act to lyse exosomes but also act to 
denature the proteases in the solution.  
One of the major challenges was working with low concentrations of protein, even 
after extraction and concentration down to small volumes. Both in the collection 
and concentration of the samples, and in obtaining an accurate estimate of protein 
concentration from low amounts of protein. Most conventional protein assays such 
as the Bradford assay or to BCA assay are confounded by many of the components 
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of protein buffers, such as the detergents in Laemmli and lysis buffers, free amino 
acids such as cysteine in culture media, or reducing agents such as DTT. Many 
different assays were tested and subsequently the detergent-compatible protein 
assay reagent (BioRad) was chosen. This was coupled with a method using the 
Nanodrop spectrophotometer, to avoid consumption of up to 40% of the sample 
using the standard microplate method (Methods 2.6). The resulting total secretome 
yield for both cell types was an interesting observation as promastigotes were found 
to secrete fivefold more protein per cell than amastigotes. Promastigotes are much 
larger than amastigotes, but in stationary phase they are only around double the 
size (Bates 1994), not fivefold larger. We can therefore reinforce the observation 
that amastigotes are more metabolically quiescent than promastigotes (Jara et al. 
2017; Saunders et al. 2014). 
3.4.4 Protein identification and validation 
Visualisation of the electrophoretic profiles of the secretome samples was 
improved using silver staining. In contrast, other methods included radioisotope 
labelling and using known counts/min to run on the gel to overcome problems with 
protein assays, and for gel visualisation (Chenik et al. 2006; Silverman et al. 2008). 
However, these methods are costly, time consuming and require expertise in use 
of radioisotopes. Resolution of the differences between lysate and secretome was 
increased by additionally performing 2D electrophoresis. Comparison of the 
secretome and lysate showed clear, qualitative differences between the two 
fractions (Chapter 4, Figure 4-2). 
Analysis of blank serum-free base media appeared to yield a significant hit to a 
Leishmania protein. However, upon closer inspection the same query matched a 
trypsin autolysis peptide in the contaminants database (Table 3-9). Thus, this was 
concluded to be a spurious match by chance to a Leishmania peptide and the 
identification was excluded from the significant hits in the Leishmania secretome. 
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Table 3-9 Spectral query that was matched to the mass and fragmentation of two different 
peptides. 
Trypsin-Sus scrofa(Pig). 
        
Query Observed Mr(expt) Mr(calc) Delta Miss Score Expect Rank Unique Peptide 
877 421.7720 841.5294 841.5022 0.0273 0 36 0.00023 1 U R.VATVSLPR.S 
           
LmxM.31.1700 
         
Query Observed Mr(expt) Mr(calc) Delta Miss Score Expect Rank Unique Peptide 
877 421.7720 841.5294 841.4658 0.0637 0 32 0.017 1 U K.AVEAVTPR.L 
 
Comparison of estimated protein abundance in the experimentally determined 
proteome to the parasite secretome illustrates that the proteins that are common 
to both the lysate and secretome are not simply a fraction of the most abundant in 
the lysate. Additionally, there are abundant lysate proteins that do not appear in 
the secretome. Only one previous study in Leishmania has reported the percentage 
of proteins shared between the secretome and control proteome, at 52%, with the 
overlap between the secretome and control proteome observed to be higher than 
this in stationary phase cultures than procyclic promastigote cultures (Santarém et 
al. 2013b). It is important to note that some abundant proteins in the lysate are 
present in the secretome. They have not, however, been discounted from the 
secretome analyses in the following chapters of this thesis, as they could play 
important roles in the natural environment of the parasite. 
As further validation of the collective isolation of secreted proteins, between 45 
and 86% of the promastigote proteins identified in this study can be observed in 
other Leishmania secretome studies, supporting their identification as secreted 
proteins, which are presented and discussed in Chapter 4 of this thesis. 
Although we show the presence of many low abundance proteins in the secretome, 
there are still some proteins which have been identified as secreted by L. mexicana 
in individual studies, which do not appear in the secretome presented here. Often, 
these proteins are identified by highly sensitive immunological methods such as 
ELISA or Western blot, or by activity assays. It is clear that, although we have 
eliminated abundant serum proteins, many abundant proteins in the secretome are 
still masking those that are secreted at low abundance. Improvements to MS 
identification are always sought after to improve dynamic range. Further 
separation of the secretome prior to MS, such as using strong cation exchange (SCX) 
chromatography before C18 liquid chromatography could improve this.   
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3.5 Summary 
The final technique and methodologies presented here for the isolation and 
extraction of the Leishmania secretome can be used to study the secretome of the 
promastigote and amastigote life-cycle stages. Further development was the 
inclusion of exosomes by lysing, showing all secreted proteins as one data set. 
There are several advantages of the techniques employed here for the collection 
of the secretome, including being able to study promastigotes and amastigotes in 
vitro in parallel with direct comparison, and free from host interactions and 
contamination. However, there are disadvantages such as lack of in vivo stimuli 
which may affect the secretome obtained. 
We aimed to implement and optimise a method for the secretome extraction and 
collection from L. mexicana, which we have shown here. We have evaluated and 
adapted current methods for the secretome extraction from Leishmania 
promastigotes and applied them to the study of L. mexicana promastigote and 
amastigote cultures, with the aim that these secretome extraction methods will 
allow us to obtain a global secretome from which the promastigote and amastigote 
life cycle stages and their survival mechanisms can be investigated. We have taken 
into account a number of complications and considerations such as parasite viability 
and protein concentration methods, which have been addressed and provide a basis 
and methodology for a comparative study of the L. mexicana promastigote and 
amastigote secretomes. The flow-chart below in Figure 3-10 summarises the final 
methodology used for subsequent studies presented in this thesis, a method for the 
analysis of the secretome providing insight into disease virulence and parasite 
pathogenicity. 
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Figure 3-10 Flow chart summarising the method implemented for the study of the L. mexicana 
promastigote and amastigote secretome.  
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4.1 Introduction 
Here, the secretome of the different lifecycle stages of the Leishmania mexicana 
parasite, promastigote and amastigote, will be investigated in more detail. The 
parasites are only introduced to the body at the vector bite location, but the 
immune system cannot control and defend against the infection. Macrophages 
phagocytose the parasites in human tissue, as they would with any microbe or 
foreign organism to remove these pathogens from the tissue. However, the 
Leishmania parasites can instead differentiate into an intracellular form and thrive 
in this environment within the macrophage. This is likely to involve modification of 
the intracellular macrophage niche to allow the parasite to develop and 
differentiate. We hypothesise, with the emergence of supporting evidence, that 
Leishmania employ secreted molecules to achieve this. 
By growing the parasites in an environment that mimics their natural host 
environment, like that in the phagolysosome, but free of other cell types, we can 
sample and collect proteins it secretes, as discussed in Chapter 3. With the 
application of proteomics, we can then characterise the secretome. We can 
investigate differences in secreted effectors between life cycle stages to deduce 
their mechanisms of survival, from combating the challenges presented by the 
macrophage, including reactive oxygen species (ROS) and hydrolytic enzymes, to 
acquiring nutrient and modulating host cell gene expression. Crucially, processes 
that are essential for parasite survival present attractive targets for therapeutic 
intervention. 
4.1.1 Secreted proteins play a key role in the virulence of parasites 
Intercellular communication is essential for biological interaction, whether within 
a multicellular organism or between microbes and their hosts. The parasite 
secretome has been attributed several roles involved in disease progression and 
virulence, with diverse parasites shown to employ this mechanism including 
protozoa, nematodes and trematodes. The role of secreted proteins in establishing 
and mediating host:microbe interactions is challenging to assess in vitro, especially 
for intracellular pathogens. 
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Protozoa such as Kinetoplastids and Apicomplexans have been found to secrete 
proteins into their extracellular environment, and furthermore, they play a role in 
the pathogenicity of the parasite (Mantel & Marti 2014). A number of excreted and 
secreted proteins from trypanosome procyclic forms have been implicated in 
disease progression and parasite survival (Atyame Nten et al. 2010). Further work 
in trypanosomes highlighted the important role the secretome plays in trypanosome 
infections, specifically T. cruzi secreted proteins (Bautista-López et al. 2016; 
Watanabe Costa et al. 2016). Outlined in Chapter 3, there are a number of studies 
which have begun to unravel the Leishmania secretome (Braga et al. 2014; Chenik 
et al. 2006; Cuervo et al. 2009; Hassani et al. 2011; Santarém et al. 2013b; 
Silverman et al. 2008). Of those that have investigated the host cell response to 
the secretome, effects such as promotion of Th2 polarisation (Silverman et al. 
2010b), cleavage and activation of host protein tyrosine phosphatases and 
inhibition of nitric oxide production (Hassani et al. 2011) were observed. 
Apicomplexan parasites have specialised secretory organelles, namely micronemes, 
rhoptries and dense granules. These have been shown to play a major role in 
invasion, remodelling of the host cell and immune evasion. In Plasmodium these 
proteins have been extensively characterised (Soni et al. 2016). In Toxoplasma 
dense granule proteins have been shown to modulate the parasite niche in the host, 
providing mechanisms for nutrient acquisition by the parasite in the 
parasitophorous vacuole (Gold et al. 2015). These parasites can also induce the 
secretion of proteins from their host cells to trigger strong immune responses from 
surrounding cells. Infection with Plasmodium induces secretion of extracellular 
vesicles from erythrocytes, which would otherwise be unable to produce vesicles 
due to a lack of exocytosis machinery (Mantel 2013).  
4.1.2 Parasites can alter their secretome to adapt to different 
environments and stresses 
Many different parasite species, including Leishmania, face a range of 
environments and challenges that they must overcome in a bid to survive. These 
include contrasting environments in multiple hosts or migrating to different cell 
types in the body, for example switching between high nutrient and low nutrient 
environments or between environments with differing pH. 
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As well as utilising a secretome for the establishment of disease, different life-
cycle stages of parasites use the secretome for niche modification depending on 
the host that they are infecting. Sotillo et al., present a study which shows 
differences in the proteome between different developmental stages of 
Nippostrongylus (Sotillo et al. 2014). This highlights that parasites are known to 
alter and adapt their secretome in response to changing conditions and lifecycle 
stage. For example, only 8 proteins were found in common between the secretory 
products of N. brasiliensis L3 larvae and adult worms, which inhabit distinct 
anatomical niches (Sotillo et al. 2014). This differed from S. ratti larval stages and 
adults which can both reside in the intestine, and had over 50% of their secretome 
in common between stages (Soblik et al. 2011). Alteration of protein secretion and 
vesicle cargo with life cycle stage is also observed in bacteria, for example Bacillus 
subtilis (Kim et al. 2014). 193 proteins were identified in the extracellular vesicles 
of sporulating and vegetative cells. 61 were found to be significantly more 
abundant in EV of sporulating cells, and 62 proteins were more abundant in EV shed 
by vegetative cells (Kim et al. 2014). 
Stage-specific protein secretion also occurs in protozoa such as Trypanosoma, 
showing that they alter their secretome in response to environment and their life 
cycle stage. Stage-specific cargo of extracellular vesicles from epimastigote and 
metacyclic trypomastigote T. cruzi was identified, and found to contain both 
qualitatively and quantitatively different proteins (Bayer-Santos et al. 2012). These 
observations led to the hypothesis that as Leishmania inhabit distinct 
environments, the secretion of proteins may change to adapt to different stresses. 
Differences in secreted proteins have been discovered between procyclic and 
metacyclic promastigotes of L. infantum, with overrepresentation of proteins with 
metabolic function in the procyclic secretome and overrepresentation of proteins 
with functions in folding and degradation, proteasome, and spliceosome in the 
metacyclic secretome (Santarém et al. 2013b). We therefore aim to extend these 
analyses to amastigotes. 
4.1.3 Secreted proteins are major drug targets and vaccine 
candidates 
Understanding the way a parasite interacts with its host and vector gives us insight 
into the mechanisms, biological functions, biochemical reactions and 
Chapter 4  99 
immunological process that will give protection to the host against the pathogen. 
To make advances in the development of new drugs and vaccines, parasite 
components that are required for survival need to be identified and characterised 
so that drugs may rationally be designed to target these effectors or their 
mechanisms of action. The accessibility and importance of the secretome to the 
parasite renders these proteins attractive targets for intervention, furthermore, 
secreted proteins have been revealed to be highly effective drug targets. A study 
of the properties of 148 existing drug target proteins and 3000 non-drug target 
proteins led to the conclusions that drug targets tend to be found in membranes or 
extracellularly; are more likely to be enzymes, particularly oxidoreductases or 
transferases; are secreted; and have long lifetimes, shown by the presence of 
glycosylation (Bakheet & Doig 2009). 
There are also many studies into the secretome of pathogens that have led to the 
creation of effective vaccines against these pathogens. Many currently and widely 
used vaccines against bacterial and viral pathogens are derived from secreted 
proteins. An agricultural vaccine against E. coli is based on a Type III secreted 
protein of the bacterium (Vogstad et al. 2013). Successful protein vaccines against 
human disease include the Hepatitis B vaccine, Haemophilus PS-protein vaccine, 
Meningococcal group B vaccines, Pertussis vaccine and Pneumococcus vaccine 
(Siegrist 2013). In bacterial pathogens, several other experimental and in silico 
approaches recognised secreted proteins as potential vaccine candidates. 
Anchorless surface proteins have been identified as a group A strep vaccine 
candidate (Henningham et al. 2012). Screening of non-classically secreted proteins 
as vaccine candidates in Brucella, an intracellular pathogen of phagocytes, resulted 
in the creation of a multitope vaccine using multiple secreted protein epitopes 
(Vishnu et al. 2017). Furthermore, Haemophilus secreted proteins induce a Th1 
response, therefore highlighting potential vaccine candidates from secretome 
studies (Li et al. 2015). 
Potential vaccine candidates were also found in the extracellular vesicles of the 
parasite Schistosoma mansoni, the causative agent of schistosomiasis, which were 
subsequently used to trial protein vaccines in animal models and were found to be 
efficacious (Sotillo et al. 2016). Using in silico reverse-vaccinology, non-classically 
secreted proteins were identified as possible vaccine candidates. However, no 
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vaccines are currently licensed for use in humans against parasites. Several 
vaccines for human schistosomiasis are under development and have been 
progressed to Phase I, II or III clinical trials: for example Bilhvax, an S. 
haematobium 28-kD glutathione S-transferase (rSh28GST) (Riveau et al. 2018); Sm 
14, an S. mansoni 14-kDa fatty acid-binding protein (Santini-Oliveira et al. 2016); 
and Sm-TSP-2, an S. mansoni 9-kDa surface tetraspanin (Merrifield et al. 2016). An 
Sm-p80 based vaccine is also in preparation for clinical trials against schistosomiasis 
(Siddiqui & Siddiqui 2017). Several Leishmania protein vaccine candidates have also 
begun phase I or II trials in human subjects, namely LEISH-F1 (Nascimento et al. 
2010), LEISH-F3 (ClinicalTrials.gov 2012) and Leish-111f, which has completed 
phase I and II trials in humans (Coler et al. 2007).  
Finally, there are several benefits to developing, producing and utilising a protein 
or subunit vaccine over live attenuated vaccines. These include limitations of 
vaccine preparation when producing live attenuated vaccines which involves using 
a pathogen directly. A serious consideration is the safety aspect of potentially 
inducing and causing infection when using live attenuated vaccines, which is far 
less likely with a protein or subunit vaccine. There are also increased logistical and 
infrastructure requirements for live attenuated vaccines compared to a protein or 
subunit vaccine, including increases in transport and storage costs. Understanding 
the secretome of the Leishmania parasite will lead to a greater understanding of 
the survival mechanisms and host:parasite interaction of this parasite, providing 
the information for and potentially leading to the discovery of a novel drug targets 
and vaccine candidates.  
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4.2 Aims and Hypotheses  
Here, we present a study characterising and comparing the secretome of the 
promastigote and amastigote stages of the parasite. Evidence points to the 
secretion of proteins by Leishmania which may be used to create an environment 
that is required for their successful growth, however in-depth analysis and profiling 
of the differences between the two secretomes including conclusions on the role 
these secreted proteins have in disease is yet to be achieved.  
The main aim of this study was to present a comprehensive characterisation of the 
proteins secreted by the two major life cycle stages of L. mexicana, promastigotes 
and amastigotes, and to compare the two. 
• We hypothesise that both promastigotes and amastigotes secrete proteins 
into their extracellular environment 
• We hypothesise that L. mexicana parasites alter their secretome throughout 
their life cycle 
 
  
Chapter 4  102 
4.3 Results 
Comparative secretome analyses between promastigote- and amastigote-stage 
parasites were conducted visually, by SDS-PAGE and by using different gel staining 
methods and 2D separation methods to determine differences in protein properties 
and modifications; and using shotgun LC-MS/MS to determine differences in protein 
identities, and the predicted properties thereof. 
4.3.1 Promastigote and amastigote secretomes display visually 
distinct electrophoretic profiles 
The secretome collected from L. mexicana promastigotes and amastigotes in axenic 
culture was first separated by SDS-PAGE and silver stained to reveal differences in 
electrophoretic profile between the two life cycle stages. Figure 4-1 shows the 
electrophoretic profiles of the secretome of both promastigotes and amastigotes. 
There are many more protein bands visible in the promastigote secretome 
compared to the amastigote. Additionally, the most abundant band in the 
amastigote secretome, at around 63kDa, is considerably reduced in the 
promastigote samples and difficult to distinguish. The most abundant bands in the 
promastigote samples, occurring between 70 and 97 kDa are not visible at all in the 
amastigote samples. 
Analysis of the lysate and secretome of the two life cycle stages by 2D-GE show 
both a difference between the profiles of the cellular and secreted proteins, and 
clear stage-specific differences between the secreted proteins (Figure 4-2). Similar 
to the 1D gel profiles (Figure 4-1), there are two main molecular weight areas 
where the most abundant proteins are in the 2D amastigote secretome, indicated 
by arrows (Figure 4-2d). Given that these are 12% gels and in the absence of a 
molecular weight marker on the 2D gels, we can postulate these may be 55-65kDa 
and 20-30kDa by comparison to a commercial SDS-PAGE migration chart (Appendix 
2). The presence of multiple spots in the charge-based first dimension separation, 
but all at the same molecular weight, suggests post translational modifications of 
the proteins in the secretome. 
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Figure 4-1 Secretome from L. mexicana promastigotes and amastigotes. Secreted proteins from 
conditioned axenic culture supernatant separated on 4-20% SDS-PAGE and silver stained. MW 
marker used was NEB broad range (2-212 kDa). S1/S2/S3 indicates biological repeat. 
 
Figure 4-2 2-dimensional SDS-PAGE of L. mexicana protein samples. a, Promastigote cell lysate, 
b amastigote cell lysate, c, promastigote secretome, d, amastigote secretome. Separation in the first 
dimension by isoelectric focusing with non-linear pH range 4-7, followed by electrophoresis through a 
12% polyacrylamide gel. 50 µg total protein loaded, labelled with Cy3 and imaged using the Typhoon 
imager with 532 nm laser and Cy3 emission filter. 
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4.3.2 Amastigote secretome has different physical properties 
compared to the promastigote secretome 
Amastigotes appear to have an insoluble fraction in their secretome. It becomes 
visible after freeze-thawing of the conditioned medium as a precipitate in the 
recovered supernatant. After centrifugation the insoluble component forms a white 
pellet (Figure 4-3 c + d). This phenomenon is not due to a component of the medium 
or the added protease inhibitors as both solutions were treated in the same way as 
the conditioned medium but did not give the same result (Figure 4-3 a + b). Harsher 
solubilisation was attempted with RIPA buffer, but the material was not solubilised. 
The white pellet was not easily solubilised in SDS buffer, RIPA buffer or by raising 
the pH using Tris-HCl pH 8.0. The pellet was resuspended (but not solubilised) in 
SDT buffer and subjected to trypsin digestion using the FASP protocol. The proteins 
identified are listed below (Table 4-1). Only 6 proteins were identified above the 
confidence threshold of P<0.05 and with a Mascot score of >30 (see Methods 2.14 
for scoring system). These included a superoxide dismutase, cathepsin L-like 
protease, a glycosomal carboxykinase and a putative Dopey N-terminal protein. 
 
 
Figure 4-3 The L. mexicana amastigote secretome contains an insoluble component. (a), 
Schneider’s Drosophila medium (SDM) pH  .  after freezing and thawing, (b), SDM pH 5.5 + protease 
inhibitors after freezing and thawing, (c,d), two repeats of amastigote-conditioned serum-free SDM + 
protease inhibitors after freezing and thawing. Prior to freezing no precipitate was visible. 
a b 
c d 
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Table 4-1 Proteins from the insoluble component of the L. mexicana amastigote secretome. 
Insoluble pellet was suspended in SDT buffer and transferred to a FASP column for trypsin digestion. 
Resulting peptides were analysed by LC-MS/MS. 
GeneDB 
Accession 
Protein Description Score Mass PSMs Sequences Coverage 
(%) 
emPAI 
LmxM.31.1820 iron superoxide dismutase, 
putative  
103 21994 4 1 7.2 0.18 
LmxM.08.1030 
OR 1040 OR 
1070 
cathepsin L-like protease, 
putative  
144 25997 2 1 4.2 0.15 
LmxM.27.1805 Phosphoenolpyruvate 
carboxykinase [ATP], 
glycosomal  
79 58770 4 2 4.8 0.14 
LmxM.08.1171 beta tubulin  117 50319 3 1 2.7 0.08 
LmxM.34.1830 hypothetical protein, 
conserved  
36 82713 2 1 1.8 0.05 
LmxM.31.3410 Dopey, N-terminal, putative 32 298446 3 1 0.4 0.01 
 
Amastigotes also secrete a heavily glycosylated high molecular weight (HMW) 
secretome component. This is not visible in the amastigote lysate or the 
promastigote secretome or lysate. It is very heavily glycosylated as it does not 
appear at a high concentration in the Coomassie or silver stained gel but stains very 
strongly in the PAS-stained gel (Figure 4-4). As a reference, the concentration of 
the positive control glycosylated protein loaded was 5ug. This is likely to be the 
abundantly secreted glycoprotein, aPPG, which when run without deglycosylation 
by hydrolysis was found at >200 kDa (Ilg et al. 1998). A similar double band is visible 
in the promastigote cell lysate stained with CBB and very faintly in the PAS-stained 
secretome.  
When the amastigote secretome sample is filtered through a 0.22 um filter a large 
proportion of the ~60-65 kDa band is removed. Other bands, including the HMW 
bands that remain in the stacking gel, are still present (Chapter 3, Figure 3-6a). 
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Figure 4-4 Staining of glyco-moieties on L. mexicana protein samples. + Positive glycosylated 
control = horseradish peroxidase, negative non-glycosylated control = soybean trypsin inhibitor. Cell 
lysate (CL) and replicates of secretome samples (S1-3) from L. mexicana promastigotes (P) and 
amastigotes (A) separated on 4-20% SDS-PAGE and stained for glycoprotein with a periodic acid 
schiff (PAS) stain. False coloured for clarity; red indicates PAS staining. blue indicates Coomassie 
staining (CBB). Coomassie staining was performed after PAS for all gels except amastigote S2/3 
where the samples were run and stained on separate gels. 
 
4.3.3 Mass spectrometry of culture supernatant reveals the L. 
mexicana secretome 
Table 4-2 shows the secreted proteins identified by mass spectrometry in at least 
three biological repeats of promastigote secretome collection, and Table 4-3 shows 
the secreted proteins identified by mass spectrometry in at least three biological 
repeats of amastigote axenic secretome collection. Stringent inclusion criteria 
were applied to these secretomes. Identifications in each biological repeat must 
meet a minimum Mascot score of 30 for identity and the threshold for false 
discovery was set to less than 5%. Proteins must be identified in three or more 
independent experiments for inclusion in the final list of secreted proteins. Using 
these criteria, 256 promastigote secreted proteins were identified and 36 
amastigote secreted proteins.  
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Table 4-2 Secreted proteins of L. mexicana promastigotes.  Proteins identified in three or more biological repeats. Scoring scheme, mascot score >30, see methods 
for complete settings. Accession numbers from TriTrypDB, peptide spectral matches (PSMs), sequences indicate number of different peptide sequences that the PSMs 
matched to, estimation of protein abundance = exponentially modified protein abundance index (emPAI) (Ishihama et al. 2005). 
Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.36.6480 histidine secretory acid phosphatase, putative 1276 127.5 53 18 17.890625 4.946 
LmxM.23.1020 hypothetical protein, unknown function 174 12.5 17 8 66.666667 4.623 
LmxM.23.1580 nucleoside 2-deoxyribosyltransferase, putative 245 16.9 10 5 59.354839 4.623 
LmxM.36.3910 S-adenosylhomocysteine hydrolase 618 47.8 37 19 51.029748 4.012 
LmxM.28.2770 heat-shock protein hsp70, putative 1416 71.2 77 28 44.495413 3.711 
LmxM.34.2220 kinetoplastid membrane protein-11 97 11.2 10 6 36.956522 3.642 
LmxM.25.0910 cyclophilin a, putative 155 18.8 14 6 42.372881 3.394 
LmxM.14.1160 enolase 775 46.1 39 18 53.146853 3.184 
LmxM.32.0312 heat shock protein 83-1 866 80.5 65 31 41.940086 3.042 
LmxM.08.1171 beta tubulin 491 49.7 25 12 34.988713 2.631 
LmxM.36.0180 elongation factor 2 926 94 63 32 48.52071 2.511 
LmxM.09.0910 OR 0930 calmodulin, putative 190 16.8 12 7 48.993289 2.455 
LmxM.17.0080 OR 0085 elongation factor 1-alpha 457 49.2 34 17 40.089087 2.35 
LmxM.09.0891 polyubiquitin, putative 169 14.6 12 6 43.75 1.929 
LmxM.32.2540 metallo-peptidase, Clan MA(E) Family M32 433 56.9 40 21 44.488978 1.929 
LmxM.31.2950 nucleoside diphosphate kinase b 210 16.7 10 5 43.708609 1.894 
LmxM.08_29.1160 tryparedoxin 1, putative 160 16.6 9 5 40.689655 1.848 
LmxM.17.1220 histone H2B 188 11.9 10 5 45.794393 1.848 
LmxM.20.1280 calpain-like cysteine peptidase, putative 157 16.9 8 4 36.423841 1.848 
LmxM.36.1100 ribosomal protein L24, putative 83 14.6 5 2 16.129032 1.683 
LmxM.25.0720 eukaryotic initiation factor 5a, putative 140 17.8 15 6 41.566265 1.61 
LmxM.31.1820 iron superoxide dismutase, putative 102 21.7 10 5 20 1.61 
LmxM.13.0280 alpha tubulin 541 60.1 23 12 28.467153 1.512 
LmxM.20.1310 small myristoylated protein 1 69 15 6 4 22.900763 1.512 
LmxM.34.3230 cystathione gamma lyase, putative 419 44.4 21 7 20.97561 1.462 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.36.1430 translation elongation factor 1-beta, putative 243 22.9 11 6 26.442308 1.448 
LmxM.10.0470 GP63, leishmanolysin 449 63.6 22 14 25.581395 1.39 
LmxM.14.0190 hypothetical protein, conserved 88 22.3 9 6 33.668342 1.371 
LmxM.29.3340 60S ribosomal protein L9, putative 191 21.5 12 6 35.263158 1.371 
LmxM.36.3760 60S ribosomal protein L10a, putative 206 24.6 13 7 29.439252 1.336 
LmxM.02.0550 hypothetical protein, unknown function 94 17.6 7 4 34.969325 1.31 
LmxM.23.0200 endoribonuclease L-PSP (pb5), putative 226 16.8 8 4 24.539877 1.31 
LmxM.13.0570 40S ribosomal protein S12, putative 143 15.6 10 5 28.368794 1.276 
LmxM.16.1430 Paraflagellar rod protein 2 448 68.6 29 18 40.066778 1.219 
LmxM.15.1040 OR 1160 tryparedoxin peroxidase 173 22.2 8 4 21.105528 1.154 
LmxM.16.0230 protein tyrosine phosphatase-like protein 152 19.4 7 4 25.714286 1.154 
LmxM.33.0840 translation elongation factor 1-beta, putative 264 34.1 13 8 29.283489 1.154 
LmxM.11.0630 metallo-peptidase, Clan MF, Family M17 294 56.9 19 9 22.803738 1.106 
LmxM.09.0970 elongation factor-1 gamma 152 46.2 15 9 26.237624 1.096 
LmxM.34.0820 aspartate aminotransferase, putative 238 46.2 15 9 15.533981 1.043 
LmxM.11.1190 40S ribosomal protein S15A, putative 83 14.7 8 4 23.846154 1.031 
LmxM.22.1410 centrin-4, putative 36 16.4 6 4 36.91275 1.031 
LmxM.08_29.1750 paraflagellar rod protein 1D, putative 401 68.9 26 13 23.529412 1.024 
LmxM.16.0760 transaldolase, putative 272 37 18 10 36.666667 1.009 
LmxM.14.0850 OR 0851 small myristoylated protein 3, putative / cysteine peptidase, Clan 
CA, family C2, putative 
129 12.9 6 3 26.086957 0.995 
LmxM.23.0110 mannose-1-phosphate guanyltransferase 121 41.5 13 8 24.274406 0.978 
LmxM.34.0020 pyruvate kinase 205 28.7 10 5 15.969582 0.968 
LmxM.05.0960 metallo-peptidase, Clan M-, Family M49 515 75.7 27 15 28.718704 0.954 
LmxM.14.0130 nucleoside hydrolase-like protein 163 39.2 11 6 24.715909 0.905 
LmxM.36.1940 inosine-guanosine transporter 367 54.2 15 8 17.43487 0.887 
LmxM.05.0350 trypanothione reductase 236 53.1 17 9 20.366599 0.874 
LmxM.36.1960 phosphomannomutase, putative 184 28.1 12 6 22.267206 0.874 
LmxM.36.6290 glucose transporter 2 191 61.1 10 5 13.227513 0.874 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.24.2060 transketolase, putative 330 71.8 19 11 18.181818 0.855 
LmxM.08_29.1090 ribosomal protein L1a, putative 84 47.6 12 8 20.506912 0.848 
LmxM.29.2980 glyceraldehyde 3-phosphate dehydrogenase, glycosomal 257 39.1 15 6 19.390582 0.848 
LmxM.22.1360 farnesyl pyrophosphate synthase, putative 206 41.1 10 6 17.955801 0.823 
LmxM.28.2740a hypothetical protein 264 34.4 15 6 24.038462 0.823 
LmxM.30.0010 5-methyltetrahydropteroyltriglutamate-
homocysteinemethyltransferase, putative 
295 86.1 24 13 15.844156 0.817 
LmxM.34.2350 aminopeptidase P, putative 298 53.7 17 8 15.495868 0.812 
LmxM.36.2950 succinyl-CoA ligase [GDP-forming] beta-chain, putative 71 44.1 12 8 21.549637 0.812 
LmxM.18.1370 heat shock protein, putative 512 91.9 26 15 23.08627 0.795 
LmxM.14.0310 proteasome alpha 3 subunit, putative 115 32.2 9 6 25.614035 0.778 
LmxM.15.0950 40S ribosomal protein S3, putative 182 24.5 11 6 28.310502 0.778 
LmxM.18.1520 P-type H+-ATPase, putative 406 107.4 28 15 16.837782 0.778 
LmxM.21.1700 proteasome alpha 2 subunit, putative 224 25.1 8 4 23.809524 0.778 
LmxM.21.1830 proteasome subunit alpha type-5, putative 161 26.8 8 5 21.721311 0.778 
LmxM.34.0030 pyruvate kinase, putative 329 54 14 9 25.702811 0.778 
LmxM.34.3800 60S ribosomal protein L23, putative 70 14.9 5 3 17.266187 0.778 
LmxM.26.2680 hypothetical protein, unknown function 208 40.9 11 6 18.832891 0.738 
LmxM.01.0770 Eukaryotic initiation factor 4A-1 207 51.1 15 8 20.833333 0.719 
LmxM.24.0761 malic enzyme 250 62.5 15 8 14.535902 0.719 
LmxM.26.0890 40S ribosomal protein S16, putative 103 16.7 8 4 22.818792 0.719 
LmxM.30.1440c hypothetical protein 61 46 6 3 8.5585586 0.701 
LmxM.36.6650 2,3-bisphosphoglycerate-independent phosphoglyceratemutase 472 60.8 16 9 21.699819 0.701 
LmxM.05.0830 methylthioadenosine phosphorylase, putative 114 33.3 10 5 18.300654 0.688 
LmxM.11.0240 proteasome alpha 7 subunit, putative 117 27.8 8 5 19.433198 0.688 
LmxM.16.0540 aspartate carbamoyltransferase, putative 111 35.4 8 5 23.547401 0.688 
LmxM.26.1570 thimet oligopeptidase, putative 257 77 19 10 17.518248 0.677 
LmxM.24.0850 triosephosphate isomerase 214 27 8 4 17.928287 0.668 
LmxM.08_29.2800 inosine-adenosine-guanosine-nucleosidehydrolase, putative 77 36.4 8 5 18.618619 0.65 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.27.1390 hypothetical protein 83 34.6 10 5 9.3167702 0.65 
LmxM.32.1035 hypothetical protein, conserved 104 19 5 3 23.163842 0.638 
LmxM.23.1220 T-complex protein 1, gamma subunit, putative 216 60.2 17 10 20.145191 0.632 
LmxM.27.0190 proteasome alpha 7 subunit, putative 141 25.6 6 4 18.067227 0.624 
LmxM.04.0950 hypothetical protein 193 24.5 10 4 23.474178 0.585 
LmxM.15.0200 60S ribosomal protein L13a, putative 70 25.5 9 5 20.720721 0.585 
LmxM.21.0730 60S ribosomal protein L36, putative 41 11.9 3 2 21.90476 0.585 
LmxM.21.1550 40S ribosomal protein S11, putative 79 16.3 5 3 21.276596 0.585 
LmxM.23.0360 NADP-dependent alcohol dehydrogenase, putative 119 38.5 8 5 14.204545 0.585 
LmxM.29.0880 adenosine kinase, putative 119 37.2 7 4 14.782609 0.585 
LmxM.29.2850 hypothetical protein, conserved 43 13.1 3 2 19.13043 0.585 
LmxM.29.3650 ribosomal protein L15, putative 86 24.4 8 4 16.666667 0.585 
LmxM.15.1010 glutamate dehydrogenase 519 114.6 31 17 19.27237 0.562 
LmxM.36.1600 proteasome subunit alpha type-1, putative 83 29.7 7 4 13.636364 0.551 
LmxM.13.0560 60S ribosomal protein L18, putative 118 22.1 5 2 11.111111 0.54 
LmxM.34.0750 proteasome activator protein pa26, putative 35 24.9 7 4 11.73913 0.52 
LmxM.36.4170 oxidoreductase, putative 100 36.1 5 4 22.647059 0.52 
LmxM.10.0390 GP63, leishmanolysin 256 63.8 11 7 13.621262 0.512 
LmxM.01.0520 long-chain-fatty-acid-CoA ligase, putative 122 77.5 13 8 11.468531 0.492 
LmxM.31.3270 chaperonin alpha subunit, putative 272 59.2 15 8 14.835165 0.492 
LmxM.19.0160 metallo-peptidase, Clan MG, Family M24 105 42.4 8 5 14.210526 0.487 
LmxM.03.0440 60S acidic ribosomal protein P2, putative 33 11 2 1 14.54545 0.468 
LmxM.23.0040 tryparedoxin peroxidase 91 25.4 4 3 12.831858 0.468 
LmxM.27.0760 ras-related protein RAB1A, putative 56 22.2 5 4 21 0.468 
LmxM.29.3500 S-adenosylmethionine synthetase 115 43.1 8 5 12.755102 0.468 
LmxM.33.2580 ALBA-domain protein 3 85 22.6 6 3 22.439024 0.468 
LmxM.33.4340 20s proteasome beta 7 subunit, (putative) 103 24.6 5 3 16.363636 0.468 
LmxM.36.3590 cysteine synthase, putative 143 35.4 8 4 16.216216 0.468 
LmxM.28.2910 glutamate dehydrogenase, putative 144 49 9 6 13.938053 0.453 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.04.1230 actin 139 42.1 7 4 15.957447 0.445 
LmxM.30.2600 calreticulin, putative 43 44.7 4 4 7.575758 0.445 
LmxM.25.2010 2,4-dihydroxyhept-2-ene-1,7-dioic acid aldolase, putative 80 30.3 5 3 13.620072 0.438 
LmxM.29.2490 heat shock 70-related protein 1, mitochondrial precursor, putative 336 72.5 15 8 16.516517 0.438 
LmxM.34.3840 proteasome beta 2 subunit, putative 79 27.5 4 3 12.992126 0.438 
LmxM.08_29.1720 histone H2A, putative 49 14 4 2 12.121212 0.425 
LmxM.09.0770 oligopeptidase b 272 83.5 15 8 15.731874 0.425 
LmxM.11.0820 hypothetical protein, conserved 196 37.4 5 3 16.617211 0.413 
LmxM.26.2710 glutamate 5-kinase, putative 58 29.1 5 3 13.257576 0.413 
LmxM.12.0030 proteasome beta-1 subunit, putative 216 30.5 6 3 14.487633 0.389 
LmxM.23.0840 hypothetical protein, unknown function 150 57 8 4 5.5028463 0.389 
LmxM.24.1500 IgE-dependent histamine-releasing factor, putative 147 31.1 5 3 16.666667 0.389 
LmxM.29.2580 
reticulon domain protein, 22 kDa potentially aggravating protein 
(paple22) 39 22.2 3 2 10.6599 0.389 
LmxM.34.1880 60S ribosomal protein L5, putative 198 34 9 5 14.754098 0.389 
LmxM.36.0940 40S ribosomal protein S18, putative 39 17.4 3 1 6.535948 0.389 
LmxM.24.2080 40S ribosomal protein S8, putative 89 24.7 6 3 14.678899 0.369 
LmxM.30.2150 prostaglandin f2-alpha synthase 48 31.8 4 3 14.084507 0.369 
LmxM.02.0740 peptidyl dipeptidase, putative 144 76.6 8 6 9.7345133 0.359 
LmxM.20.1180 calpain-like cysteine peptidase 158 103.5 11 6 8.137045 0.359 
LmxM.04.0190 surface antigen-like protein 224 74.1 7 5 9.0267983 0.354 
LmxM.30.2310 3'-nucleotidase/nuclease 90 41.6 6 3 7.6719577 0.35 
LmxM.36.2590 membrane-bound acid phosphatase 2, putative 121 62.6 8 5 8.7565674 0.343 
LmxM.11.1130 60S ribosomal protein L28, putative 41 16.2 4 2 12.2449 0.334 
LmxM.15.1450 proliferative cell nuclear antigen (PCNA), putative 61 32.4 6 3 8.8737201 0.334 
LmxM.16.0530 dihydroorotate dehydrogenase, putative 75 33.8 3 2 5.7507987 0.334 
LmxM.17.0735 lysine decarboxylase-like protein 79 35.3 5 3 9.3167702 0.334 
LmxM.19.0570 hypothetical protein, conserved 98 57.5 6 3 5.019305 0.334 
LmxM.25.0490 RNA-binding protein, putative, UPB1 36 19.9 2 1 4.597701 0.334 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.31.3130 ribosomal protein L3, putative 39 47.6 7 4 11.45585 0.334 
LmxM.32.0610 paraflagellar rod component, putative 32 14.2 2 1 8.8 0.334 
LmxM.32.3150 40S ribosomal protein S13, putative 59 17.5 3 2 10.596026 0.334 
LmxM.36.2020 OR 2030 chaperonin HSP60, mitochondrial precursor 250 59.6 11 6 12.566372 0.334 
LmxM.08.0290 iron superoxide dismutase A, mitochondrial 42 26.5 4 2 10.43478 0.311 
LmxM.16.0460 60S ribosomal protein L21, putative 105 18 3 2 15.09434 0.311 
LmxM.36.1370 Valosin-containing protein, putative 146 86.8 12 7 10.063694 0.308 
LmxM.06.0410 60S ribosomal protein L19, putative 73 28.2 6 3 13.360324 0.304 
LmxM.33.0140 malate dehydrogenase 139 33.7 6 3 12.025316 0.304 
LmxM.07.0680 40S ribosomal protein S9, putative 66 22.1 3 2 9.5238095 0.292 
LmxM.07.1000 RNA binding protein-like protein 70 38.5 4 2 6.557377 0.292 
LmxM.14.1360 myo-inositol-1-phosphate synthase 111 58.2 6 4 8.365019 0.292 
LmxM.21.1552 ATP-dependent RNA helicase SUB2, putative 133 49.4 7 4 8.9655172 0.292 
LmxM.30.0440 hypothetical protein 89 79.8 8 6 12.569061 0.292 
LmxM.34.1230 short chain dehydrogenase, putative 41 28.1 4 2 7.086614 0.292 
LmxM.04.0320 hypothetical protein 85 44.3 5 3 8.0200501 0.28 
LmxM.12.1130 NADH:flavin oxidoreductase/NADH oxidase, putative 93 41.4 5 3 8.59375 0.28 
LmxM.36.1260 fructose-1,6-bisphosphate aldolase 38 40.8 5 3 7.54717 0.28 
LmxM.22.1520 40S ribosomal protein L14, putative 89 20 4 2 11.428571 0.274 
LmxM.31.0430 60S ribosomal protein L17, putative 48 19.1 3 2 9.6385542 0.274 
LmxM.32.1330 glutamine aminotransferase, putative 103 46.1 6 3 7.0048309 0.269 
LmxM.18.0510 aconitase, putative 217 97.4 12 7 9.1517857 0.267 
LmxM.12.0630 alanine aminotransferase, putative 158 54.9 6 4 10.060362 0.266 
LmxM.04.1030 hypothetical protein 54 21.3 2 1 4.639175 0.259 
LmxM.19.0850 ATG8/AUT7/APG8/PAZ2, putative 70 12.8 2 1 9.6 0.259 
LmxM.22.1460 i/6 autoantigen-like protein 55 22.9 4 2 13.72549 0.259 
LmxM.24.1770 inhibitor of cysteine peptidase 43 12.7 2 1 16.81416 0.259 
LmxM.36.2360 tyrosine aminotransferase, putative 51 49.5 3 2 9.5982143 0.259 
LmxM.11.0100 seryl-tRNA synthetase 62 52.9 7 4 7.1729958 0.252 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.21.0540 Lupus La protein homolog, putative 118 37.2 6 2 10.619469 0.25 
LmxM.34.0400 40S ribosomal protein S3A, putative 111 30 4 2 11.742424 0.245 
LmxM.08.1030a hypothetical protein 139 57.5 6 3 6.1913696 0.241 
LmxM.32.2300 udp-glc 4'-epimerase, putative 99 43.5 5 3 8.6956522 0.241 
LmxM.15.1230 nucleoside transporter 1, putative 89 54.1 3 2 4.2769857 0.233 
LmxM.27.1730 hypothetical protein, conserved 86 37.8 2 2 6.1764706 0.233 
LmxM.29.0850 surface protein amastin, putative 52 21.1 2 1 5.0505051 0.233 
LmxM.36.3770 transcription factor btf3, putative 78 11.6 1 1 15.53398 0.233 
LmxM.36.6910 T-complex protein 1, theta subunit, putative 124 58.2 6 4 8.3798883 0.227 
LmxM.19.0440 nucleosome assembly protein, putative 52 39.8 3 2 5.9659091 0.222 
LmxM.36.3210 14-3-3 protein 1, putative 152 29.7 4 2 13.178295 0.222 
LmxM.08_29.0060 tryptophanyl-tRNA synthetase, putative 50 45.3 4 3 7.0707071 0.218 
LmxM.27.1805 Phosphoenolpyruvate carboxykinase [ATP], glycosomal 115 58.4 4 3 7.8095238 0.218 
LmxM.29.2740 TPR domain protein, conserved 92 45.1 6 3 8.4577114 0.218 
LmxM.21.1090 T-complex protein 1, delta subunit, putative 108 59.7 7 4 6.3520871 0.216 
LmxM.25.0820 hypothetical protein, conserved 41 14.7 1 1 7.874016 0.212 
LmxM.13.1220 40S ribosomal protein S4, putative 69 47.3 5 3 7.6744186 0.205 
LmxM.20.0110 phosphoglycerate kinase B, cytosolic 58 44.8 4 3 9.8321343 0.205 
LmxM.29.0460 aspartyl-tRNA synthetase, putative 105 62.3 8 4 6.7272727 0.198 
LmxM.34.3340 6-phosphogluconate dehydrogenase, decarboxylating, putative 95 52.1 6 3 7.0981211 0.194 
LmxM.36.6940 protein disulfide isomerase 2 67 52.2 6 3 7.6109937 0.194 
LmxM.10.0290 isocitrate dehydrogenase [NADP], mitochondrial precursor, 
putative 
83 48.4 5 3 6.4367816 0.189 
LmxM.11.0350 14-3-3 protein 2, putative 57 29.1 4 2 6.3241107 0.186 
LmxM.25.1120 aldehyde dehydrogenase, mitochondrial precursor 91 54.2 6 3 5.01002 0.184 
LmxM.22.0460 40S ribosomal protein S15, putative 34 17.4 1 1 10.52632 0.179 
LmxM.13.0090 metallo-peptidase, Clan MA(E) Family M32 86 57.2 6 3 5.7654076 0.174 
LmxM.24.2050 60S ribosomal protein L26, putative 42 16.2 2 1 6.293706 0.166 
LmxM.07.0510 60S ribosomal protein L7a, putative 69 33.8 3 2 6.3545151 0.155 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.19.1420 cysteine peptidase A (CPA) 50 38.7 2 1 3.6723164 0.155 
LmxM.34.3700 glycosomal membrane protein 45 24.9 2 1 3.555556 0.155 
LmxM.36.0250 eukaryotic translation initiation factor 3 subunit l 56 62.7 5 3 4.5955882 0.155 
LmxM.08_29.1500 hypothetical protein, conserved 43 73.5 3 2 4.315476 0.15 
LmxM.26.2700 6-phosphogluconolactonase 40 28.4 2 1 3.745318 0.145 
LmxM.36.6750 prolyl endopeptidase 34 77.9 5 3 6.743185 0.145 
LmxM.26.1960 hypothetical protein, conserved 94 89.4 7 4 5.4931336 0.143 
LmxM.33.2820 regulatory subunit of protein kinase a-like protein 97 71.7 5 3 5.2631579 0.142 
LmxM.12.0400 3'-nucleotidase/nuclease, putative 49 41 2 1 2.6246719 0.136 
LmxM.18.0680 citrate synthase, putative 48 52.2 4 2 3.4042553 0.136 
LmxM.23.1480 hypothetical protein, conserved 52 27.3 2 1 3.265306 0.136 
LmxM.24.2110 3-hydroxy-3-methylglutaryl-CoA synthase, putative 33 55.3 3 2 2.794411 0.136 
LmxM.26.1380 prefoldin-like protein 74 22.2 2 1 6.185567 0.136 
LmxM.06.0140 proteasome beta 6 subunit, putative 37 27.9 2 1 4.048583 0.129 
LmxM.08_29.1960 fumarate hydratase, putative 87 24.5 2 1 5.4794521 0.129 
LmxM.29.0180 2-hydroxy-3-oxopropionate reductase, putative 72 31 2 1 7.0234114 0.129 
LmxM.36.5100 hypothetical protein, conserved 81 105.8 4 3 4.4715447 0.129 
LmxM.15.0440b hypothetical protein 67 73.3 4 3 10.502283 0.12 
LmxM.34.0640 beta-fructofuranosidase-like protein 71 121.1 5 3 3.9233577 0.118 
LmxM.27.1310 arginyl-tRNA synthetase, putative 42 78 5 3 4.624277 0.114 
LmxM.34.0500 OR 0500a 
OR 0520b 
proteophosphoglycan ppg3, putative  145 121456 8 4 3.5 0.11 
LmxM.34.3860 T-complex protein 1, eta subunit, putative 44 61.7 3 2 5.087719 0.11 
LmxM.17.0010 eukaryotic translation initiation factor 3 subunit a 41 87.6 5 3 4.521964 0.107 
LmxM.32.3070partial hypothetical protein 110 96.4 5 2 12.735327 0.107 
LmxM.30.2080 hypothetical protein, conserved 57 87.1 4 2 3.9653036 0.105 
LmxM.26.1240 heat shock protein 70-related protein 70 70.6 2 2 6.0842434 0.099 
LmxM.27.1870 trypanothione synthetase 97 74.4 4 2 3.9877301 0.099 
LmxM.31.0400 ATP-dependent RNA helicase HEL67 84 67.7 3 2 3.2154341 0.099 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.27.1300 hypothetical protein, conserved 61 60 3 2 4.9149338 0.094 
LmxM.19.1160 hypothetical protein, conserved 38 41.3 2 1 5.149051 0.093 
LmxM.31.0840 hypothetical protein, conserved 86 56.7 2 1 3.0828516 0.093 
LmxM.22.1290 ribonucleoside-diphosphate reductase small chain, putative 50 44.4 2 1 3.3163265 0.089 
LmxM.18.1380 pyruvate dehydrogenase E1 component alpha subunit, putative 48 42.7 2 1 2.9100529 0.08 
LmxM.16.1010 hypothetical protein, conserved 68 104.8 3 2 3.4267913 0.077 
LmxM.25.0750 protein phosphatase, putative 37 45.2 2 1 2.463054 0.077 
LmxM.32.2270 hypothetical protein, conserved 32 83.3 3 2 51.04809 0.073 
LmxM.25.1170 ATP synthase subunit beta, mitochondrial, putative 55 56.2 1 1 2.285714 0.07 
LmxM.08.1100 hypothetical protein, conserved 58 42.2 2 1 6.027397 0.068 
LmxM.12.1090 promastigote surface antigen protein PSA 39 55.4 2 1 2.140078 0.068 
LmxM.13.0160 protein kinase A regulatory subunit 30 56.3 2 1 1.590457 0.066 
LmxM.22.1540 alanyl-tRNA synthetase, putative 83 106.1 4 2 1.7671518 0.061 
LmxM.36.5620 isoleucyl-tRNA synthetase, putative 57 125.7 5 3 2.1838035 0.056 
LmxM.15.0230 lysyl-tRNA synthetase, putative 42 67.1 1 1 1.365188 0.054 
LmxM.23.0540 acetyl-CoA synthetase, putative 68 79.2 2 1 1.2622721 0.051 
LmxM.30.0930 sodium stibogluconate resistance protein, putative 33 68.4 2 1 1.127214 0.051 
LmxM.27.1260 T-complex protein 1, beta subunit, putative 31 57.7 1 1 3.780718 0.05 
LmxM.21.0810 methionyl-tRNA synthetase, putative 38 83.8 2 1 1.07095 0.044 
LmxM.33.0080 glucose-6-phosphate dehydrogenase 49 63.7 2 2 4.8042705 0.044 
LmxM.31.2150 hypothetical protein, conserved 49 117.4 2 1 0.9242144 0.042 
LmxM.12.0250 cysteinyl-tRNA synthetase, putative 66 88.4 2 1 1.2755102 0.041 
LmxM.36.6980 eukaryotic translation initiation factor 3 subunit c 81 81.7 2 1 1.9178082 0.04 
LmxM.11.1170 eukaryotic release factor 3, putative 34 84.7 2 1 0.912647 0.038 
LmxM.08_29.2200 dynamin-1-like protein 33 76.9 1 1 1.157742 0.036 
LmxM.30.3090 peptidase, putative 33 118.6 1 1 1.203704 0.036 
LmxM.34.1410 threonyl-tRNA synthetase, putative 70 89.7 2 1 1.3977128 0.036 
LmxM.34.3100 ATP-dependent RNA helicase, putative 45 100.8 2 1 1.4038877 0.032 
LmxM.13.1100 leucyl-tRNA synthetase, putative 53 121.9 2 1 0.8372093 0.03 
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Accession Description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.34.2080 calcium motive p-type ATPase, putative 43 133.8 2 1 1.469388 0.029 
LmxM.31.2270 membrane associated protein-like protein 45 163.8 2 1 12.90102 0.019 
LmxM.27.0500 cysteine peptidase, Clan CA, family C2, putative 128 653.7 5 4 1.2167565 0.018 
LmxM.14.1120 kinesin K39, putative 86 297.4 3 2 17.574164 0.016 
 
 
 
 
Table 4-3 Secreted proteins of L. mexicana amastigotes. Proteins identified in three or more biological repeats. Scoring scheme, mascot score >30, see methods for 
complete settings. Accession numbers from TriTrypDB, peptide spectral matches (PSMs), sequences indicate number of different peptide sequences that the PSMs 
matched to. Estimation of protein abundance by the exponentially modified protein abundance index (emPAI). 
Accession Protein description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.10.0460 GP63, leishmanolysin 810 69.6 34 15 25.2 2.2 
LmxM.10.0465 GP63, leishmanolysin 651 69 31 14 23.1 2.2 
LmxM.24.0850 triosephosphate isomerase 299 27 15 9 40.2 2.2 
LmxM.29.1510 p1/s1 nuclease 200 35.2 11 7 21.2 2.0 
LmxM.09.0891 polyubiquitin, putative 203 14.6 9 6 46.1 1.9 
LmxM.31.2950 OR 2951 nucleoside diphosphate kinase b 196 16.7 9 6 50.3 1.9 
LmxM.09.1490 cytochrome b5-like protein, putative 115 12.9 6 3 46.2 1.7 
LmxM.08.1030a hypothetical protein [cysteine protease, putative] 345 57.5 23 10 20.6 1.5 
LmxM.16.1310 cytochrome c, putative 97 12.2 5 4 29.2 1.5 
LmxM.08_29.0867 guanine deaminase, putative 316 49.1 11 7 20.3 1.4 
LmxM.15.1040 tryparedoxin peroxidase 208 22.2 8 4 23.6 1.2 
LmxM.09.0910, 0920 OR 
0930 
calmodulin, putative 140 16.8 4 3 30.2 0.7 
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Accession Protein description Mascot Score Mass [kDa] PSMs Sequences Coverage (%) emPAI 
LmxM.23.0040 tryparedoxin peroxidase 138 25.4 7 3 19.9 0.7 
LmxM.29.0970 p22 protein precursor, putative 118 25.8 4 4 19.3 0.7 
LmxM.08.1040 OR 
1070partial 
hypothetical protein [cysteine protease, putative] 323 55.5 15 4 13.3 0.62 
LmxM.17.0360 cytidine deaminase-like protein 107 19.3 4 3 16.5 0.6 
LmxM.28.2770 heat-shock protein hsp70, putative 300 71.2 17 10 17.7 0.6 
LmxM.29.2490 heat shock 70-related protein 1, mitochondrial precursor, putative 260 72.5 18 12 10.1 0.6 
LmxM.32.1750 macrophage migration inhibitory factor-like protein 60 12.7 2 2 13.3 0.6 
LmxM.08_29.1160 tryparedoxin 1, putative 39 16.6 3 2 13.8 0.5 
LmxM.30.1900, 2030 OR 
36.3530partial 
ubiquitin-fusion protein  68 14.96 2 1 12.5 0.36 
LmxM.29.2550 heat shock 70-related protein 1, mitochondrial precursor, putative  252 71.34 16 4 6.9 0.3 
LmxM.33.0140 malate dehydrogenase 169 33.7 5 2 8.2 0.3 
LmxM.28.1200 luminal binding protein 1 (BiP), putative 106 71.7 5 4 5.5 0.2 
LmxM.28.2910 glutamate dehydrogenase, putative 100 49 5 3 10.8 0.2 
LmxM.29.2980 glyceraldehyde 3-phosphate dehydrogenase, glycosomal 32 39.1 2 2 7.2 0.2 
LmxM.31.0840 hypothetical protein, conserved 51 56.7 3 2 5.2 0.2 
LmxM.36.2020 chaperonin HSP60, mitochondrial precursor 73 60.3 4 4 5.7 0.2 
LmxM.07.0990 nucleolar RNA-binding protein, putative 31 36.3 1 1 2.9 0.1 
LmxM.14.0310 proteasome alpha 3 subunit, putative 44 32.2 1 1 3.5 0.1 
LmxM.26.0660 protein disulfide isomerase, putative 30 40.9 1 1 1.8 0.1 
LmxM.26.1960 hypothetical protein, conserved 111 89.4 5 3 5.5 0.1 
LmxM.36.3990 ATP-dependent protease subunit HslV, putative 52 24.7 1 1 5.3 0.1 
LmxM.27.0240 kinetoplast-associated protein-like protein 67 145.6 2 1 81.7 0.0 
LmxM.32.0312 heat shock protein 83-1 52 80.5 2 1 1.7 0.0 
LmxM.33.3230 hypothetical protein, conserved 37 243.7 2 1 0.3 0.0 
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4.3.4 Comparative analyses of the predicted properties of 
Leishmania secreted proteins 
The predicted properties of the secretome from each of the life cycle stages also 
show overall differences, summarised in Table 4-4. 9.8% of the proteins in the 
promastigote secretome were predicted to contain a signal peptide directing the 
protein to the classical secretion pathway, and 20.7% were predicted to be non-
classically secreted, using the SignalP and SecretomeP algorithms, respectively. 
Whereas 13.9% of amastigote secretome proteins are predicted to contain a signal 
peptide and a further 33.3% are predicted to be non-classically secreted. If we 
compare this to the total percentage of classically and non-classically secreted 
proteins predicted in the whole cell proteome for promastigotes and amastigotes, 
this is only 6.9% SigP Pro and 13.5 % SigP Ama%, respectively (Supplementary Data 
I). 
Gene ontology (GO) functions were assigned to the proteins in the promastigote 
and amastigote secretome (Figure 4-5 a, b). The most abundant functions in the 
promastigote secretome were ribosomal-associated proteins, protein degradation, 
carbohydrate metabolism and protein biosynthesis. The most abundant functions 
in the amastigote secretome were protein degradation, redox and 
chaperones/stress induced proteins. 
Proteins extracted from parasites and identified by LC-MS/MS were searched 
against the L. mexicana genome database at TriTrypDB.org and exported with their 
predicted isoelectric points. Figure 4-6 shows the percentages of proteins with 
specific predicted pI in the experimental proteome and secretome of promastigotes 
and amastigotes. The mean isoelectric point is recorded in brackets next to the 
key. When the predicted isoelectric points of the secretome and proteome proteins 
are investigated on a pH by pH basis there appears to be a shift in the pI of the 
amastigote secretome proteins to a more basic pI between 7 and 9. 
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Table 4-4 Predicted molecular properties of proteins secreted from L. mexicana promastigotes 
and amastigotes. Predictions of protein size, pI and number of trans-membrane domains were 
exported from the L. mexicana annotated genome database at tritrypdb.org. Signal peptide predictions 
were made using the online SignalP server, and the online SecretomeP server was used to predict 
non-classical secretion, found at cbs.dtu.dk/services/SignalP/ and cbs.dtu.dk/services/SecretomeP/, 
respectively. 
 Promastigote Amastigote 
Total number of reproducible secretome proteins 256 36 
Proteins with TM Domains 10.9% 22.22% 
Proteins with Predicted Signal Peptide 9.8% 13.9% 
Proteins Predicted as Non-Classically Secreted 20.7% 33.3% 
Average Isoelectric Point 6.82 6.61 
Average Molecular Weight 51,090 49,750 
Average Protein Length 462.3 455.5 
 
 
 
 
Figure 4-5 Gene ontology (GO) of the promastigote (a) and amastigote (b) secretome. 
Percentages assigned by number of different proteins with function, does not take protein abundance 
into account. Not accounting for proteins which can fit into multiple categories. 
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Figure 4-6 Predicted isoelectric point of L. mexicana promastigote and amastigote proteins 
from the proteome and the secretome. Proteins from the experimental proteome and secretome of 
both promastigotes and amastigotes were grouped according to their predicted isoelectric point 
assigned on TriTrypDB. 
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4.3.5 Validation and experimentation using Western Blot 
Figure 4-7a shows Western blot testing of the antibodies for the promastigote and 
amastigote cell lysate proteins. In addition to providing a positive control for the 
antibody response to L. mexicana proteins, these show interesting stage-dependent 
differences between the life cycle stages. GP63 is recognised in both promastigotes 
and amastigotes using polyclonal antisera raised against GP63, but is not recognised 
in amastigotes with a monoclonal antibody to GP63 raised against promastigote 
purified GP63, demonstrating stage-dependent isoforms of GP63 in L. mexicana. 
Enolase (ENO) shows the presence of a common band at ~44 kDa, but multiple 
stage-specific differences at 22-25 kDa and 74-92 kDa.  Similar stage-dependent 
differences are observed for glutamate dehydrogenase (GDH). Β-tubulin antibody 
clone KMX detected β-tubulin in promastigotes but not in amastigotes. And as 
expected and demonstrated previously (Nugent et al. 2004), amastigote-specific 
antigens cysteine protease and HASPB were only detected in the amastigote cell 
lysate. 
Figure 4-7b shows Western blotting demonstrating the presence of proteins 
identified in the secretome by MS. In the absence of any proteins equivalent to 
housekeeping genes in the secretome, equal sample loading has been shown by 
silver staining of the same samples. Secretory acid phosphatase and enolase, which 
were not identified in the amastigote secretome by MS, were also not detected in 
the amastigote secretome by Western blot. GP63 was detected in both the 
promastigote and amastigote secretome, consistent with the MS findings. 
Oligopeptidase B (OPB) was identified in some but not three or more replicates of 
the secretome using MS and was therefore not included in the amastigote 
secretome list for further analysis. However, the results of the Western blot clearly 
show the presence of OPB in all three replicates of the amastigote secretome.  
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Figure 4-7 Western blots of L. mexicana parasite lysates (a) and secreted proteins (b). a. 10 µg 
of promastigote and amastigote lysate, separated by SDS-PAGE and blotted on PVDF membrane, 
were probed with polyclonal or monoclonal antibodies to glycoprotein 63 (GP63), oligopeptidase b 
(OPB), enolase (ENO), cysteine protease (Cys Prot), β-tubulin clone KMX, hydrophilic acylated 
surface protein B (HASPB), and glutamate dehydrogenase (GDH). b. To test the antibodies against 
Leishmania proteins and determine total cell differences between promastigotes and amastigotes. 0.4 
µg of promastigote and amastigote secretome, equivalent to secretion from approx. 107 promastigotes 
and 5 x 107 amastigotes, were blotted with the above antibodies and additional secretory acid 
phosphatase (SAP) antibody. Sample loading is shown by silver staining.  
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4.4 Discussion 
4.4.1 The Leishmania secretome 
Previously characterised Leishmania secreted proteins such as histidine secretory 
acid phosphatase (SAP) (Ilg et al. 1991), GP63 (Gómez et al. 2009a), PPGs (Peters 
et al. 1997b), and iron superoxide dismutase (Marín et al. 2007) were identified 
within the isolated promastigote secretome presented here. Figure 4-8 shows the 
number of proteins in common with this study and the others. 80.5% of the Hamilton 
secretome has been previously identified in other published Leishmania 
promastigote secretomes with 65% in two or more other published secretomes. 75% 
of the amastigote secretome has been identified in other published Leishmania 
promastigote secretomes, with only 54% of amastigote secretome found in two or 
more published promastigote secretomes. This is the first study to report the 
secreted proteome of Leishmania amastigotes. 
Paape et al. identified 67 potential amastigote secreted proteins from the 
supernatant of a FACS analysis when amastigotes were sorted from macrophage 
cell debris and lysed cells (Paape et al. 2010). They identified 67 proteins in this 
fraction, however, only 3 proteins are in common between these data and the 
amastigote secretome presented here (Figure 4-9). While this was an interesting 
additional analysis by Paape et al. to ensure fuller coverage of the amastigote 
proteome, the supernatant was likely contaminated with proteins from parasite 
and host cell lysis and thus would not accurately represent an amastigote 
secretome. 
In addition to the proteins which have been previously observed in promastigote 
secretome studies, there were other proteins of interest identified here which have 
not previously been described as secreted, and which may therefore be novel 
secreted proteins. Here, 19.5% of the protein identifications were unique to the 
Hamilton promastigote secretome (excluding hypothetical proteins) and 25% were 
unique to the amastigote secretome.  
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Figure 4-8 Venn diagram showing overlapping Leishmania secreted protein identifications. 
Diagram generated at http://bioinformatics.psb.ugent.be/webtools/Venn/. Secreted proteins isolated 
from promastigotes of L. mexicana (Hassani et al. 2011, Hamilton), L. donovani (Silverman et al. 
2008), and L. infantum (Braga et al. 2014; Santarém et al. 2013b), and from amastigotes of L. 
mexicana (Hamilton_Ama). Total number of secreted protein identifications, minus hypothetical 
proteins, are shown adjacent to the data reference name. Protein orthologues with the same name 
are grouped as one unique element. 
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Figure 4-9 Venn diagram showing common identifications between L. mexicana amastigote 
putatively secreted proteins Excluding hypothetical proteins. Proteins identified from culture 
supernatant of axenic amastigotes (Hamilton) or from the supernatant of FACS-sorted amastigotes 
isolated from macrophages (Paape et al. 2010). 
Using the putative annotations of the proteins identified we can infer possible roles 
in niche modification, such as involvement in alternative activation of macrophages 
or inhibition of apoptosis in macrophages. These processes have been observed in 
Leishmania infection (Kamir et al. 2008; Lisi et al. 2005; Moore & Matlashewski 
1994; Ruhland et al. 2007), but the mechanisms not deduced. Secreted proteins 
are also known to play roles in the inactivation of macrophage transcription factors 
(Contreras et al. 2010) and altering the nucleopore complex in the host macrophage 
(Isnard et al. 2015). 
Molecular chaperones calreticulin and protein disulphide isomerase were both 
found in the promastigote secretome and have been shown to be involved in the 
control of protein secretion in L. donovani (Duncan et al. 2011). 
90.2% of the promastigote secretome and 86.1% of the amastigote secretome did 
not contain a classical signal peptide, suggesting alternative secretion pathways 
including the presence of nonclassical secretory signals or release from the parasite 
via exosomes (Nickel & Rabouille 2009). Indeed, some putative exosomal proteins, 
such as Rab1A, and membrane proteins were identified in the promastigote 
secretome (Simpson et al. 2008). This was not to the extent that other studies have 
observed (Silverman et al. 2008) as orthologues to proteins from the endosomal 
sorting complexes required for transport (ESCRT) pathway (Schmidt & Teis 2012) 
were not identified here. These have previously been found in other studies in 
    3
Hamilton
Paape
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Leishmania, albeit in low abundance before vesicle purification (Silverman et al. 
2008, 2010a). However, by comparison to the analyses performed by Silverman et 
al. (2008), we found that of the proteins identified in the L. donovani secretome 
as vesicle-associated, using the exosomal proteins of B lymphocytes, dendritic cells 
and adipocytes, 67% were also present in our promastigote secretome (Appendix 
3). 
4.4.2 Comparison of promastigote and amastigote secretome 
As we can see from the summary of the properties of the promastigote and 
amastigote secretome (Table 4-4), L. mexicana amastigotes secrete qualitatively 
and quantitatively different proteins to promastigotes, likely reflecting their 
adaptation to different environments within the host. 
Here, the discovery of proteins detected in promastigotes but not amastigotes, or 
vice versa, provides validation on the differences between promastigotes and 
axenic amastigotes. One such example is the detection of secretory acid 
phosphatase only in promastigote samples. It is known that amastigotes do not 
produce a secretory acid phosphatase (Menz et al. 1991). Antibody to promastigote 
soluble acid phosphatase did not precipitate any enzyme activity from lysed 
amastigotes or amastigote culture supernatant (Menz et al. 1991). Secretory acid 
phosphatase was found to be the most abundant protein secreted by promastigotes 
in this study but was not detected in the secretome of amastigotes by MS or by 
Western blot. 
The total numbers of proteins identified for each of the two life cycle stages differs 
greatly. 256 proteins were identified in the promastigote secretome, with only 36 
proteins in the amastigote secretome. It is unclear if this is a technical effect or a 
reflection of reduced secretion in amastigotes. The evidence points to a 
combination of the two. In terms of total secreted protein isolated from 
promastigotes and amastigotes, we have shown that promastigotes secrete 
approximately five times more protein per cell than amastigotes. This of course 
will, in part, be due to the smaller size of the amastigotes at approximately 4 µm 
compared to late-log and stationary phase promastigotes at between 7.5 and 8 µm 
(Bates 1994). We increased the numbers of amastigotes per secretion assay to 
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account for this, but as this is only a two-fold reduction in size this does not fully 
account for the observed reduced secretion in amastigotes. The reduction in 
secretion could therefore also be explained by the slower growth rate of 
amastigotes and their adoption of a stringent metabolic state (Saunders et al. 
2014), thus longer incubation time may be required to give a fuller picture of 
amastigote secretion. 
Nevertheless, we have shown by Western blot of OPB that proteins which were not 
identified in all replicates of the amastigote secretome by MS were indeed present 
in all three replicates, detectable by specific antibodies. This demonstrates the 
variability in the identification of low-abundance proteins by MS particularly in 
protocols where only the three most abundant peptides are selected from the 
survey scan for fragmentation. Due to the length of this investigation and the 
optimisation steps involved, the corresponding mass spectrometry equipment and 
protocols had been changed and improved over the course of the investigation. Due 
to time constraints and limited sample availability, not all replicates were analysed 
using the latest method (2.13) which selects the top 20 most abundant peptides 
per scan for fragmentation. This could therefore account for some of the 
discrepancy. Finally, an increase in glycosylation of amastigote PPG and potentially 
other proteins, demonstrated here (Figure 4-4) and by others (Peters et al. 1997a), 
may prevent the efficient trypsin digestion of the proteins to the appropriate 
peptides for database matching. A deglycosylation step in the amastigote 
secretome isolation protocol could therefore be added to investigate this. 
The predicted isoelectric point (pI) of many of the amastigote secreted proteins 
has shifted towards a more basic pH than that of the promastigote, away from a pI 
of between 4 and 6 (Figure 4-6). Proteins are least soluble in solutions which are 
the pH of their isoelectric point. Thus, this could indicate an increase in the 
solubility of amastigote secreted proteins at acidic pH, correlating with the acidic 
environment of the parasitophorous vacuole of pH 5 (Antoine et al. 1998), into 
which these proteins are delivered by intracellular amastigotes. This observation is 
supported by the comparison of the secretome protein profiles in 2-dimensional 
electrophoresis (Figure 4-2). 
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We also observed differences in physical properties of the secretome. When 
isolating the amastigote secretome we observed a viscous ‘gel’ like substance in 
the sample pellet after precipitation. This property is commonly observed in 
preparations of glycoproteins or mucins (Davies et al. 2012; Davies & Carlstedt 
2000). An insoluble component was also observed in the amastigote secretome 
after freezing. It is not known where the insoluble component originated from but 
it is unique to amastigote-conditioned medium as the phenomenon did not occur in 
cSDM alone or in cSDM with the addition of protease inhibitors. A similar 
phenomenon occurs in urinary samples, where a precipitate is formed after 
freezing (Saetun et al. 2009). These were characterised as calcium crystals and 
calcium oxalate, with the addition of CaCl2 found to increase sediment formation. 
This is an interesting observation as amastigote media, cSDM, contains calcium in 
the form of CaCl2, whereas HOMEM does not. Saetun and colleagues also note that 
the sedimentation entrapped a considerable amount of protein, and if discarded 
severely diminished the total protein content of the samples (Saetun et al. 2009). 
This may provide an explanation for the reduced protein concentration in the 
amastigote samples when compared to the promastigote samples. Proteomic 
analysis of the precipitate, however, was inconclusive as it showed the presence 
of only a few peptides, most of which matched to proteins already identified in the 
amastigote secretome. These observations require further investigation as this is a 
significant difference between the promastigote and amastigote secretome. 
Chelation of calcium by amastigotes may be a potent virulence mechanism used by 
the parasite, as dysfunctions in infected host cells have been previously related to 
abnormal intracellular Ca2+ homeostasis (Olivier 1996). Indeed, macrophages 
infected with Leishmania major amastigotes were shown to contain approximately 
40% more intracellular calcium than uninfected cells. This was attributed to the 
strong calcium-binding capacity of an amastigote ‘excreted factor’, as the effect 
could be replicated using other cell types coated with excreted factor (Eilam et al. 
1985). Taken together, we can postulate that amastigote excreted factor may be 
binding calcium in the media and precipitating upon freezing. This excreted factor 
may be the abundant amastigote PPG (aPPG) which may be difficult to identify in 
proteomic analyses, as discussed below. 
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4.4.3 Predicted functions and categories of secreted proteins 
i. Glycoproteins 
Leishmania are known to express multiple proteophosphoglycans (PPGs). 
Promastigote PPG 2 (pPPG2) is a glycoisoform of amastigote PPG (aPPG), with the 
same protein backbone but different glycosylation (Klein et al. 1999). Due to the 
different ultrastructure of the protein it was found to be smaller than the aPPG, 
eluting from a Superose 6 gel filtration column between 300 and 500 kDa (Klein et 
al. 1999). Promastigotes also express a filamentous PPG (fPPG). When staining for 
glyco-moieties in the SDS-PAGE gel, two high molecular weight glycosylated bands 
were observed in the amastigote secretome (Figure 4-4). This is likely to be the 
abundant aPPG. The level of glycosylation of amastigote aPPG may be responsible 
for the concentration visualised in the gel which exceeds any other component of 
the secretome. The ppg2 gene encodes the common backbone of aPPG and pPPG2 
secreted by amastigotes and promastigotes, respectively. Amastigotes and 
promastigotes exhibit stage-specific phosphoglycosylation patterns. The serine-rich 
repeats in the sequence are targets for Ser phosphoglycosylation in Leishmania 
mexicana (Gopfert et al. 1999). However, the level of glycoprotein staining 
observed in promastigotes was much less than in amastigotes. This could be due to 
the small amounts of secretome proteins loaded onto the gels, with amastigote 
staining visible due to extensive glycosylation of aPPG. 
This same result was not seen in the LC-MS/MS amastigote secretome potentially 
due to extensive glycosylation. Abundant glycoproteins were identified by MS in 
the secretome of the promastigotes, but not seen in amastigotes. There are two 
main reasons this is thought to occur. Ilg et al. observed a reduction or absence of 
aPPG in cultured amastigotes whereas aPPG was identified in ex-vivo parasites. In 
this case the authors suggest that the synthesis of aPPG may rely on signals from 
the macrophage, and therefore they did not see it in the supernatant of axenic 
parasites (Ilg et al. 1998). However, we observe the presence of a high molecular 
weight and heavily glycosylated protein by SDS-PAGE. Therefore it is likely that in 
a mass spectrometry analysis of the protein as opposed to the glyco moieties, the 
extensive and branched glycosylation on the aPPG could be preventing the action 
of trypsin by steric hindrance thereby preventing the production of the unique 
tryptic peptides necessary for sequence matching and identification (Aebischer et 
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al. 1999; Yang et al. 2017). As discussed above it is possible that aPPG is analogous 
to amastigote ‘excreted factor’ and forms the precipitate observed in the thawed 
secretome. 
Secretory acid phosphatase (SAP) is another well-known Leishmania glycoprotein 
(Ilg et al. 1991). A previous publication has shown that L. mexicana SAP appears in 
two distinct bands for SAP1 and SAP2, at ~95 and >180 kDa, respectively (Klein et 
al. 1999). Results presented here are consistent with this when analysing the 
secretome from Western Blotting. Whereas, fPPG was located in the stacking gel 
which also correlates with findings presented herein. Furthermore, PPG has been 
shown to form a gel in concentrated solutions (Ilg et al. 1995), which was further 
observed here during the preparation of the amastigote secretome. In addition this 
was proteinase resistant (Ilg et al. 1995). It was been described that secreted aPPG 
causes vacuole formation in macrophages (Peters et al. 1997b), an example of 
niche modification. 
Searching in Mascot for glycan modifications is very new and involves creating a 
custom database of your organism of interest with multiple glycan modifications. 
A method for this has now been designed but the field is still in its infancy (Bollineni 
et al. 2018). It may be possible to add extra modifications and missed cleavages to 
the amastigote secretome mascot search to look for glycosylated peptides, 
however this would require extensive data analysis and constitutes future 
development and work.  
ii. GP63 in amastigotes 
It is shown here that GP63 is an abundant component of the amastigote secretome. 
This initially appears surprising given that surface-bound and released GP63 is more 
often associated with promastigotes, however there is abundant evidence of stage-
specific isoforms and localisation of GP63. Amastigote GP63 could not be surface-
labelled to the same extent as promastigote GP63 and lacked a PI membrane 
anchor. In addition, the majority of the GP63 in the amastigote localised to the 
flagellar pocket (Medina-Acosta et al. 1989; Paape et al. 2008). Nugent et al. used 
a monoclonal antibody to promastigote GP63 which did not recognise amastigote 
GP63. In this study, monoclonal GP63 antibody did not recognise GP63 in 
amastigotes, but polyclonal antisera did recognise a protein in amastigotes and 
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promastigotes showing that there is a fundamental difference in epitope and 
different forms are expressed in these cells. This may give an indication as to why 
GP63 appears to be the most abundant secreted protein in amastigotes where it 
was previously not associated with amastigotes. Also there is different 
electrophoretic mobility between amastigote and promastigote GP63 (Chaudhuri 
et al. 1989). Amastigote GP63 was found in the soluble fraction of the lysate but 
not the membrane fraction as with promastigotes and appeared at higher apparent 
molecular weight than its promastigote counterpart (Bahr et al. 1993). Transcripts 
of the large GP63 gene family were found to be differentially processed in 
promastigotes and amastigotes (Frommel et al. 1990; Medina-Acosta et al. 1989), 
and later it was discovered that these are encoded by different members of the 
GP63 gene family in promastigotes and amastigotes (Medina-Acosta et al. 1993). 
We also postulate that the ~66.4 kDa band seen in amastigotes is a form of GP63 
and is possibly found in secreted vesicles. This is because when the amastigote 
secretome is filtered through a 0.22 µm membrane before detergent extraction and 
SDS-PAGE, the intensity of the 66.4 kDa band decreases, but the intensity of other 
bands do not, including high molecular weight bands. Presence of a 66 kDa GP63 
has been observed before in amastigotes but not in promastigotes (Hsiao 2008). 
Secretion of GP63 by amastigotes as well as promastigotes is further substantiated 
by the identification of GP63 in the secreted exosomes of Leishmania-infected 
macrophages (Hassani & Olivier 2013). Parasite-derived GP63 was found in these 
host exosomes demonstrating active transfer of GP63 from intracellular parasites 
into the host cell. It is well established that GP63 is a major virulence factor in 
Leishmania promastigotes (Contreras et al. 2010; Gómez et al. 2009a; Hassani et 
al. 2014) and it will be interesting to extend these findings to amastigotes. 
iii. Secretion of antioxidants 
Phagocytes employ the production of reactive oxygen species including oxygen 
radicals, superoxide, and hydrogen peroxide, as a mechanism of immune attack 
against parasites (Castro et al. 2017; Van Assche et al. 2011). In defence, many 
parasites, including Leishmania, employ counter-mechanisms and implement 
pathways to counteract the host’s immune attack. This includes the expression of 
antioxidants, for example: superoxide dismutases (SODs), catalases, glutathione 
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and thioredoxin peroxidases, and peroxiredoxins. In helminths, secreted 
antioxidant enzymes include B. malayi glutathione peroxidase and SOD (Bennuru 
et al. 2009). Another example is thioredoxin peroxidase from F. hepatica, which is 
further implicated in the alternative activation of macrophages (Donnelly et al. 
2005). 
Antioxidants secreted from Leishmania are also likely to be involved in intracellular 
survival of the parasite, such as iron superoxide dismutase, providing protection 
from oxidative burst during phagocytosis and from intracellular free radical attack 
(Castro et al. 2017; Van Assche et al. 2011). Iron superoxide dismutase has 
previously been shown to be a key player in the survival of Leishmania within the 
macrophage, detoxifying reactive superoxide radicals produced by activated 
macrophages (Ghosh et al. 2003). Tryparedoxin peroxidase has also been shown to 
protect the parasite from peroxide-induced damage (Castro et al. 2002). Another 
secreted protein which putatively interacts with the antioxidant network is 
cystathionine gamma lyase (CGL) (Giordana et al. 2014). T. cruzi CGL has been 
shown to establish interactions with proteins in the complex system involved in 
maintaining the cellular redox status, such as tryparedoxin 1 (Piñeyro et al. 2011). 
Here, we observe the secretion of a host of antioxidants from both promastigotes 
and amastigotes. Namely tryparedoxin 1 and two tryparedoxin peroxidases, in 
promastigotes and amastigotes, in addition to iron superoxide dismutases, 
trypanothione reductase, oxidoreductase and cystathione gamma lyase in 
promastigotes. 
iv. Nutrient salvage 
A functional category which is important in parasite survival in order to preserve 
and maintain parasite growth is nutrient acquisition. Endoribonuclease, an enzyme 
implicated in this category has been previously shown to the secreted by 
Leishmania promastigotes (Silverman et al. 2008). Our findings are consistent with 
this. Nucleases are an important addition when discussing parasite intracellular 
survival. Nucleases may aid in purine salvage which is essential for Leishmania 
survival because they are incapable of de novo purine synthesis. We also observe 
that a p1/s1 nuclease is one of the main proteins secreted by amastigotes.  
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Extracellular 3’-nucleotidase was also detected in the promastigote secretome. 
This enzyme is known to be expressed on the surface of Leishmania (Dwyer & 
Gottlieb 1984) where it can specifically cleave DNA and RNA into nucleotides and 
phosphate (Guimarães-Costa et al. 2014). Furthermore its role in evasion of the 
immune response has been demonstrated, as it mediates parasite escape from 
neutrophil extracellular traps (NETs) (Guimarães-Costa et al. 2014). 
v. Proteases 
Oligopeptidase B is involved in secreted serine protease activity. Parasite proteases 
are thought to mediate intracellular survival, through proteolytic activities against 
degradative enzymes found in phagolysosomes. Cysteine proteases are one of the 
most abundant proteins in the amastigote secretome. Another hypothesised role 
for parasite proteases is through degradation of major histocompatibility complex 
class I and II molecules, for example by cysteine proteases (De Souza Leao et al. 
1995). 
vi. Moonlighting proteins and other secreted proteins of interest 
Many of the proteins secreted by Leishmania, and in fact many other organisms, 
appear to already have defined roles in the cell. However, they consistently appear 
in the secretome of these organisms, and are now considered ‘moonlighting’ 
proteins. The expression ‘moonlighting proteins’ was established as a term when 
the phenomenon was reviewed by C. Jeffery in 1999 for proteins that perform 
multiple functions (Jeffery 1999). Some groups of these proteins have been 
extensively studied and reviewed for a number of organisms such as the glycolytic 
enzymes of parasites (Gómez-Arreaza et al. 2014), and bacteria (Henderson & 
Martin 2011). Other proteins were found to have many different functions in 
pathogenic protozoa, fungi and multicellular parasites (Karkowska-Kuleta & Kozik 
2014). 
Several molecular chaperones are present in the secretome of both promastigotes 
and amastigotes, listed in Table 4-5. 5.5% of the promastigote secretome was 
composed of molecular chaperones and 19.4% of the amastigote secretome. 
Bacterial molecular chaperones have been found to modulate phagocyte function 
(Henderson & Martin 2011). 
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Table 4-5 Molecular chaperone proteins present in the L. mexicana promastigote and 
amastigote secretome. 
Promastigote Secretome  
GeneDB Accession Protein Description 
LmxM.30.2600 calreticulin, putative 
LmxM.31.3270 chaperonin alpha subunit, putative 
LmxM.36.2020 OR 2030 chaperonin HSP60, mitochondrial precursor 
LmxM.29.2490 heat shock 70-related protein 1, mitochondrial precursor, putative 
LmxM.26.1240 heat shock protein 70-related protein 
LmxM.32.0312 heat shock protein 83-1 
LmxM.18.1370 heat shock protein, putative 
LmxM.28.2770 heat-shock protein hsp70, putative 
LmxM.36.6940 protein disulfide isomerase 2 
LmxM.27.1260 T-complex protein 1, beta subunit, putative 
LmxM.21.1090 T-complex protein 1, delta subunit, putative 
LmxM.34.3860 T-complex protein 1, eta subunit, putative 
LmxM.23.1220 T-complex protein 1, gamma subunit, putative 
LmxM.36.6910 T-complex protein 1, theta subunit, putative 
Amastigote Secretome  
GeneDB Accession Protein Description 
LmxM.36.2020 chaperonin HSP60, mitochondrial precursor 
LmxM.29.2490 heat shock 70-related protein 1, mitochondrial precursor, putative 
LmxM.29.2550 heat shock 70-related protein 1, mitochondrial precursor, putative  
LmxM.32.0312 heat shock protein 83-1 
LmxM.28.2770 heat-shock protein hsp70, putative 
LmxM.28.1200 luminal binding protein 1 (BiP), putative 
LmxM.26.0660 protein disulfide isomerase, putative 
. 
 
Nucleoside-diphosphate kinases are enzymes that catalyze the exchange of 
phosphate groups between different nucleoside diphosphates. However, in addition 
to its house-keeping functions, Leishmania-released nucleoside diphosphate kinase 
has been shown to prevent ATP-mediated cytolysis of macrophages (Kolli et al. 
2008).  
Enolase, found here to be secreted by Leishmania, is also secreted by many 
pathogenic microorganisms. Enolase is known to be associated to the external 
surface of the Leishmania parasite and in this location, does not appear to have 
enzymatic activity (Avilán et al. 2011). Extracellular enolase functions as a 
plasminogen-binding protein (Figuera et al. 2013). Plasminogen/plasmin binding is 
involved in several processes such as degradation of fibrin and other extracellular 
matrix proteins. Acquisition of this host protease allows pathogens to invade and 
disseminate in the host. In L. mexicana, plasminogen and plasmin bind to both the 
promastigote and amastigote forms. In vivo, host fibrin could provide a barrier 
which could limit the interaction between parasites and macrophages, limiting the 
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invasion and dissemination of the parasites. Parasite surface-bound plasmin could 
therefore break down this fibrin (Gómez-Arreaza et al. 2014). 
Macrophage migration inhibitory factor (MIF) is a cytokine homologue, and highly 
enriched in amastigote secretome as it was below the detection limit in our 
amastigote whole cell proteome. MIF mRNA was also previously found to be more 
abundant in amastigotes than promastigotes (Leifso et al. 2007). Multiple 
protozoan parasites express MIF homologues that play a role in pathogenesis and 
immune evasion, such as E. histolytica (Ngobeni et al. 2017), Plasmodium spp. 
(Shao et al. 2008; Sun et al. 2012; Zhang et al. 2012), T. gondii (Sommerville et al. 
2013), Leishmania (Holowka et al. 2016; Kamir et al. 2008; Richardson et al. 2009), 
T. vaginalis (Twu et al. 2014) and various helminths (Falcone et al. 2001; Sharma 
et al. 2012; Wang et al. 2017; Wu et al. 2003; Younis et al. 2012; Zang et al. 2002). 
The importance of MIF in the host:parasite interaction was investigated using 
macrophage exosomes collected from noninfected cells (NILX), Leishmania-
infected cells (LEISHX), and LPS-stimulated cells (LPSX). These were used to 
stimulate naïve macrophages and the responding differentially regulated genes 
were assessed (Hassani & Olivier 2013). Stimulation with LPSX induced a substantial 
downregulation of MIF in the naïve macrophages, which was not induced by 
exposure to LEISHX (Hassani & Olivier 2013). The mechanisms responsible for these 
effects in the host cells have not been deduced, but suggest the importance of MIF 
in the host:parasite interaction in Leishmania infection. 
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4.5 Summary 
We hypothesised that both promastigotes and amastigotes secrete proteins into 
their extracellular environment and we have subsequently shown that this is the 
case having successfully isolated and characterised a secretome from both life 
cycle stages of the parasite. 
We also hypothesised that L. mexicana parasites change their secretome in 
response to their changing environments encountered their life cycle. We have 
shown here through proteomic analysis that the secretome differs between the life 
cycle stages. 
Through analysis of predicted protein function and comparison to other known 
parasite virulence factors, we postulate that these secreted proteins play a role in 
the virulence of the parasite in the host and in parasite survival in a variety of 
broad functional categories: nutrient acquisition, antioxidant function, signalling 
disruption and directing the host immune response to the parasite’s advantage. 
Leishmania parasites cause debilitating disease and any further work into their 
mechanisms of disease bring us closer to understanding the parasite and potentially 
allowing the development of a novel treatment strategy or vaccine. 
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5.1 Introduction 
As discussed previously, the secretome of Leishmania parasites has been implicated 
in the pathology of Leishmaniasis (Diniz Atayde et al. 2016). Previous results 
presented in this thesis have detailed and provided new insight into the composition 
of the Leishmania mexicana secretome throughout the life cycle. However, to gain 
further insight into the biological role of Leishmania secreted proteins, parasite 
lines expressing different disease phenotypes with regards to host cell infection 
and disease outcome were chosen to initiate a comparative proteomic analysis of 
the secretome under differing conditions. These include an attenuated strain of 
Leishmania mexicana, able to be cultured as promastigotes and amastigotes. In 
addition, parasite isolates from six Colombian patients were sourced, three of 
which exhibited chronic infection, and three exhibiting a self-healing infection. 
5.1.1 Quantitative Proteomics Methods 
Quantitative proteomic analyses can be performed using several methods which 
fall into two main categories, label-free quantitation (Wong & Cagney 2010) and 
chemical labelling techniques, which use stable isotopes to differentially label the 
samples. Chemical labelling of proteins can be performed metabolically, using 
Stable Isotope Labelling by Amino acids in Cell culture (SILAC), commonly 
employing 13C-lysine and 13C-arginine (Ong & Mann 2007). Alternatively, labelling 
of proteins or peptides takes place after extraction from the organism or cells of 
interest, by chemical incorporation of stable isotopes. Multiple techniques are 
available, for example isotope-coded affinity tags (ICAT) (Gygi et al. 1999), using 
dimethyl labelling (DiMe) (Hsu et al. 2003), or isobaric tags, utilised in isobaric tag 
for relative and absolute quantitation (ITRAQ) (Ross et al. 2004) and tandem mass 
tagging (TMT) (Thompson et al. 2003). 
In this study we performed TMT6 labelling. TMT6 employs six isobaric tags, which 
are reporter tags of the same nominal mass but with discrete stable isotope 
incorporation positions, pictured in Figure 5-1. The tags are attached via amide 
linkages to peptides in trypsin-digested samples. After labelling, the six different 
samples can be combined and analysed together by LC-MS/MS. Each tag releases a 
unique reporter ion in MS/MS, enabling relative quantitation for peptides derived 
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from each of the 6 samples. Figure 5-2 shows a schematic of the TMT labelling 
process. 
SILAC is not a suitable approach for the study on Leishmania presented here. This 
is because previous studies of Leishmania have shown that the parasites are 
difficult to label metabolically, and the approach takes many passages in culture 
to achieve high incorporation of the label (Ong & Mann 2007). This is unsuitable for 
field samples such as patient isolates of L. panamensis, as extended culture in vitro 
could cause these cells to adapt metabolically and genetically, and subsequently 
lose their disease phenotype. TMT labelling is performed after isolation and 
digestion of the samples therefore the cultures can be treated the same way as 
they were in earlier studies presented previously in this thesis, thus providing 
method consistency and reproducibility. The reaction also allows multiplex 
experimental design, reducing run-to-run variation which can complicate label-free 
quantitation. 
 
Figure 5-1 Diagram depicting the structural chemistry of Thermo Scientific Tandem Mass Tags 
(TMT™) (a) The general composition of each tag, containing a mass reporter, a linker which is 
cleavable by fragmentation with higher energy collision dissociation (HCD), a region to normalise the 
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Figure has been removed due to Copyright restrictions. 
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mass to make all six tags equal, and an amine-reactive group to bind to the peptide. (b) The TMT 6-
plex kit contains tags with mass reporters ranging from an m/z of 126 to 131. (Adapted from Thermo 
Scientific TMTsixplex™ webpage found at: thermofisher.com/order/catalog/product/    1) 
 
Figure 5-2 Schematic of the quantitative Tandem Mass Tagging (TMT™) process from sample 
preparation to mass spectrometry analysis. (a) Six protein samples, for example control (C) and 
treatment (T), are processed by denaturing, reducing, alkylating and trypsin digesting. Resulting tryptic 
peptides are then tagged and the six differentially labelled samples combined to be analysed by LC-
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MS/MS in one run. (b) The top three precursor ions from the MS scan are selected for fragmentation 
by collision induced dissociation (CID) for peptide identification and by higher energy collision 
dissociation (HCD) for reporter ion quantitation. 
5.1.2 Quantitative proteomics data analysis 
Numerous studies have applied quantitative analyses to the study of large proteome 
data sets. Two approaches utilised in previously published studies were identified 
as appropriate software packages for the study presented here. The first is 
Proteome Discoverer™ (Thermo Fisher Scientific), for processing of the raw MS data 
to annotate and quantitate the peptides and the reporter tags. Followed by an 
adapted “Linear Models for Microarray Data” (LIMMA) model (D’Angelo et al. 2017; 
Kammers et al. 2015), to statistically test the differential abundance of the 
proteins identified in Proteome Discoverer. 
Proteome Discoverer allows for the identification and quantitation of proteins in 
complex biological samples. The software first takes the spectrum files generated 
by the mass spectrometer in .RAW format and processes these in one of two ways. 
1. Spectrum selector and Mascot nodes are used to map and identify peptides from 
the raw spectra, and 2. the Reporter Ions Quantifier node is used to analyse the 
spectra in the region of the mass tag (Figure 5-3a). The MSF files generated by the 
Mascot node are then used in the consensus workflow (Figure 5-3b). This workflow 
groups, validates and filters the peptides and subsequently assigns them to 
proteins. 
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Figure 5-3 Proteome Discoverer™ Software processing and consensus workflows. (a) The 
Processing Workflow contains nodes to extract the data from the spectrum files for peptide matching 
and reporter ion-based quantification. (b) The Consensus Workflow contains nodes for enhanced 
annotation and quantitative analysis of the identifications from the previous workflow. 
 
Identification and quantitation of the proteins in the secretome was then followed 
by statistical testing and data visualisation in R (Ver 3.5.1). Differential abundance 
of proteins in a secretome can be tested for statistical significance using a method 
modified from an approach commonly used in gene expression analysis, LIMMA 
(Linear Models for Microarray Data) as demonstrated and reviewed by Kammers et 
al. (2015) and presented as a freely available software vignette (Kammers et al. 
a 
b 
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2015). One of the main advantages of this method is it allows for biological 
variances to be handled with a more realistic distribution, as opposed to assuming 
constant variance. Traditional methods using two-sample t-tests assume constant 
variance across the data range. As genes, or in this case proteins, that display large 
fold change between samples also tend to have higher sample variance, this can 
result in proteins with large fold changes being declared less significant than 
proteins with smaller fold changes and lower sample variance, particularly when 
the number of samples is small. LIMMA uses an empirical Bayes method which 
calculates a pooled estimate of variance across samples and shrinks the variance 
of individual proteins towards this estimate. Used in conjunction with a moderated 
t-test, this technique for accommodating realistic biological variance greatly 
increases the inferential power of the model, increasing confidence in fold changes 
and resulting in fewer false positives (Smyth 2004). 
D’Angelo et al. (2017) evaluated several statistical models, including LIMMA, for 
quantitative proteomics data using TMT-tagged test data. They created simulated 
proteomic data sets using known concentrations of proteins and also using a spike-
in method. They then analysed the data sets using a general linear model (GLM), 
LIMMA, and mixed models, while also varying the method of normalisation. LIMMA 
was concluded to be their preferential method over GLM and mixed models for 
TMT-based quantitative proteomics (D’Angelo et al. 2017). 
Here, we successfully applied previously established methods to relevant clinical 
isolates and obtained secretome profiles for each of the 6 parasite isolates, three 
from patients with chronic infection and three from patients with self-healing 
infections. Furthermore, using a quantitative proteomic approach we have 
compared the relative abundances of these secreted proteins between the two 
groups and found significant upregulation and downregulation of several proteins 
in the secretome of parasites from chronic infections, compared to self-healing 
infections. 
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5.1.3 Attenuated L. mexicana parasites and clinical isolates of L. 
panamensis 
To initiate a comparative analysis, a virulence-attenuated cell line which does not 
divide in host cells or in mice was sourced. The attenuated parasites are taken up 
by host macrophages but do not sustain an infection, as shown in Figure 5-4a 
(Daneshvar et al. 2003a). Additionally, these parasites no longer sustain an 
infection in mice and can be utilised to sensitize mice to L. mexicana and produce 
an immune response when infected with wild type parasites thereafter (Figure 
5-4b) (Daneshvar et al. 2003b, 2003a). This approach is being used to develop an 
attenuated vaccine in trials with L. infantum species (Daneshvar et al. 2014). The 
L. mexicana version is compared here to the wild type to look for differences in 
the secreted protein profile. We hypothesise that the differences in the parasites’ 
virulence phenotype in the host cell may, in part, be due to differing secreted 
proteins. Any changes identified would give us an indication as to the functionality 
of the secretome in virulence.  
 
Figure 5-4 Virulence of L. mexicana wild type (WT) and attenuated (H-line) parasites and 
efficacy of the H-line as a vaccine in mice. (a) Percentage of infected bone marrow-derived 
macrophages after exposure to stationary-phase WT or attenuated promastigotes. (b) Lesion size 
after infection with WT L. mexicana in BALB/c mice vaccinated with stationary-phase promastigotes 
of L. mexicana H-line (n=14). Data from (Daneshvar et al. 2003a). 
The second phenotypic comparison was from parasites isolated from patients with 
cutaneous Leishmaniasis (CL) in Colombia. Parasites were isolated from three 
different patients presenting with self-healing CL and from three different patients 
with chronic CL. CL in Colombia is mainly caused by parasites of the subgenus L. 
(Viannia), and within this subgenus the species L. (V) panamensis is one of the more 
predominant species in Colombia (Alvar et al. 2012). CL can have varied disease 
outcomes from asymptomatic infections and infections that cause lesions that self-
heal, to chronic and exacerbated disease. Chronic disease caused by L. panamensis 
b a 
Figure has been removed due to Copyright restrictions. 
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is refractory to chemotherapy and characterised by a high degree of inflammation 
and few parasites at the lesion site (Navas et al. 2014). Early expression of 
chemokines and their receptors by the host cell is modulated upon infection by 
Leishmania, which results in recruitment of host cells to the site. This is thought 
to cause the uncontrolled immunopathology (Navas et al. 2014). Rather than being 
an effect of immune variation between individuals, this effect on host cell 
chemokine response was shown to be parasite-mediated in L. braziliensis infection 
by researchers who showed that two distinct isolates of the same species could 
produce different chemokine stimulatory responses in the host cell (Teixeira et al. 
2005). We hypothesise that parasites of the same species isolated from patients 
with chronic disease and patients with self-healing disease would have different 
secretome profiles, which leads to this modulation of the immune response. We 
aim to examine the secretion of proteins by L. panamensis parasites isolated from 
patients with chronic and with self-healing disease in collaboration with CIDEIM 
(Cali, Colombia), to identify mechanisms by which the parasites may be driving the 
divergent outcomes of this disease. If hyperactivation of the immune response was 
found to be parasite-mediated, therapeutic intervention targeting the responsible 
parasite factors could allow clearing of the infection to prevent chronic disease.  
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5.2 Aims and hypotheses 
The overall aim was to take the methods developed in research presented in 
previous chapters in this thesis, for isolating and analysing the secretome of 
Leishmania parasites, and apply them to an attenuated L. mexicana parasite line 
and to clinical parasite isolates, obtained in collaboration with a Colombian 
research and treatment centre. 
The aim of the L. mexicana analyses were to investigate the role of the secretome 
in the establishment of infection and parasite survival inside the host cell. We 
hypothesised that there would be a significant difference in the parasite secretome 
between wild type and attenuated L. mexicana promastigotes and amastigotes. 
The aim of the secretome analysis was to investigate the potential functional role 
of the Leishmania panamensis secretome in the outcome of the disease. The 
comparative analyses were as follows: 
• Parasites from three different patients with chronic cutaneous Leishmaniasis 
VS parasites from three different patients with self-healing cutaneous 
Leishmaniasis. 
• The study also looked at differences in parasite incubation temperature, at 
25°C VS 34°C, to mimic the temperature stimulus upon entry to the skin 
during infection. 
We hypothesised that there would be a significant difference in the parasite 
secretome between isolates from chronic cutaneous Leishmaniasis compared to 
isolates from self-healing cutaneous Leishmaniasis. We also hypothesised that a 
change in temperature would alter the parasite secretome.  
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5.3 Results 
To further investigate the Leishmania secretome, comparative proteomic analyses 
were employed on parasites with differing growth and disease phenotypes, to 
search for secreted proteins with potential roles in parasite survival in the host cell 
and in chronicity of the disease.  
5.3.1 Growth and morphology of L. mexicana wild type and 
attenuated parasites 
The first cell line used for the comparative secretome analyses was an attenuated 
line of L. mexicana, known as the H-line (Daneshvar et al. 2003a, 2003b). This line 
was generated by repeated sub-passage in the presence of gentamicin, and 
confirmed as attenuated by infection of primary mouse macrophages, where no 
parasite proliferation was observed in the host cell (Daneshvar et al. 2003a). 
We observed no difference in the axenic growth of H-line promastigotes compared 
to that of wild type parasites freshly isolated from mice, passage 2 (WT), or wild 
type parasites after repeated sub-passage without gentamicin (HWT) (Figure 5-5a). 
All three parasite lines display logarithmic growth over 72 h between 1 x 105 and 1 
x 107 cells/ml and enter late-logarithmic and stationary phases thereafter, slowly 
increasing to a maximum of 2 x 107 cells/ml before plateauing. As amastigotes, 
there is some delay in the growth of the H-line, but both H and HWT cell lines reach 
a maximum density exceeding 107 cells/ml over 150 to 200 h, with the H-line taking 
approximately 48 h longer to reach this density (Figure 5-5b). 
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Figure 5-5 Growth of wild type and attenuated L. mexicana promastigotes and amastigotes in 
vitro. Promastigotes (a) and amastigotes (b) were cultured in complete HOMEM and SDM, 
respectively, and aliquots removed every 24h for counting using a haemocytometer. WT – wild type 
parasites maintained between 4 – 15 passages, HWT – wild type parasites maintained to the same 
passage number as the attenuated cells, H-line – parasites attenuated by repeated culture in complete 
medium with gentamicin. n = 3. 
With regards to parasite morphology, there are some differences in stationary 
phase promastigotes as shown in Figure 5-6a-c, with the average cell length and 
width significantly larger in the H-line, with the average length increasing from 10 
µm to 14 µm, and the average width increasing from 1.1 µm to 1.9 µm. No 
significant difference in flagellum length was observed between the cell lines. Both 
cell types successfully differentiate to amastigotes and divide and grow as axenic 
amastigotes (Figure 5-5b). There appeared to be a delay in the differentiation to 
amastigotes in the H-line as the cells were still significantly different from the wild-
type in length and width at day 1 after amastigote induction (Figure 5-6d,e). 
However, after 48 h the cell sizes of both parasite lines had reduced, indicating a 
complete morphological change to amastigotes (Figure 5-6f-i). 
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Fig. X. Growth of HWT and H-line L. mexicana as axenic amastigotes. Parasites were
maintained as stably growing axenic amastigotes by weekly passage in Schneider’s medium
supplemented with 20% iFCS, haemin and adjusted to pH 5.5, and incubated at 34°C with 5%
CO2. Aliquots were withdrawn and counted at various times.
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Figure 5-6 Measurements of L. mexicana wild type (WT) and attenuated (H) parasites during 
axenic growth. Stationary phase promastigotes, cultured in complete HOMEM, were sampled at a 
density of 1.4 x 107 cells/ml and air dried on slides, fixed and giemsa stained (a, b, c). These stationary 
cultures were then used to start amastigote cultures in complete SDM, pH 5.5, at a starting density of 
1 x 106 cells/ml. Samples were taken at 24 h (Day1) (d, e), 48 h (Day2) (f, g) and 144 h (Day6) (h, i) 
and stained as above. Measurements were made using Fiji image analysis software. Graphs and 
analysis of significance were made using GraphPad Prism. Box plot whiskers denote min to max 
values. Means were compared using a two-tailed T-test with Welch’s correction for unequal variance 
*** P = <0.0001, ** P = 0.003, ns = not significant. n = 100 cells imaged and measured per condition. 
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5.3.2  Secretome collection and visualisation from L. mexicana 
wild type and attenuated parasites 
The successful differentiation and growth of both parasite lines as axenic 
amastigotes allowed for the parasite-only secretome to be isolated and analysed 
from both WT and H-line promastigotes and amastigotes and analysed using direct 
comparative approaches. 
Visualising the profiles of the secreted proteins isolated from the axenic culture 
supernatants by SDS-PAGE and using densitometry analysis to plot and overlap the 
profiles showed good sample reproducibility, both for the WT and H-line 
promastigotes (Figure 5-7a,b) and for WT amastigotes (Figure 5-8a). H-line 
amastigotes displayed a more variable secretome (Figure 5-8b). 
Overlaying and taking the average of the densitometry plots of the WT and H-line 
secretomes showed distinct secretome profiles for the promastigote stages (Figure 
5-7c). At least 8 or more bands showed differences in density of more than 2-fold. 
In contrast, the comparison of the amastigote secretome profiles showed minimal 
differences between the two cell lines, with the differential peak at ~40 kDa only 
present in one of three H-line replicates (Figure 5-8c). 
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Figure 5-7 Densitometry profile plots of the L. mexicana promastigote secretome. Secreted 
proteins collected from the supernatant of wild type (W) and attenuated (H) axenic cultures were 
separated by SDS-PAGE and stained with silver stain. Densitometry analysis was performed using 
ImageJ and plotted and overlaid using GraphPad Prism. Replicates of W (a) and H (b) parasite 
secretome were compared to investigate their reproducibility, and representative lanes of W and H 
were compared (c) to illustrate any visible differences. 
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Figure 5-8 Densitometry profile plots of the L. mexicana amastigote secretome. Secreted 
proteins collected from the supernatant of wild type (W) and attenuated (H) axenic cultures was 
separated by SDS-PAGE and stained with silver stain. Densitometry analysis was performed using 
ImageJ and graphed using GraphPad Prism. Replicates of W (a) and H (b) parasite secretome were 
compared to investigate their reproducibility, and an average of the densitometry values of W and H 
were compared (c) to illustrate any visible differences. 
 
Difference gel electrophoresis (DiGE) was used to further separate and increase the 
resolution of the visual secretome comparisons (Figure 5-9). The WT and H 
secretome samples were differentially labelled with spectrally distinct Cy3 and Cy5 
dyes, respectively, combined, then separated in two dimensions. This allowed for 
co-migration of the proteins in both samples under identical conditions 
(Westermeier et al. 2008). Clear differences were again observed in the 
promastigote secretome, both in isoelectric point of the proteins and in molecular 
weight (Figure 5-9a). Subtle differences in the molecular weight of some proteins 
248163264128256
0
200
400
600
WT1
WT2
WT3
MW
B
a
n
d
 i
n
te
n
s
it
y
248163264128256
0
200
400
600
H1
H2
H3
MW
B
a
n
d
 i
n
te
n
s
it
y
248163264128256
0
200
400
600
WT
H
MW
B
a
n
d
 i
n
te
n
s
it
y
a 
b 
c 
kDa 
212 
158 
97.2 
66.4 
55.6 
34.6 
27.0 
20.0 
6.5 
kDa 
212 
158 
97.2 
66.4 
55.6 
34.6 
27.0 
20.0 
6.5 
Chapter 5  153 
are visible, not only indicating alterations in protein expression, but also in protein 
isoforms and post-translational modifications. As before, fewer differences are 
observed in the amastigote secretome between WT and H than the promastigote 
(Figure 5-9b). However, with the increased resolution some changes are evident 
that could not be observed in the 1D gel separation. 
 
Figure 5-9 L. mexicana secretome proteins separated by 2-dimensional electrophoresis. 
Promastigote secretome (a) and amastigote secretome (b) from wild type and attenuated parasites 
were differentially labelled with Cy3 and Cy5 dyes before combining and separating in two dimensions.  
2-dimensional separation, first by isoelectric focusing (IEF) within pH range 4-7, followed by 
electrophoresis through a 12% polyacrylamide gel. 
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5.3.3 Quantitative analysis of the L. mexicana WT and attenuated 
parasite secretome using isobaric peptide tagging 
The comparison of L. mexicana WT and attenuated parasite secretomes was studied 
by using LC-MS/MS to identify the proteins and employing isobaric peptide tagging 
to quantitate the proteins. The tryptic peptides from each secretome sample were 
differentially labelled before combining and analysing by LC-MS/MS. Using 
clustering analysis on the full list of promastigote protein identifications and their 
corresponding quantitation values (Figure 5-10) we can see that the three biological 
repeats of WT and H samples cluster together and shows that the secretomes of 
the two cell lines are quantitatively distinct. Repeat 3, labelled with 128 and 131 
for WT and H cell line, respectively, clusters slightly further from repeats 1 and 2 
for both cell lines. This cluster, along with the clustering of up- and downregulated 
proteins, was then used to create the heat map depicted in Figure 5-11. This heat 
map shows a visual representation of both the level of change in abundance and 
the reproducibility of the biological replicates. A total of 52 proteins were 
reproducibly up- or downregulated in each of the three replicates from both cell 
lines, with a p-value of ≤0.05, and exhibiting a fold change of ≥±1.5. Each protein 
is assigned a colour based on the scale of Euclidean distance. 
 
Figure 5-10 Cluster dendrogram of L. mexicana promastigote quantitative secretome data. - 
Created in RStudio using Euclidean distance to show the similarity or dissimilarity between 
observations. The replicates for each of the two sample types cluster together. Labels X126-X131 
denote the quantitation channels for each TMT reporter tag. X126-128 are wild type samples 1-3 and 
X129-131 are attenuated samples 1-3. 
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Figure 5-11 Heat map of quantitative differences between secreted proteins of L. mexicana 
promastigote wild type and attenuated cell lines. Colour denotes value assigned to distance. 
Columns are the samples and rows are the quantitated proteins. -log10p-value = 1.3 (0.05) and log2FC 
of 0.58 (1.5).  
The volcano plot in Figure 5-12a shows the level of up- or downregulation of all the 
secreted proteins in the promastigote secretome for the WT and H line parasites 
against the p-value for reproducibility of the replicates. The proteins marked in 
red indicate proteins with a p-value of ≤0.05 over three biological repeats from 
each cell line and with a fold change in abundance of ≥1.5 fold. In the plot depicted 
in Figure 5-12a, the ordinary p-values from individual t-tests are used to plot the 
data, with a total of 42 proteins above the significance thresholds. In Figure 5-12b, 
an alternative method of significance estimation has been used and the resulting 
modified p-values used to plot the data. Using this method, a total of 52 proteins 
were found to change reproducibly between the secretomes of the two parasite 
lines. Table 5-1 contains the descriptions of each of the proteins. 
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Figure 5-12 Volcano plots of 6-plex TMT™ quantitation of L. mexicana promastigote secretome 
from wild type (WT) and attenuated (H) parasites. (a) Volcano plot of the fold change of each 
protein in WT and H samples against the p-values of the sample variability using standard t-tests.(b) 
Reanalysis of p-values using Kammers et al.(D’Angelo et al. 2017; Kammers et al. 2015) method of 
using moderated t-statistics from the empirical Bayes procedure LIMMA. Statistical testing performed 
and figures made in RStudio. -log10 p-value cut off of ≥1.3 (≤0.05), log2FC of ±0.58 (FC 1.5). 
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Performing clustering analysis on the amastigote protein identifications and their 
corresponding quantitation values (Figure 5-13), we can see that the three 
biological repeats of the WT and H cell line samples cluster together. In contrast, 
comparing the promastigote and amastigote clustering analysis, the height of the 
cluster for amastigote samples, which relates to the Euclidean distance or similarity 
of the values, is much smaller than that of the promastigote samples, shrinking 
from a range of 0-20 shown in Figure 5-10 to 0.5-3.5 shown in Figure 5-13. This 
suggests that although the amastigote WT and H-line samples do show enough 
differences to cluster separately, they are not as different as the promastigote 
samples. This cluster, along with clustering of up- and downregulated proteins, 
were then used to create the heat map in Figure 5-14 which shows a visual 
representation of both the level of change in abundance and the reproducibility of 
the biological replicates. Only two proteins were found to be reproducibly up or 
downregulated between the cell lines, with a p-value of ≤0.05, and exhibiting a 
fold change of ≥±1.5. Each protein is assigned a colour based on the scale of 
Euclidean distance. 
 
 
Figure 5-13 Cluster dendrogram of L. mexicana amastigote quantitative secretome data 
Created in RStudio using Euclidean distance to show the similarity or dissimilarity between 
observations. The replicates for each of the two sample types cluster together. Labels X126-X131 
denote the quantitation channels for each TMT reporter tag. X126-128 are wild type samples 1-3 and 
X129-131 are attenuated samples 1-3. 
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Figure 5-14 Heat map of quantitative differences between secreted proteins of L. mexicana 
amastigote wild type and attenuated cell lines. Colour denotes value assigned to distance. 
Columns are the samples and rows are the quantitated proteins. -log10p = 1.3 (0.05) and log2FC of 
0.58 (1.5).  
The volcano plot in Figure 5-15a shows the level of up- or downregulation of all the 
secreted proteins in the amastigote secretome for WT and H line parasites, against 
the p-value for reproducibility of the replicates. The proteins marked in red 
indicate proteins with a p-value of ≤0.05 over three biological repeats from each 
cell line and with a fold change in abundance of ≥1.5 fold. In plot Figure 5-15a, the 
ordinary p-values from individual t-tests are used to plot the data, with one protein 
above the significance thresholds. In the plot depicted in Figure 5-15b, an 
alternative method of significance estimation has been used and the resulting 
modified p-values used to plot the data. Using this method, two proteins were 
above the significance thresholds. Table 5-2 contains the names of the two 
proteins. 
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Figure 5-15 Volcano plots of 6-plex TMT™ quantitation of L. mexicana amastigote secretome 
from wild type (WT) and attenuated (H) parasites. (a) Volcano plot of the fold change of each 
protein in WT and H samples against the p-values of the sample variability using standard t-tests.(b) 
Reanalysis of p-values using Kammers et al.(D’Angelo et al. 2017; Kammers et al. 2015) method of 
using moderated t-statistics from the empirical Bayes procedure LIMMA. Statistical testing performed 
and figures made in RStudio. -log10 p-value cut off of ≥1.3 (≤0.05), log2FC of ±0.58 (FC 1.5). 
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Table 5-1 L. mexicana promastigote secretome proteins significantly up- or down-regulated in attenuated parasites compared to wild-type. 
ProTMT - sigtable_kammod 0.58, 1.3 
Accession Description Log2FC FC p-value 
LmxM.04.1030 COPI associated protein, putative 2.056667 4.16024 8.91E-05 
LmxM.30.0950 hypothetical protein (sodium stibogluconate resistance protein, putative) 1.898667 3.728684 0.000496 
LmxM.34.0500 proteophosphoglycan ppg3, putative 1.748333 3.359702 0.026442 
LmxM.15.1240 nucleoside transporter 1, putative 1.720333 3.295125 0.032675 
LmxM.36.1940 inosine-guanosine transporter 1.645667 3.128924 0.019077 
LmxM.17.0084 elongation factor 1-alpha 1.605667 3.043364 0.000137 
LmxM.17.0085 elongation factor 1-alpha 1.459667 2.750448 0.00277 
LmxM.27.1730 Flabarin, putative 1.439333 2.711955 0.00106 
LmxM.20_36.6480a hypothetical protein (histidine secretory acid phosphatase, paralogue) 1.417 2.670297 0.000324 
LmxM.23.1020 hypothetical protein, unknown function 1.347333 2.544414 0.021558 
LmxM.30.3070 ferrous iron transport protein 1.311667 2.482281 0.003627 
LmxM.36.6300 glucose transporter 1 1.199333 2.296335 0.005797 
LmxM.04.0210 surface antigen-like protein 1.187667 2.27784 0.014788 
LmxM.20.1310 polyubiquitin, putative 1.183667 2.271534 0.014547 
LmxM.30.2310 3'-nucleotidase/nuclease 1.180333 2.266291 0.011325 
LmxM.12.0400 3'-nucleotidase/nuclease, putative 1.137333 2.19974 0.023561 
LmxM.17.0085 P-type H+-ATPase, putative 1.136333 2.198216 0.014775 
LmxM.08.1040 hypothetical protein 1.062667 2.088789 0.002404 
LmxM.11.0100 seryl-tRNA synthetase 1.059 2.083487 0.003393 
LmxM.33.0140 malate dehydrogenase 1.043667 2.06146 0.005545 
LmxM.15.0440 tb-292 membrane associated protein-like protein 1.041 2.057653 0.023591 
LmxM.01.0470 fatty acyl CoA syntetase 1, putative 1.039 2.054803 0.001327 
LmxM.34.1010 casein kinase, putative 1.008 2.011121 0.002739 
LmxM.09.0891 polyubiquitin, putative 0.97 1.958841 0.001721 
LmxM.01.0520 long-chain-fatty-acid-CoA ligase, putative 0.940667 1.919415 0.008733 
LmxM.16.0230 protein tyrosine phosphatase-like protein 0.923667 1.89693 0.001709 
LmxM.23.0840 hypothetical protein, unknown function 0.918333 1.889931 0.032427 
LmxM.34.2080 calcium motive p-type ATPase, putative 0.915667 1.886441 0.014332 
LmxM.18.1520 hypothetical protein, conserved 0.876333 1.835704 0.027104 
LmxM.18.1510 P-type H+-ATPase, putative 0.857667 1.812105 0.016324 
LmxM.26.1960 hypothetical protein, conserved 0.828 1.775223 0.005078 
LmxM.30.0440 cytoskeleton-associated protein CAP5.5, putative 0.820333 1.765814 0.024928 
LmxM.19.1160 small myristoylated protein 1 0.799333 1.740297 0.013879 
LmxM.34.3340 6-phosphogluconate dehydrogenase, decarboxylating, putative 0.725333 1.653283 0.018112 
LmxM.24.0761 malic enzyme 0.717333 1.64414 0.043628 
LmxM.30.3090 peptidase, putative 0.687 1.609932 0.026089 
LmxM.32.0794 beta tubulin 0.625 1.542211 0.03045 
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Accession Description Log2FC FC p-value 
LmxM.13.0160 protein kinase A regulatory subunit -0.60433 1.520276 0.019488 
LmxM.36.3590 cysteine synthase, putative -0.66133 1.581544 0.019688 
LmxM.33.2820 regulatory subunit of protein kinase a-like protein -0.75633 1.689192 0.006143 
LmxM.36.6980 eukaryotic translation initiation factor 3 subunit c -0.78433 1.722296 0.013003 
LmxM.31.2270 membrane associated protein-like protein -0.794 1.733875 0.030022 
LmxM.14.0190 Thioredoxin-like, putative -0.82567 1.772354 0.015225 
LmxM.34.4130 polyadenylate-binding protein 2 -0.90267 1.869518 0.006154 
LmxM.08_29.1750 paraflagellar rod protein 1D, putative -0.94333 1.922966 0.046177 
LmxM.10.0390 GP63, leishmanolysin -1.09067 2.129724 0.005788 
LmxM.24.2110 3-hydroxy-3-methylglutaryl-CoA synthase, putative -1.18933 2.280473 0.012294 
LmxM.23.0040 tryparedoxin peroxidase -1.23267 2.35001 0.002691 
LmxM.34.1230 short chain dehydrogenase, putative -1.251 2.380063 0.01981 
LmxM.04.0420 Tetratricopeptide repeat, putative -1.26233 2.398834 0.010782 
LmxM.13.0570 40S ribosomal protein S12, putative -1.39667 2.632925 0.036789 
LmxM.31.1820 iron superoxide dismutase, putative -1.97467 3.930374 0.005858 
 
 
Table 5-2 L. mexicana amastigote secretome proteins significantly up- or down-regulated in attenuated parasites compared to wild-type.AmaTMT. 
Kammersmod, sigtable 0.58, 1.3 
Accession Description Log2FC FC p-value 
LmxM.15.1040; 
LmxM.15.1160 tryparedoxin peroxidase 0.966 1.953417 0.009588 
LmxM.07.0990 nucleolar RNA-binding protein, putative -0.93633 1.913658 0.016499 
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5.3.4 Secreted protein identities and quantitation are validated by 
immunodetection 
The identities of a selection of the secreted proteins identified by LC-MS/MS were 
validated by immunoblotting with antibodies raised against Leishmania proteins. 
The quantitation could also be validated for a proportion of the proteins for which 
Leishmania-specific antibodies could be obtained. Figure 5-16 shows the 
quantitation values for each protein in each of the 6 samples and the 
corresponding Western blot of the same samples separated by SDS-PAGE including; 
Oligopeptidase B (OPB), enolase (ENO), secretory acid phosphatase (SAP), 
glycoprotein 63/leishmanolysin (GP63). A silver stained gel has been included to 
serve as the loading control in the absence of any known constitutively secreted 
proteins across the two cell types. 
In most cases there appears to be an anomaly with the TMT quantitation of W3 - 
tag 128. The quantitation of the other samples and reporter tags correlates well 
and the quantitation looks accurate except for W3-tag 128. Re-analysis of the fold 
change and significance excluding reporter ion 128 could be performed to study 
this anomaly, however due to time constraints and sample availability this was 
not performed.  
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Figure 5-16 Western blots of L. mexicana secreted proteins paired with quantitation values 
from the same samples analysed by LC-MS/MS. (a) Promastigote secretome probed with 
antibodies to oligopeptidase b (OPB), enolase (ENO) and secretory acid phosphatase (SAP). 
Quantitative measurements of proteins from analysis of TMT-labelled peptides from the secreted 
proteome, quantified using Proteome Discoverer, are shown above the immunoblots. (b) Amastigote 
secretome probed with antisera to glycoprotein 63 (GP63) and oligopeptidase b (OPB). OPB was 
not detected in the TMT-labelled MS analysis therefore quantitation values are not shown. Sample 
loading is shown by silver staining. 
 
5.3.5  Secretome collection and visualisation from L. panamensis 
parasites causing chronic and self-healing disease 
L. panamensis parasites were isolated from three patients with chronic cutaneous 
lesions (Chr) and from three patients with self-healing cutaneous lesions (SH). The 
parasites were cultured axenically at 25°C in serum-supplemented RPMI 1640 
media to obtain high numbers of parasites that were then incubated in a serum-
free medium to collect the secretome (samples from the parasites of each disease 
phenotype will be denoted as Chr / SH). This collection was performed at both 
25°C and 34°C, to evaluate if a temperature increase would alter the secretome, 
as this mimics the parasites’ entry to the skin. The secretome was then analysed 
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by SDS-PAGE and mass spectrometry, using the TMT™ kit from Thermo Fisher to 
label tryptic peptides with isobaric tags. 
To assess and minimize contamination with proteins released through cell lysis, 
the viability of the parasites was monitored before and after incubation in serum-
free collection medium. The typical viability of the L. panamensis field isolates 
lies at around 70% in culture which is much lower than the laboratory strains of L. 
mexicana which are typically >95% viable in culture. This complicates the 
secretome analysis as there is a higher chance of products of cell lysis being 
present in the secretome. However, lower cell viabilities of between 60-80% 
remained consistent between the 6 isolates both before and after incubation in 
secretome collection medium, therefore a comparative analysis could be 
performed between the samples whilst also making use of a control cell lysate 
proteome.  
Table 5-3 L. panamensis promastigote cell viability in vitro. Cell viabilities were measured before 
incubation, when the cells were in normal culture in cRPMI at 25°C, and after four-hour incubations 
in sfRPMI at the temperatures stated. Measured by counting with trypan blue and motility 
assessment. n=2 for samples with SD. 
 
Before Incubation After 4h at 25°C After 4h at 34°C 
Sample Viable % SD Viable % SD Viable % SD 
[SH] A1 80.72 - 85.5 - 88.3 - 
[SH] A2 85.95 ±9.26 81.15 ±3.04 83.15 ±0.21 
[SH] A3 79.65 ±1.91 71.75 ±2.47 76.4 ±7.07 
[Chr] B1 88.5 ±0.71 90.85 ±5.87 87.1 ±5.51 
[Chr] B2 63.5 ±4.95 61 ±5.66 57.5 ±2.12 
[Chr] B3 63 - 71 - 63.5 - 
 
From the mass spectrometry data of the control whole cell proteome compared 
to the secretome, enrichment of secreted proteins was evident from the 
observation that 11% of proteins in the secretome were too rare to be identified 
at all in the control proteome (Figure 5-17). This was due to the limitation of 
dynamic range in the mass spectrometer. 
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Figure 5-17 L. panamensis cell lysate proteome and secretome comparison 
Proteome and secretome obtained by LC-MS/MS and protein identifications from Mascot compared 
using Excel. Overlap indicates proteins present in both samples. 
 
Figure 5-18 SDS-PAGE separation of L. panamensis promastigote secretome. 0.13 μg of each 
secretome sample was loaded per lane of a 4-20% polyacrylamide gel and silver stained. A 
secretome isolated from parasites from self-healing infections, B secretome isolated from parasites 
from chronic infections. 
Using SDS-PAGE and silver staining, reproducible visual differences between 
secreted proteins in the self-healing and chronic groups are clear (Figure 5-18). 
These differences were investigated in more detail by aligning the profiles of each 
lane in graphical format (Figure 5-19) where proteins 1 and 6 – 10 were visible as 
being more abundant in Chr and 2-5 and 11 – 15 are noticeably downregulated in 
the Chr. A similar pattern is evident in the secretome samples from the 34°C 
incubation (Figure 5-20), where the central bands 6 & 7 are upregulated in Chr 
11% 89% 
Secretome 
Cell lysate 
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and bands 8 & 9 are downregulated in Chr. No striking differences were observed 
at this stage between the secretome of parasites incubated at 25 and 34°C. 
 
Figure 5-19 Lane profiling of L. panamensis 25°C secretome. A representative lane from each 
group was selected and the band intensities profiled using ImageJ software and plotted using Prism. 
 
Figure 5-20 Lane profiling of L. panamensis 34°C secretome. One lane from each group was 
selected and the band intensities profiled using ImageJ software and plotted using Prism. 
 
Chr SH 
SH 
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5.3.6  Quantitative analysis of the L. panamensis secretome using 
isobaric peptide tagging 
After visual confirmation of the integrity of the samples and the identification of 
differences between the groups, TMT labelling was used for relative quantitation 
to determine the differences in protein abundance between the parasites of the 
two disease outcomes. The full list of protein identifications and quantitation for 
the L. panamensis promastigotes can be found in Supplementary Data II. 
Using clustering analysis on the full list of protein identifications and their 
corresponding quantitation values, the three biological replicates of Chr and SH 
samples cluster together and shows that the secretomes of the two cells lines are 
quantitatively distinct for both 25°C and 34°C secretome collection (Figure 5-21, 
Figure 5-23). The heat maps in Figure 5-22 and Figure 5-24 demonstrate both the 
level of change in abundance and the reproducibility of the biological replicates 
for the 25°C and 34°C samples, respectively. A total of 12 proteins were 
reproducibly up or down-regulated with a p-value of ≤0.05, and exhibiting a fold 
change of ≥±1.5 in the 25°C samples (Figure 5-22). A total of 16 proteins were 
reproducibly up or down-regulated with a p-value of ≤0.05, and exhibiting a fold 
change of ≥±1.5 in the 34°C samples (Figure 5-24). Each protein is assigned a 
colour based on the scale of Euclidean distance. 
 
 
Figure 5-21 Cluster dendrogram of L. panamensis promastigote quantitative 25°C secretome 
data comparing replicates collected from self-healing parasites and from chronic parasites. 
Created in RStudio using Euclidean distance to show the similarity or dissimilarity between 
observations. The replicates for each of the two sample types cluster together. Labels X126-X131 
denote the quantitation channels for each TMT reporter tag. X126-128 are self-healing samples 1-3 
and X129-131 are chronic samples 1-3. L. panamensis 25°C self-healing vs chronic 0.58 1.3. 
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Figure 5-22 Heat map of quantitative differences between secreted proteins of L. panamensis 
parasites causing self-healing and chronic disease, collected at 25°C. Colour denotes value 
assigned to distance. Columns are the samples and rows are the quantitated proteins L. panamensis 
25°C self-healing vs chronic 0.58 1.3. 
 
 
Figure 5-23 Cluster dendrogram of L. panamensis promastigote quantitative 34°C secretome 
data comparing replicates collected from self-healing parasites and from chronic parasites. 
Created in RStudio using Euclidean distance to show the similarity or dissimilarity between 
observations. The replicates for each of the two sample types cluster together. Labels X126-X131 
denote the quantitation channels for each TMT reporter tag. X126-128 are self-healing samples 1-3 
and X129-131 are chronic samples 1-3 L. pan. 34°C Chr/SH 0.58 1.3. 
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Figure 5-24 Heat map of quantitative differences between secreted proteins of L. panamensis 
parasites causing self-healing and chronic disease, collected at 34°C. Colour denotes value 
assigned to distance. Columns are the samples and rows are the quantitated proteins L. pan. 34°C 
Chr/SH 0.58 1.3. 
 
Figure 5-25 shows the spread of all the confidently identified proteins over the 
three biological repeats with the differences in abundance shown between chronic 
and self-healing patients. Figure 5-26 shows the same for 34°C. In each of the 
data sets there are around 10 proteins reliably up or downregulated in chronic 
compared to self-healing. Table 5-4 shows the data/detail of the secreted proteins 
from parasites incubated at 25°C identified by LC-MS/MS with a differential 
abundance ratio of over or under 0.58 or -0.58, respectively.  
Table 5-5 shows the secretome from parasites incubated at 34°C, and selected 
with the same criteria. Temperature does not appear to play a major role in 
altering the content of the secretome as there were very few differences between 
the two sample sets. 
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Figure 5-25 Volcano plots of 6-plex TMT™ quantitation of L. panamensis promastigote 
secretome collected from Chronic (Chr) and Self-healing (SH) disease-causing parasites at 
25°C. (a) Volcano plot of the fold change of each protein in Chr and SH samples against the p-values 
of the sample variability using standard t-tests.(b) Reanalysis of p-values using Kammers et 
al.(D’Angelo et al. 2017; Kammers et al. 2015) method of using moderated t-statistics from the 
empirical Bayes procedure LIMMA. Statistical testing performed and figures made in RStudio.L. 
panamensis secretome 25°C volcano plot ord (top) and modified p-values. p=<0.05, FC 1.5 Proteins 
in red are significantly upregulated or downregulated in chronic secretome compared to self-healing, 
with a fold change of ±1.5 and p-value of ≤ .  . 
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Figure 5-26 Volcano plots of 6-plex TMT™ quantitation of L. panamensis promastigote 
secretome collected from Chronic (Chr) and Self-healing (SH) disease-causing parasites at 
34°C. (a) Volcano plot of the fold change of each protein in Chr and SH samples against the p-values 
of the sample variability using standard t-tests.(b) Reanalysis of p-values using Kammers et 
al.(D’Angelo et al. 2017; Kammers et al. 2015) method of using moderated t-statistics from the 
empirical Bayes procedure LIMMA. Statistical testing performed and figures made in RStudio. L. 
panamensis secretome 34°C volcano plot ord (top) and modified p-values. p=<0.05, FC 1.5 Proteins 
in red are significantly upregulated or downregulated in chronic secretome compared to self-healing, 
with a fold change of ±1.5 and p-value of ≤ .  . 
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Table 5-4 L. panamensis secretome proteins significantly up- or down-regulated in parasites from chronic infection compared to self-healing 
infection. Incubation at 25C, significant proteins <0.05 pvalue and changing greater than 1.5 fold. 
Accession Description Log2FC FC p-value 
LPAL13_040007600; 
LPAL13_040007500 surface antigen-like protein 1.590333 3.011188451 0.02655 
LPAL13_110010200 aminopeptidase, putative 1.514333 2.856667254 0.012281 
LPAL13_040008600 beta-fructofuranosidase, putative 1.240667 2.36307759 0.00704 
LPAL13_140019200 inositol-3-phosphate synthase 1.154667 2.2263293 0.000811 
LPAL13_000007400; 
LPAL13_000038100; 
LPAL13_070014200 hypothetical protein, conserved 0.902 1.868654694 0.011998 
LPAL13_340054800 proteasome alpha 1 subunit, putative 0.833 1.781385801 0.029099 
LPAL13_350049000 hs1vu complex proteolytic subunit-like, threonine peptidase, Clan T(1), family T1B 0.744 1.674812975 0.017769 
LPAL13_150019600 proliferative cell nuclear antigen (PCNA), putative 0.677667 1.599551009 0.025176 
LPAL13_350006800 elongation factor 2 -0.645 1.563739286 0.039623 
LPAL13_010011900 eukaryotic initiation factor 4a, putative -1.06633 2.09409951 0.003728 
LPAL13_140006900 Thioredoxin-like, putative -1.15667 2.229422424 0.015686 
LPAL13_250013500 eukaryotic initiation factor 5a, putative -1.35067 2.550305363 0.025692 
 
Table 5-5 L. panamensis secretome proteins significantly up- or down-regulated in parasites from chronic infection compared to self-healing 
infection. Incubation at 34C significant proteins <0.05 pvalue and changing greater than 1.5 fold. 
Accession Description Log2FC FC p-value 
LPAL13_040007600; 
LPAL13_040007500 surface antigen-like protein 1.488667 2.806295 0.017811 
LPAL13_110010200 aminopeptidase, putative 1.060667 2.085895 0.024808 
LPAL13_200061900 small myristoylated protein-3, putative 0.762667 1.696624 0.004201 
LPAL13_340040200 structural maintenance of chromosome (SMC) family protein, putative 0.761667 1.695448 0.017767 
LPAL13_350006800 elongation factor 2 -0.59133 1.506639 0.011721 
LPAL13_280035900 heat-shock protein hsp70, putative -0.59367 1.509077 0.007335 
LPAL13_300032600 hypothetical protein, conserved (T. brucei PFR component, putative) -0.64067 1.559049 0.009798 
LPAL13_280036000; 
LPAL13_280035900 heat-shock protein hsp70, putative -0.75367 1.686073 0.010274 
LPAL13_260021000 thimet oligopeptidase, putative -0.75767 1.690754 0.030429 
LPAL13_000007500 paraflagellar rod protein 1D, putative -0.78 1.717131 0.005178 
LPAL13_340023200 60S ribosomal protein L5, putative -0.92 1.892115 0.00493 
LPAL13_010011900 eukaryotic initiation factor 4a, putative -0.964 1.950711 0.000816 
LPAL13_140013400 small myristoylated protein-3, putative -0.97233 1.962011 0.000338 
LPAL13_160019400 paraflagellar rod protein 1D, putative -1.391 2.622604 0.000121 
LPAL13_140006900 Thioredoxin-like, putative -1.60233 3.03634 0.000112 
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5.4 Discussion 
Further insight into the role proteins play in parasitic diseases is crucial. It is 
already understood that Leishmania parasites secrete numerous proteins which are 
implicated in the disease pathophysiology (Diniz Atayde et al. 2016). Here we 
present a quantitative study looking at differences in these secreted proteins 
between different isolates responsible for varying disease phenotypes and provide 
crucial insight into the roles these may proteins play. 
5.4.1 Quantitative analysis using isobaric tags 
TMT labelling has been shown to be a valuable tool in quantitative proteome 
analysis (Ahrné et al. 2016; Thompson et al. 2003). It allows for the quantitation 
of proteins in a complex biological sample and when coupled with high resolution 
mass spectrometry and analytical data analysis software, employing statistical 
robustness to fold changes and subsequent results, we can gain confidence in our 
findings and come to novel conclusions, inferring functionality of the role proteins 
play in disease pathophysiology. 
Although a powerful and extremely useful approach, TMT labelling has the 
disadvantage of ratio distortion with isobaric multiplexing (Ahrné et al. 2016). 
Contaminating tagged ions co-elute or co-fragment with the fragments of interest 
which adds to the overall intensity of the tag at certain times therefore potentially 
skewing results and giving false positives. Precursor isolation window widths were 
therefore set to 1.0 m/z, to obtain the best trade-off between ratio compression 
and identification, in agreement with previous studies (Ahrné et al. 2016; Savitski 
et al. 2011). 
5.4.2 Statistical testing for analysis of quantitative proteomic data 
It is recognised that detecting statistically significant changes in protein abundance 
is a fundamental task in quantitative mass spectrometry experiments. This includes 
analyses and comparisons of treated to untreated cells, wild types to mutants, or 
samples from diseased and non-diseased subjects. Statistical approaches and 
analyses of comparative experiments are typically based on standard 2-sample t-
tests (Kammers et al. 2015). These tests typically analyse and compare the 
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measured relative or absolute abundances for each peptide or protein across the 
differing conditions of interest. Small sample sizes, however, encourage 
uncertainty in the sample variance estimates and can subsequently reduce the 
power of the analysis. In extreme cases, results can be falsely rejected based on 
large sample variance or conversely, small fold changes might be accepted and 
declared statistically significant based on small sample variance (Kammers et al. 
2015). Statistical models such as the moderated t-test have to be applied to take 
into account higher variance with higher fold changes, thus making these more 
significant, and lower variance with lower fold changes, thus making these less 
significant (Smyth 2004). As described in the introduction of this chapter, D’Angelo 
et al. evaluated the application of GLM; LIMMA, which is popular in microarray data 
analysis but not commonly applied in proteomic analysis; and mixed models, to 
TMT-tagged proteomic data, and concluded LIMMA to have the best overall 
statistical properties, regardless of the normalisation method (D’Angelo et al. 
2017). 
We therefore utilised R scripts from (Kammers et al. 2015) and used a two-stage 
analysis, reducing the data to independent summary measures of the proteins and 
performing the statistical analysis using the independent measures. Here, in a 
modification to Kammers et al. data analysis, proteins identified by only one 
peptide were retained in the secretome analyses due to the nature of the sample. 
Not only is the secretome a small fraction of the whole proteome, we are also 
searching for the presence of rare proteins. We are using data-dependent 
acquisition (DDA) and therefore will only see the top n peptides in any particular 
scan, therefore rare proteins may only be identifiable by one peptide. 
5.4.3 L. mexicana attenuated parasites display delayed 
progression through the life cycle 
The first parasite phenotype used in the comparative studies was an attenuated 
line of L. mexicana. These parasites were attenuated under gentamicin pressure in 
vitro, subsequently losing the ability to sustain infection in bone marrow-derived 
macrophages and to induce cutaneous lesions in BALB/c mice (Daneshvar et al. 
2003a). However, the mechanism of attenuation is unknown. 
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Although the growth rates of WT and attenuated (H-line) L. mexicana 
promastigotes were similar in axenic culture, the attenuated parasites exhibited 
slightly delayed growth as axenic amastigotes. Metacyclogenesis is characterised 
phenotypically by a reduction in cell length and width (Wheeler et al. 2011) 
therefore we can infer that the H-line are either not undergoing the transformation 
to metacyclic stage parasites as quickly as the WT or are not transforming as 
efficiently due to differences in cell size. Consequently, the rate at which the 
parasites differentiate into amastigotes is also affected, which is evident in the 
difference in cell size at days 1 and 2 after stimulus, with the H-line displaying 
slower growth as amastigotes. The major difference between the WT and H-line 
parasites appears to be at the metacyclic stage. This could indicate that the 
attenuation occurs in the processes which establish infection. When analysing the 
secretome samples it is seen that there were far fewer differences between the 
two cell lines in the amastigote stage. 
5.4.4 Comparative analysis of the secretome of L. mexicana wild 
type and attenuated parasites 
In addition to gaining insight into the mechanisms of attenuation in the H-line 
parasites, our aim of this comparative analysis was to reveal secreted proteins with 
potential roles in the virulence of L. mexicana. We undertook a quantitative 
analysis to not only detect qualitative differences, but to compare the relative 
abundance of the proteins secreted by these two cell lines. 
Unfortunately, due to the low abundance of the secretome and difficulties in 
collecting large amounts of protein whilst minimising cell stress and inadvertent 
cell death, the identification of the modulated proteins highlighted in the DiGE 
analysis was difficult. Normally, a preparative gel is run in parallel to a DiGE gel 
with a higher amount of protein and no dyes. The spot patterns are then matched 
between the gels using DeCyder™ software (GE Healthcare), and any protein spots 
of interest identified in the DiGE gel can be picked from the preparative gel and 
analysed by mass spectrometry (Westermeier et al. 2008). However, insufficient 
secretome sample was available to run a preparative gel in addition to a DiGE gel. 
Protein spots of interest were instead picked from the DiGE gel to attempt MS 
identification, however this was unsuccessful. Thus, a gel-free quantitative 
approach was undertaken. 
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We can infer the role of the secretome in cell survival and infection outcome by 
assigning identified proteins their putative functional role. Additionally, previous 
studies have implicated several of these proteins in the pathology of the disease. 
Proteins up or downregulated by ≥1.5 were categorised by their putative ontologies 
which were assigned by their known functional roles according to gene ontology 
annotations on the TriTryp database (Aslett et al. 2010) and to other studies. The 
ontologies were then grouped by percentage of the secretome with this function 
and by up or downregulation in the attenuated samples, as shown in Figure 5-27. 
 
Figure 5-27 Pie chart indicating the percentage of the L. mexicana promastigote secretome 
with certain activity or location associations. (a) Functional categories of proteins upregulated in 
the secretome of attenuated parasites (H). (b) functional categories of proteins downregulated in 
attenuated parasites (H) versus wild type (WT). 
An increase in proteins associated with vesicle trafficking and membrane proteins 
was observed in the H-line. This suggests a dysregulation of vesicle trafficking and 
exosome budding. This is not to say production of vesicles is not associated with 
virulence, but rather that vesicular dysregulation, in combination with delayed 
progression through the life cycle, suggests that the attenuated parasites are 
readily recognised in the host cell and do not have the tools to withstand anti-
microbial attack before they can fully differentiate to amastigotes.  
In addition, there is a downregulation in secretion of the antioxidants superoxide 
dismutase, tryparedoxin peroxidase and thioredoxin-like protein in the H-line 
compared to wild-type. This is consistent with previous findings by Daneshvar et 
al. who undertook a comparative analysis of the proteome of the WT and H-line. 
a b 
Up in attenuated   FC > 1.5 H/WT Down in attenuated FC < 1.5 H/WT 
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They found differential expression of a number of isoforms of tryparedoxin 
peroxidase, a reduction in trypanothione reductase activity and trypanothione-
dependent peroxidase activity in the H-line and significant sensitivity of the H-line 
to hydrogen peroxide in comparison to the wild type (Daneshvar et al. 2012). This 
demonstrates the crucial role of a strong and immediate antioxidant defence to 
the survival of Leishmania upon entry to the host cell (Mittra et al. 2013; Olmo et 
al. 2015). Upregulation of iron superoxide dismutase has also been shown to trigger 
the differentiation of promastigotes to amastigotes (Mittra et al. 2017), therefore 
a reduction of this protein in attenuated parasites may delay their differentiation 
to amastigotes. 
Crucially, a downregulation in the secretion of GP63 is also observed in the 
attenuated line. GP63 has been shown to play many roles in the disruption of 
signalling in the macrophage, as it can gain access to the macrophage cytosol 
(Gómez et al. 2009b). Overall host translation and protein synthesis is 
downregulated upon infection with Leishmania (Jaramillo et al. 2011), which 
occurs through a variety of mechanisms mediated by GP63. For example cleavage 
of c-Jun, a component of AP-1 transcription factor (Contreras et al. 2010); cleavage 
and thus activation of protein tyrosine phosphatases, preventing JAK-STAT 
signalling (Gómez et al. 2009b); and cleavage of mTOR, which activates the 
downstream translational repressor 4E-BP1 (Jaramillo et al. 2011). Our results 
further demonstrate the importance of GP63 to the virulence of the parasite in the 
host as its downregulation appears to be detrimental to the survival of the H-line 
in the macrophage. Further to the suppression of host translation by GP63, the 
secretion of a Leishmania eukaryotic translation initiation factor (LeTIF) was also 
downregulated in the H-line. Interestingly, expression of one copy of an L. 
infantum LeTIF in yeast interfered with the translation machinery, resulting in 
growth inhibition (Barhoumi et al. 2006). Therefore secretion of LeTIF may also 
play a role in disruption of host translation, and therefore parasite virulence. 
LeTIF has also been shown to induce the secretion of IL-10 by host cells, directing 
the immune response towards a Th2, anti-inflammatory response, a response which 
favours parasite persistence (Carrillo et al. 2018). This, coupled with our 
observation of LeTIF downregulation in the H-line, is consistent with the findings 
of Daneshvar et al., who found that infection with the H-line directed the immune 
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system towards a Th1 response in mice (Daneshvar et al. 2003b). However, LeTIF 
can also induce the secretion of IL-12 in addition to IL-10 (Barhoumi et al. 2013), 
IL-12 stimulating a Th1 response, and so the complex interplay between the 
parasite and host is not altogether straightforward and doubtless relies on the 
presence of a number of different factors secreted by the parasite. 
GP63 has also been implicated in playing a role in exosomal protein sorting in 
Leishmania (Hassani et al. 2014). Analysis of exosomes from GP63 knock-out (KO) 
parasites showed major differences between the proteomic content of KO and WT 
exosomes. KO exosomes contained higher percentages of hypothetical and 
transmembrane proteins, with higher percentages of proteins containing putative 
GP63 cut-sites in the WT exosomes (Hassani et al. 2014). Our results are consistent 
with these findings as the attenuated parasites, which show a downregulation in 
GP63, also display an increase in the secretion of membrane-associated proteins 
(Figure 5-27a). 
5.4.5 L. panamensis secretome 
The second phenotype investigated was parasites isolated from patients with 
chronic (Chr) and self-healing (SH) lesions. These L. panamensis parasites were 
isolated in collaboration with CIDEIM in Cali, Colombia. This comparison was 
initiated to indicate which proteins in the secretome may play a role in the 
exacerbation of the disease. For example, causing the excessive inflammation and 
uncontrolled immunopathology that is typically seen in chronic cutaneous 
leishmaniasis (Navas et al. 2014). The difficulty with the immune responses to L. 
panamensis cutaneous disease is that the traditional Th1/Th2 dichotomy, where 
upregulation of the Th1 response results in parasite clearing, does not always apply. 
From the quantitative proteomic results, in the chronic samples we observe a 
down-regulation of proteins such as elongation factor 2 and eukaryotic initiation 
factors 4a and 5a, which have been shown to stimulate a mixed immune response 
in the host, with stimulation of IL-10 and IL-12 (Barhoumi et al. 2013). A down-
regulation of receptor activated kinase C is also seen, implicated as an 
immunomodulatory protein used as a vaccine candidate (Sinha et al. 2013). 
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There is an up-regulation of aminopeptidase and threonine peptidase in the chronic 
samples, shown to result in exacerbation of the inflammatory response, and 
enhancement of macrophage phagocytic activity (Goto et al. 2011). Up-regulation 
of surface antigen-like protein is also observed in chronic parasites. Up-regulation 
of the secretion of SMP-3 is seen in Chr parasites. Little is known about SMP-3 in 
comparison to SMP-1, which is known to play roles in normal flagellar function (Tull 
et al. 2010), and as a potent plasminogen binding protein found in Leishmania 
extracellular vesicles (Figuera et al. 2013). However, reduction of SMP-3, amongst 
other proteins, was observed in parasites with loss of virulence, implicating this 
form of SMP as a potential virulence factor (Magalhães et al. 2014).  
The increase in temperature may trigger degradation of the flagellum, as 
paraflagellar rod proteins are seen in the secretome of the 34°C parasites but not 
the 25°C parasites (Suppl II). Few other differences were observed between 25°C 
and 34°C, with the differentially regulated proteins between Chr/SH remaining 
constant between the two independent experiments. We therefore reject the 
hypothesis that temperature alone alters the proteins present in the secretome. 
This analysis did not take into account the total amount of protein secreted at each 
of the different temperatures, however. This has been shown previously to affect 
the amount of protein secreted but not necessarily the protein content (Hassani et 
al. 2011). Therefore, this could be investigated in more detail in future. Another 
future study looking at environmental factors would be to try a lowered pH as this 
appeared to have an effect on the secreted proteins when studied in L. major 
(Chenik et al. 2006). 
5.5 Summary 
Here, the overall aim was to take methods developed for isolating and analysing 
the secretome of Leishmania parasites and apply them to an attenuated L. 
mexicana parasite line, and to clinical parasite isolates. We aimed to investigate 
the role of the secretome in the establishment of infection and parasite survival 
inside the host cell. We hypothesised that there is a significant difference in the 
parasite secretome between wild type and attenuated L. mexicana promastigotes 
and amastigotes. 
Chapter 5  180 
These results highlight significant differences in the parasite secretome between 
wild type and attenuated L. mexicana promastigotes. From the differential 
regulation of secreted proteins from these two phenotypes we can conclude that 
secretion of antioxidant protein is important for virulence of the promastigote 
stage in the host cell. Furthermore, our results further substantiate the role of 
GP63 as a virulence factor. And may also point to its putative role as a regulator of 
exosomal cargo. 
We aimed to investigate the potential functional role of the Leishmania panamensis 
secretome in the outcome of the disease. Through comparative analyses looking at 
parasites of the same species that establish different disease phenotypes. We 
hypothesised that as other studies point to the differing disease outcomes being 
parasite-mediated, there may be a significant difference in the parasite secretome 
between isolates from chronic cutaneous Leishmaniasis compared to isolates from 
self-healing cutaneous Leishmaniasis. We identified modest but consistent 
differences in the secretomes of the two isolates. Many of the differentially 
regulated proteins have little-known functions in the Leishmania secretome, 
particularly in the complex immune responses associated with chronic cutaneous 
Leishmaniasis. However, the upregulation of peptidases in the chronic isolates may 
play a role in local inflammatory responses.  
Here we have provided crucial insight into Leishmania survival and further 
implicated the secretome in virulence and disease progression. Leishmania lack an 
adequate vaccine and leishmaniasis an appropriate treatment therapy. Results here 
may be used for vaccine targets and provide a basis for future secretome analysis.  
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 Concluding Remarks 
This thesis presents a comprehensive analysis of the secretome of Leishmania 
promastigotes and amastigotes. Here, we demonstrate implementation and testing 
of a secretome collection method. The method was successfully adapted from 
previous protocols to the study of promastigotes and amastigotes. Analysis of the 
secretome compared to the whole cell lysate proteome provided validation and 
confidence of the method, demonstrating that it is the secretome that has been 
extracted and analysed. This enabled comparative analyses between the secretome 
of promastigotes and amastigotes. In addition, we have shown the method to be 
applicable both to laboratory strains and to clinical isolates, allowing for 
conclusions in the secretomes role in disease phenotype to be made. Quantitative 
analyses were implemented for the analysis of wild-type and virulence-attenuated 
parasites, and to parasites causing chronic and self-healing cutaneous disease in 
patients. 
6.1 Change in environmental niche is accompanied by life 
cycle progression and alterations to protein secretion 
Leishmania inhabit contrasting environments in the insect vector and mammalian 
host. To cope with challenges of these different conditions the parasite both adapts 
its form and modifies its niche. We demonstrated that the promastigote secretome 
contains a myriad of membrane proteins, plasminogen binding proteins, redox 
proteins and other proteins which appear to have nutritional function. Here, we 
have shown that amastigotes show an increase in the proportion of protein 
degradation, redox proteins, and chaperones/stress-induced proteins in their 
secretome. We have further shown the abundance of GP63 in the amastigote 
secretome, which is a different form to promastigote GP63. In addition changes in 
the abundance of MIF are observed. 
Studies presented here are focused on in vitro cell culture models. Future work is 
required to improve these models to further mimic in vivo conditions but still 
provide a controlled, defined environment. More information may be gleaned from 
the addition of factors to the culture which better replicate the stresses 
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encountered by the amastigotes in vivo. For example addition of superoxide or 
hydrolases may stimulate secretion of proteins in amastigotes, akin to the effects 
of stimulation by temperature increase in promastigotes (Atayde et al. 2015; 
Hassani et al. 2011). 
6.2 Changes in secretion are associated with virulence 
Developed methods were applied to parasites with differing host morphology and 
disease phenotypes. This allowed the consolidation of the secretome to a selection 
of highly influential proteins. 
Here, we note a downregulation of antioxidants in virulence-attenuated parasites 
compared to wild-type parasites, highlighting their role in virulence. Antioxidants 
including FeSOD, tryparedoxin peroxidase and thioredoxin-like protein were shown 
to be down-regulated. The downregulation of GP63, tetratricopeptide repeat 
protein, translation initiation factor 3 and polyadenylate binding protein 2 are also 
associated with the loss of virulence. Analysis of the total percentage of up and 
down regulated proteins grouped together according to functionality reveals 
functional differences between the secretomes. The largest differences between 
the up and down regulated proteins have roles in membrane association and 
oxidation-reduction activity. 
Further, we highlight the secretomes role in the exacerbation of inflammatory 
mediators in chronic disease. Surface antigen-like protein was resolved from 
analyses presented here and was found to be upregulated in parasites derived from 
chronic manifestations. In addition, aminopeptidase was too found to be 
upregulated in the same parasite line. Overall, these results provide evidence and 
implications for niche modification in disease outcome, inducing disease phenotype 
through inflammation. Identification of these differentially regulated factors 
narrows the secretome down to a few key proteins for further study. 
First of all, further replicates are required. Results presented here present a 
relatively small sample set but robust biological replicates were utilised, using 
parasites isolated from different patients with the same condition. However, 
technical replicates of the process as a whole would be very valuable in confirming 
the results presented here and providing method validation. These replicates would 
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be of particular value due to the difficulties in culturing field isolates. Their 
viability in axenic culture is lower than that of the laboratory strains. Therefore, 
additional replicates are required to solidify the inclusion of proteins to the 
secretome. 
6.3 Further analyses of the secretome as a whole 
The physical differences between the secretome of promastigotes and amastigotes 
are intriguing but require further analysis. Further research and analysis into the 
amastigote secretome further would represent future work here. The observation 
of a viscous gel-like pellet visible when precipitating the amastigote secretome 
with organic solvents or TCA and an insoluble component to the amastigote 
secretome upon freeze-thawing could reveal novel proteins or molecules excreted 
by Leishmania. 
Through the use of attenuated parasites and parasites with differing disease 
phenotypes, we have been able to indicate potential roles for various secreted 
proteins in the host. As a next step to address the functionality of the secretome, 
we propose various experiments to investigate the host cell response to the 
secretome investigating the following. Application of a wild-type secretome could 
prime host cells and influence the survival of an attenuated parasite. We would 
investigate how the host cell response differs in response to the secretome from: 
promastigotes, amastigotes, attenuated cells, chronic disease inducing parasites, 
and self-healing disease parasites. Analyses could include qPCR array plate looking 
at cytokine/chemokine response or an ELISA based methodology as previously 
described (Pollock et al. 2003).  
In addition, potential exosomal proteins were identified in this study. Therefore, 
isolation of exosomes using ultracentrifugation and classification of bona fide 
exosomes by electron microscopy, differential digestion using detergents and 
trypsin, and density gradient purification would corroborate and increase the 
evidence for the production of exosomes in Leishmania. Crucially, this would 
extend these analyses to the amastigote stage. What is known about the 
mechanisms of secretion in Leishmania is still largely based on confirmation of the 
presence of secretory organelles and multivesicular bodies (McConville et al. 2002). 
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The processes involved in and the locations of physical egress of exosomes, 
however, remain to be elucidated. Exosomal release from the flagellar pocket is a 
previously presented hypothesis in kinetoplastids, with evidence of the production 
of nanotubes which bud off producing vesicles from T. brucei (Szempruch et al. 
2016b). However, images of Leishmania show vesicles budding from or associated 
with various regions on the cell surface and flagella (Hassani et al. 2011). In support 
of this, our data demonstrate the presence of numerous membrane proteins in the 
promastigote secretome, both cell body and flagellar membrane-associated. The 
lack of membrane proteins in the amastigote secretome requires further 
investigation as this, coupled with the relatively small number of proteins 
identified in the secretome, could indicate that adjustments are required to the 
incubation time during the secretion assay.  
To summarise, further work into the secretome as a whole and its role in the host 
cell is required. Here we provide a discovery study looking as the secretome of 
differing Leishmania cell lines and draw initial conclusions of their secretomes role 
in disease.  
6.4 Proposal of protein candidates for further analyses 
In addition to characterising the role of the secretome in the cell biology of the 
parasite, the ultimate goal in this discovery project is the identification of potential 
candidates for therapeutic intervention or vaccination. Here, we have begun with 
characterising the secretome as a whole, looking at global analysis of the 
secretome using shotgun proteomic approaches, then narrowing the proteome 
down based on functionality using comparative analyses. Based on the comparative 
analyses and placing in literature, we have identified some promising candidates 
for further analysis. These proteins would provide the basis of future work to move 
forward and go on for further analysis.  
One methodology that would have been useful in looking at specific protein 
function is loss-of-function screens using RNA interference (RNAi). Unfortunately, 
RNAi cannot be used in L. mexicana due to the lack of RNAi machinery in this 
species (Lye et al. 2010). Traditional methods of genetic manipulation are time 
consuming and complicated by multiple gene copies and variable ploidy (Cruz et 
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al. 1993). A more suitable method would be the use of the CRISPR-Cas9 system for 
knock-out or tagging in Leishmania described by the Gluenz group (Beneke et al. 
2017). Knock-out experiments look for the effect on cell survival and 
differentiation, virulence, and effect on host cell, for example, lesion-forming in 
the host. Tagging experimental design could include tagging of proteins to identify 
the localisation to and in exosomes and location within the host cell. 
We have identified several secreted proteins as candidates for further analyses. 
The first is the amastigote-secreted migration inhibition factor homologue (MIF). 
In addition to its high enrichment in the secretome of amastigotes, MIF has been 
shown to regulate host immunity to promote parasite persistence in other studies 
(Holowka et al. 2016; Kamir et al. 2008). This therefore makes it an attractive 
candidate for therapeutic intervention. 
Further candidates for further analysis include; amastigote GP63, SMP-3, Iron 
superoxide dismutase, tryparedoxin peroxidase and thioredoxin-like protein. 
Amastigote GP63 differs in antibody reactivity to promastigote GP63. Previously 
discovered to be a major virulence factor in promastigotes, further investigation is 
required to understand whether this is a major virulence factor in amastigotes. Iron 
superoxide dismutase, tryparedoxin peroxidase and thioredoxin-like protein were 
all upregulated in the secretome of wild-type, virulent parasites compared to 
avirulent parasites. Superoxide dismutase A (SODA) has been previously 
demonstrated to be essential for L. amazonensis virulence (Mittra et al. 2017). 
SMP-3 is a little-known version of the Leishmania SMPs. However, it has been 
implicated in the virulence of L. amazonensis by the observation of its reduction in 
parasites with loss of virulence (Magalhães et al. 2014). 
In summary, results presented here implicate a number of candidates for further 
investigation. Leishmaniasis is a debilitating disease affecting millions world-wide. 
The lack of a suitable treatment strategy or an appropriate, commercially available 
vaccine make this disease a research priority. Any research highlighting potential 
mechanisms into disease virulence and targets for therapeutic intervention or 
vaccination are a must in order to help combat this disease. 
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Appendices 
 
Appendix 1 Analysis of the secretome of L. mexicana promastigotes cultured in chemically 
defined medium. (a) Lysate (Lys) and 24h secretome collection (Sec) from L. mexicana 
promastigotes cultured in chemically defined medium run on 4-20% SDS-PAGE and stained with 
Coomassie. (b) Proteins identified by LC-MS/MS from two serum-free secretome collections (SF-A, 
SF-B) and defined medium collection (DM). Total proteins numbers are indicated beside sample 
names. 
 
Appendix 2 Molecular Weight marker migration chart from abcam Precast Gel SDS-PAGE 
system. Found at www.abcam.com. 
  
kDa 
212 
158 
116 
97.2 
66.4 
55.6 
42.7 
34.6 
27.0 
20.0 
14.3 
6.5 
Lys Sec a b 
Figure has been removed due to Copyright 
restrictions. 
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Appendix 3 Microvesicle associations of Leishmania secretome proteins. From (Silverman et 
al. 2008) 
GeneDB 
Accession No. 
Protein Identification Microvesicle 
Association 
Present in L. 
mexicana 
promast. 
secretome 
GeneDB 
Accession 
LmjF36.6910 chaperonin, putative,T-complex protein 1 
(theta subunit), putative 
AP Yes LmxM.36.6910 
LmjF28.2860 cytosolic malate dehydrogenase, putative * AP Yes LmxM.33.0140 
LmjF33.2550 isocitrate dehydrogenase, putative AP   
LmjF35.3860 t-complex protein 1, eta subunit, putative AP Yes LmxM.34.3860 
LmjF14.1160 enolase AP Yes LmxM.14.1160 
LmjF36.2030 chaperonin Hsp60, mitochondrial precursor AP Yes LmxM.36.2030 
LmjF23.1220 t-complex protein 1, gamma subunit, putative AP Yes LmxM.23.1220 
LmjF36.2020 chaperonin Hsp60, mitochondrial precursor AP Yes LmxM.36.2020 
LmjF36.1630 clathrin heavy chain, putative AP   
LmjF31.1070 biotin/lipoate protein ligase-like protein AP   
LmjF27.1260 T-complex protein 1, beta subunit, putative AP Yes LmxM.27.1260 
LmjF36.1600 proteasome alpha 1 subunit, putative AP Yes LmxM.27.0190 
LmjF35.4850 proteasome alpha 1 subunit, putative AP Yes LmxM.11.0240 
LmjF32.0230 dynein light chain, flagellar outer arm, putative AP   
LmjF10.0290 isocitrate dehydrogenase [NADP], 
mitochondrial precursor, putative 
AP Yes LmxM.10.0290 
LmjF08.0550 translation initiation factor-like protein AP Similar LmxM.33.0840 
LmjF01.0410 ribosomal protein S7, putative AP Similar LmxM.31.3130 
LmjF32.1000 chaperonin containing t-complex protein, 
putative 
AP Similar LmxM.21.1090 
LmjF25.1120 aldehyde dehydrogenase, mitochondrial 
precursor 
AP   
LmjF24.2070 40S ribosomal protein S8, putative AP   
LmjF21.1770 ATP synthase F1 subunit gamma protein, 
putative 
AP   
LmjF35.3060 ubiquitin-activating enzyme E1, putative AP   
LmjF30.2820 chaperonin HSP60/CNP60, putative AP, GLY   
LmjF21.1860 beta tubulin BC Yes LmxM.08.1171 
LmjF35.0030 pyruvate kinase, putative BC, AP   
LmjF28.2770 heat-shock protein hsp70, putative BC, DC, AP  LmxM.28.2770 
LmjF26.1240 heat shock protein 70-related protein BC, DC, AP  LmxM.26.1240 
LmjF29.0510 cofilin-like protein DC   
LmjF11.0350 14-3-3 protein, putative DC  LmxM.36.3210 
LmjF10.0910 small GTP-binding protein Rab11, 
putative,Rab11 GTPase, putative 
DC Similar LmxM.27.0760 
LmjF15.0010 histone h4 DC   
LmjF01.0770 eukaryotic initiation factor 4a, putative DC,  AP Yes LmxM.01.0770 
LmjF36.3210 14-3-3 protein-like protein DC, AP Yes LmxM.11.0350 
LmjF04.1230 actin DC, AP Yes LmxM.04.1230 
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